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Abstract 
Over half of the vaccines used in developing countries’ immunisation programs are 
supplied by developing country manufacturers. The viability of vaccine production in 
developing countries play a significant role in securing the global capacity of vaccine 
supplies. These producers however, face challenges in balancing between meeting the 
needs of the large population sizes and high disease burden typically found in 
developing country markets with uncertainties in demand forecasting and low 
profitability. Economic studies on the viability of vaccine production in developing 
countries are limited. An identification and better understanding of the critical elements 
influencing local vaccine production is crucial and timely, given the present need to 
secure and enhance the capacity of global vaccine supplies in the face of emerging 
and re-emerging diseases.  
This thesis focuses on the viability of local vaccine production in developing countries 
by conducting three assessments on cost structures, revenue sizes and percent market 
shares, and vaccine prices. The objective of the first assessment, cost structure, is to 
address the supply-side barriers of local vaccine production. In the second 
assessment, the research utilises revenue sizes and percent market shares as a proxy 
of viability and quantifies the influence of vaccine viability factors on developing country 
vaccine production. The third assessment on vaccine prices addresses the demand 
side barriers to vaccines produced by developing countries and observes the influence 
of procurement factors on prices of vaccines produced by developing countries.  
For the first assessment, on cost structures, primary data were collected from existing 
vaccine producers in developing countries and analysed using a cost-analysis method. 
Three hypothetical scenarios using different production scale and scope were applied 
to estimate the costs-per-dose of vaccines. The findings showed that the scale and 
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scope of production are essential in achieving and sustaining viability. The findings 
also showed that the main factors influencing viability were strong domestic sales and 
consistent supply, this also holds for companies planning to expand into export 
markets. Further, a step-cost characteristic for fixed costs, and failure rates ranging 
between 2% to 45%, were identified.  
In the second assessment, factors were assessed for their influence on revenue sizes 
and percent market shares of vaccine products supplied by developing country 
manufacturers for immunisation programs. A multilevel regression model was built 
using a hierarchical dataset for years 2012 – 2014, for the overall global market as well 
as the domestic and export markets specifically. The findings showed that revenue 
sizes were influenced by national income levels, consistent production supplies and 
the ability to meet the needs of immunisation programs in procuring countries. While 
factors identified as influencing percent market share were: having consistent 
production, the ability to meet the needs of immunisation programs in procuring 
countries as well as having vaccines with prequalification status. The third assessment, 
on vaccine prices, was based on a mixed effects regression on a panel dataset of 
vaccine prices for years 2005 to 2015. The analysis found that procurement volume, 
method and size of vaccine formulation were influential in determining vaccine prices, 
for both traditional and modern technology types.  
The overall findings suggest that the cost of producing vaccines in developing countries 
are an average of $2.05 per dose ranging between US$0.92 and $4.40. These 
estimates are within the cost range suggested for multinational companies (Mercer 
Management Consulting (2002): $0.05 to $3-4 per dose). Whilst the vaccine markets 
that developing country producers face are not premium markets like those found in 
high-income countries, this is likely compensated by the vast size of these markets and 
the lack of domestic competition. Their production viability however becomes 
challenged once they expand their production into export markets and when they 
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produce newer technology vaccines. It is in these situations where knowledge of critical 
factors becomes important.  
This thesis not only adds to what is known about the viability of vaccine production in 
developing countries, but also provides robust evidence for developing countries and 
global health advocates to understand better the factors driving viability in regards to 
costs, revenue sizes and percent market shares as well as prices. This may allow 
policymakers to navigate and develop policies that can further support local vaccine 
producers and other developing countries that are considering investing into local 
vaccine production. 
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 Introduction 
1.1. Overview 
Vaccines have been commended as one of the most cost-effective breakthroughs in 
public health, only second to provision of clean water (WHO, 2003). Launched in 1974 
to deliver vaccines against diphtheria, tetanus, pertussis, polio, measles and 
tuberculosis, the expanded program for immunization (EPI) has saved approximately 
20 million lives in the two decades that followed its launch (World Bank, 1993). Since 
then, with the advances in biotechnology and immunology, increasing numbers of 
vaccines are being developed and have become available. The adoption of these new 
and underused vaccines (NUVs) into national immunisation programs however, has 
not taken place in as timely a manner as expected. 
The World Health Organization (WHO) estimates that to date 2 to 3 million deaths each 
year are currently prevented through immunisation programs (WHO, 2016b) and that 
there is increased access to new vaccines for low and middle income countries1. 
However, despite these impressive achievements, the immunisation programs still face 
major challenges, both in sustaining vaccination coverage levels as well as in ensuring 
equal access to new and underused vaccines (NUV) in populations that need them 
most, as much as 1.5 million vaccine-preventable deaths are still recorded (WHO, 
2012, 2016b).  
The WHO midterm review of the Global Vaccine Action Plan (GVAP) found that though 
many countries have achieved the 2015 global immunisation target of 90%, the 
average global immunisation coverage still falls short from achieving this target. These 
coverage rates have only risen by 1% since 2010. Whilst 16 countries recorded 
                                               
1 In 2015, 99 low and middle-income countries were recorded introducing one or more NUVs, 
exceeding the target of 90 countries set by the WHO Global Vaccine Action Plan (WHO, 2016a). 
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increases in their coverage levels, 26 countries reported no change and 25 countries 
experienced a net decrease from their coverage levels in 2010 (WHO, 2016a). 
Global vaccine supplies are essential in ensuring that the aims of immunisation 
programs continue to be achieved, and in increasing accessibility to all populations 
around the world. The UNs Sustainable Development Goals (SDGs) promote the 
research and development of vaccines as a means to achieve universal health 
coverage, and enable access to affordable quality medicines and vaccines (UNDP, 
2016).  
The vaccine markets in developing and developed countries are quite distinct in terms 
of profitability, size and epidemiological needs. This poses a considerable challenge 
for vaccine manufacturers to fulfil public health needs for both developing and 
developed country markets in an equitable manner. WHO data show that profits and 
revenues are mostly generated from vaccine markets in industrialised countries. 
However, it is in developing country markets that population sizes and burdens of 
disease are highest. If left to market forces, manufacturers will most likely opt to 
produce vaccines for developed countries where profits are highest. This was 
demonstrated in a 1990 report by the Commission on Health Research for 
Development where a 10/90 gap was shown to exist (Milstien, Kaddar, & Kieny, 2006); 
in that only 10 percent of the global budget for health research is allocated to research 
and development (R&D) for 90 percent of the global health burden. Children in 
developing countries therefore are not benefitting from vaccine technology advances 
that have been accessible to those in developed countries. 
Both policy-makers and manufacturers must address a mix of technological, political, 
financial, and logistical issues that affect sustainable production in many developing 
countries. This includes the impact of multilateral and bilateral trade agreements on the 
economic and public health situation of countries, such as the impact of removal of 
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trade barriers for national manufacturers. The development of a skilled local workforce, 
through governmental incentives and education policies to prevent brain drain is 
another consideration. 
This thesis examined the supply and demand side barriers of vaccine production, which 
are vaccine production costs and vaccine prices; and further, using revenue sizes and 
percent market shares as proxies for viability, to assess the factors that are critical to 
viability. This thesis applies economic concepts and methods in its assessments. 
This research on the economic aspects of existing local vaccine producers will help 
developing countries and global health advocates to better understand the factors 
driving viability in regards to costs, revenue sizes and percent market shares as well 
as prices. This may allow policymakers to navigate and develop policies that can 
further support existing local vaccine producers and might assist other developing 
countries that are considering investing into new local vaccine production. 
1.2. Aims of the thesis 
The overarching aim of this thesis was to investigate how existing vaccine 
manufacturers in developing countries remain viable and what are the factors that are 
critical for them to gain and sustain viability in the face of changes within global vaccine 
markets. Critical factors for the viability of local vaccine production in developing 
countries were assumed to encompass three areas related to commercial production 
(McElliogott, 2009), these were: cost structures; revenue sizes and percent market 
shares; and prices.  
Several research questions need to be addressed in order to examine the aspects 
surrounding viability of local vaccine production. These are: 
 Cost structure - What are the cost structures in establishing vaccine manufacturing 
facilities in developing countries?; 
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 Percent market size and shares - How do vaccine viability factors influence the 
revenue sizes and percent market share of DCVMs?; 
 Vaccine prices – How do procurement factors influence the prices of vaccines 
supplied by developing countries?.  
1.3. Background 
Local producers supply over half of the vaccines used in developing countries’ 
immunisation programs and are recognised as important players in the industry (CVI 
& WHO, 1999; Jadhav, Gautam, & Gairola, 2014). These vaccine manufacturers have 
made huge strides over the past 30 years, expanding their production and switching 
their focus from primarily domestic markets and traditional vaccines to becoming a 
supplier of the global market by increasing capacity, improving facilities and developing 
NUVs. 
Public health advocates are highlighting DCVMs as a central part of their strategic 
agenda in securing the global supply of vaccines (Hendriks, Holleman, de Boer, de 
Jong, & Luytjes, 2011). They are seen not only as a means to ensure adequate supply 
but also acknowledged for their important impact in influencing access to NUVs (WHO, 
2011a). Much has changed from 30 years ago when the debate focused on whether 
or not supplying vaccines produced in developing country facilities was a good idea 
(UNIDO, 1986) (Muraskin, 1998). 
A turning point in the prioritisation of DCVMs was during the emergence of the H5N1 
influenza pandemic (Hendriks et al., 2011). In 20015, as requested by the World Health 
Assembly2, the WHO together with its international and national partners developed 
strategies to expand global vaccine manufacturing capabilities, particularly in 
developing countries (Kieny et al., 2006). Among its strategies was the creation of a 
                                               
2 The World Health Assembly is the decision-making body of WHO. It is an annual assembly of 
WHO’s member states which make decisions and determine the policies and priorities for 
WHO’s mandate and agenda.  
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hub model, which in contrast to a typical bilateral technology transfer arrangement, has 
a single technology donor that transfers to multiple numbers of technology recipients. 
The hub model managed to boost the global capacity of influenza vaccines, in an 
unprecedented timeframe (Friede et al., 2011).  
The importance of building capacity in developing countries to secure global supply of 
vaccines has been increasingly high on the global health agenda. A large part of this 
has been achieved through technology transfer projects (Friede et al., 2011).  Some 
examples of technology transfer projects include the NIH dengue vaccine technology 
to local manufacturers like Instituto Butantan, São Paulo, Brazil, Vabiotech, Hanoi, 
Vietnam and Panacea Biotec Inc., New Delhi, India, Serum Institute, Puna India.   
1.4. Scope of the research 
The overall scope of this thesis was the human vaccines3 market accessible to DCVMs 
within the context of public health programs4. This includes both production and sales 
of vaccines by DCVMs, limited to those used for immunisation programs5. These 
include immunisation programs in developing countries and elsewhere. 
The research questions examined by this thesis are specific to the viability of public-
market vaccine production that is owned6 by developing countries – and more 
specifically, the critical factors influencing costs, revenue sizes and percent market 
shares as well as vaccine prices. The critical factors relating to these three aspects are 
analysed separately. 
                                               
3 further referred to as ‘vaccines’ 
4 This will be referred to as national immunisation programs in this thesis.  
5 Two markets exist for vaccines: public and private market. Public market vaccines are those 
procured by governments and used in immunisation programs, while private market vaccines 
are procured by individuals and administered privately by health personnel. This thesis focuses 
on public-market vaccines only. 
6 This thesis takes on production based on ownership as opposed to a location basis, where 
the latter may include production facilities owned by multinational manufacturers and based in 
developing countries. 
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This thesis refers to two groups of vaccine manufacturers, based on their country of 
origin and income levels. These two groups are developing country vaccine 
manufacturers (DCVMs)7 and developed/industrialised country vaccine manufacturers 
(ICVMs). This thesis focuses on the vaccines market relevant to DCVMs only. 
Therefore, though local producers8 also exists in developed countries9, the term local 
production/local producers in this thesis refers only to DCVMs.  
In this thesis, classification of countries follows the World Bank’s classifications based 
on Gross National Income (GNI) per capita, using the Atlas method10 (Appendix 2.1). 
These are: high income countries (HIC) ($12,736 or more), middle income countries 
(MIC) (more than $1,045 but less than $12,736) and low income countries (LIC) 
($1,045 or less). The term ‘developing countries’ refers to the latter two, while 
‘developed countries’ refers to those in the HIC bracket. MIC countries are further 
segregated by lower-middle (LMIC) and upper middle (UMIC) with a GNI per capita 
threshold of $4,125. This thesis was not intended to study the difference between the 
lower and upper middle groups in the middle income bracket but may refer to these 
classes when needed. Furthermore, a network of DCVMs does exist, also known as 
the Developing Country Vaccine Manufacturers Network (DCVMN), yet this thesis 
refers to DCVMs based on their country status and not membership of the DCVMN11 
because some DCVMN members include those that are no longer categorised as 
developing countries. 
                                               
7 DCMs are also often referred to as local producers and emerging suppliers. 
8 Refers to manufacturers based in a country and majority of ownership is by an entity of that 
country, either public or privately owned 
9 Many local producers in developed countries however have become privatised, acquired or 
dissolved, such as those in the Netherlands (RVIM/Bilthoven), Italy (Sclavo SpA), etc. 
10 Using the Atlas methodology in calculating GNI reduces the impact of exchange rate 
fluctuations caused by inflation. The Atlas conversion factor is based on the a country’s 
exchange rate, taken as an average of a given year and its two preceding years, and then 
adjusts the difference between the inflation rate of the country and at the international level 
(World Bank data methodology, 2016).   
11 This thesis therefore excludes some DCVMN members that are developing countries which 
production data may not appear during the study period observed; as well as members that are 
now high income countries such as Republic of Korea, Taiwan, etc. 
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An example of this would be the Republic of Korea (hereafter referred to as South 
Korea). South Korea was classified in the past as a developing country, and is now 
considered a HIC due to the rise in its national income level12. Two of its vaccine 
manufactures however, are local producers13. Studies in the past, including some 
recent studies have included Korean production when reviewing DCVMs. However, for 
consistency, the countries included in the research are those that were classified as 
either low or middle income in 2012 (the start of the study period), thereby excluding 
South Korea. Of note, Argentina’s classification switched from middle income (2012 – 
2013) to high income in 2014 but data from Argentina in 2014 were included in this 
thesis as per the criterion described above. Furthermore, in Chapter 4, the DCVMs that 
were present in the observed timeframe were all in countries that are classified as 
middle income. This is partly due to progress and changes in the economic status of 
these producing countries over time. It is also important to highlight that in Chapter 5 
the panel dataset period is longer than mentioned above (2005 – 2015). The observed 
manufacturers were still consistent however with those included in Chapter 4. As such, 
the thesis includes DCVMs in countries that were classified as middle-income countries 
in 2012. 
1.5. Organisation of the thesis 
Following on from this introductory chapter, which covers the aims and scope of the 
research, the thesis is comprised of five subsequent chapters: 
Chapter 2, presents a review of the existing literature to identify gaps in knowledge and 
provide context for the research. The literature review focused on local production of 
vaccines in developing countries, with a particular emphasis on vaccines supplied for 
immunisation programs globally. The chapter provided the reasoning and background 
                                               
12 GNI per capita is often referred to as national income level, while total GNI is referred to as 
national income size. 
13 One of these producers have now been acquired by a multinational, therefore only one 
remains a local producers. 
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as to how local production of vaccines has emerged and contributed to the global 
supply of vaccines, and discussed the economics and production process of vaccines, 
providing the foundations on which the analyses in chapters 3, 4 and 5 were 
established.  
Chapter 3, “The cost structures of establishing new vaccine manufacturing facilities in 
developing countries”, is the first of three analysis chapters. This chapter used a cost 
analysis method to assess vaccine production costs in developing countries. Given the 
sensitivity of the topic, the data were derived from a questionnaire with self-reported 
responses and used cost ranges. The study used three hypothetical scenarios of 
production scale and scope to enable comparative analysis. Data were generated from 
eight vaccine manufacturers from different countries, which provided data for 12 
vaccine products. The results included estimates of the costs-per-dose from fixed and 
variable cost components, as well as the patterns of these costs overall and for a 
number of cost drivers. The cost drivers analysed in this chapter were: production scale 
and scope, vaccine technology types and vaccine formulations.  
Chapter 4, “A multilevel modelling analysis of viability factors for vaccine production in 
developing countries”, examined the viability determinants of developing country 
vaccine production. A three-level hierarchical panel dataset14 for a three-year period 
(2012 – 2014) was developed for this chapter. The dataset was compiled from 
disaggregated panel datasets developed by WHO, the World Bank, UNICEF and other 
relevant sources. Using global, domestic and export revenue sizes as well as global 
and export market shares as proxies for viability, the influence of a range of determining 
factors was analysed using multilevel regression. 
                                               
14 level one: vaccine type; level two: manufacturer; level three: producing country. The data 
structure was hierarchical/nested. 
35 
 
Chapter 5, “A mixed-effects model of the association between procurement factors and 
prices of vaccines produced by developing countries”, assessed the influence of 
procurement factors on vaccine prices from developing country manufacturers. Using 
a vaccine price database across 11 years (2005 – 2015), a mixed-effects regression 
was undertaken. The analysis was conducted at the transactional level, and a 
comparison was made between factors influencing prices of vaccines produced by 
developing countries in general, as well as by technology level, defined as traditional 
vaccine types and NUVs. 
Chapter 6, “Discussion”, interpreted the findings of the analyses presented in chapters 
3, 4 and 5 within the context of the overarching aim, examined their implications for 
global vaccine manufacturing policy and practice, outlined the study limitations and 
suggested future research work.  
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 Background 
2.1. Introduction 
This chapter reviews the existing literature on vaccine production in developing 
countries, particularly vaccines supplied to immunisation programs. The literature 
review is organised in nine sections. The next two sections (2.2 and 2.3) provide a 
historical perspective as well as the landscape of recent developments in vaccine 
production that have shaped DCVMs. An overview of the economics of vaccines is 
featured in section 2.4. This is then followed by sections 2.5 and 2.6 that present 
studies on the merit and challenges of DCVMs and their production viability. The last 
two sections of the chapter present existing literature on vaccine production costs and 
vaccine prices. This chapter closes with a summary and rationale of the three specific 
aims encompassing the thesis. 
2.2. Historical perspective 
Though there seems to be a clear divide at the present time between vaccine 
producers in developing countries and those in the industrialised world, vaccine 
producers before advent of the 21st century had many similarities, primarily in that they 
were not established for profit gains. Vaccine production in the past was mainly a 
government activity, and was meant to supply public health programs with newly 
developed vaccines. Vaccine manufacturers were mostly research institutes, hospitals 
and universities, while some were public-private, non-profit foundations such as the 
Mérieux Biological Institute and the Pasteur Institute. (Milstien, Costa, Jadhav, & 
Dhere, 2009; van Noort, 1992).  
As for the production of vaccines in developing countries, this was mainly initiated 
during the colonial era. During this period, international travel exposed citizens of 
colonizing countries to tropical diseases (de Knecht-van Eekelen, 1989; Moulin, 1992). 
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This, along with some non-colonized country requests15, instigated the Pasteur Institute 
in France to establish laboratories in various developing countries as early as 1891 
(Saigon, Vietnam) (Figure 2.1). Their mission was to research and develop products 
such as the Bacillus Calmette–Guérin (BCG) and diphtheria–tetanus–pertussis (DTP) 
vaccines as well as the rabies vaccine, anti-toxins and antivenins (Guénel, 1999) 
(Milstien et al., 2009). As documented by Dedet (2008) and shown in Figure 2.1, 57 
Pasteur Institutes were established world-wide, yet only 22 are still in operation (shown  
Figure 2.1 Pasteur Institutes worldwide in 2008. Note: (Not shown are associate institutes 
and recent creations). Round symbols: 22 Pasteur Institutes still in operation: 1: Institut Pasteur 
(Paris, France); 2: Institut Pasteur de Lille (France); 3: Institut Pasteur du Brabant (now 
Brussels, Belgium); 4: Institut Pasteur de St. Petersbourg (Russia); 5: Institut Pasteur de Rome 
(Italy); 6: Institut Pasteur hellénique (Greece); 7: Institut Pasteur de Tunis (Tunisia); 8: Institut 
Pasteur d'Algérie; 9: Institut Pasteur du Maroc (Casablanca, Morocco); 10: Institut Pasteur de 
Saigon (now Ho Chi Minh City, Vietnam); 11: Institut Pasteur de Nhatrang (Vietnam); 12: Institut 
Pasteur d'Hanoi (Vietnam); 13: Institut Pasteur de Phnom Penh (Cambodia); 14: Institut Pasteur 
de Dakar (Senegal); 15: Institut Pasteur de Côte d'Ivoire (Abidjan, Ivory Coast); 16: Institut 
Pasteur de Bangui (Central African Republic); 17: Centre Pasteur de Yaoundé (Cameroon); 18: 
Institut Pasteur de Madagascar; 19: Institut Pasteur de Guadeloupe (French West Indies); 20: 
Institut Pasteur de Guyane française (French Guiana); 21: Institut Pasteur de Teheran (Iran); 
22: Institut Pasteur de Nouvelle Calédonie (New Caledonia) Caledonia. Square symbols: 35 
Pasteur Institutes which are no longer in existence: 23: Institut Pasteur de Strasbourg (France); 
24: Institut Pasteur de Lyon (France); 25: Institut Pasteur de Martinique (French West Indies); 
26: Institut Pasteur de Tanger (Tangiers, Morocco); 27: Institut impérial de Bactériologie de 
Constantinople (Turkey); 28: Institut Pasteur de Kindia (Guinea); 29: Institut Pasteur de 
Brazzaville (Congo); 30: Institut Pasteur d'Ethiopie (Addis Ababa, Ethiopia); 31: Institut Pasteur 
de Bangkok (Thailand); 32: Institut Pasteur de Chengdu (China); 33: Institut Pasteur de 
Shanghai (China); 34: Institut Pasteur de Dalat (Vietnam); 35: Institut Pasteur d'Australie 
(Sydney, Australia). Reproduced from Dedet (2008). 
                                               
15 Iran, a non-western colony, requested that the Pasteur Institute in Paris establish a laboratory 
which is now known as the Pasteur Institute of Iran, in the aftermath of the influenza pandemic 
in 1918-1919. http://www.iranicaonline.org/articles/institut-pasteur-1  
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as yellow circles in Figure 2.1), and 35 establishments (shown as blue squares in 
Figure 2.1) no longer exist.  
Many of the public manufacturers in Europe and the United States later became 
privatised as a result of the various challenges faced. These challenges included 
issues around production management, the need to acquire new technologies, as well 
as the challenges to fulfil the progressing standards of good manufacturing practices 
(GMP), where the GMP is a global regulatory standard in vaccine production practices. 
A number of mergers and acquisitions then took place and have led to the emergence 
of multinational (MNC) vaccine companies, which have now become the dominant 
entities of the vaccines industry that we know today.  
DCVMs have also evolved. After the 1960s, particularly with political developments 
regarding sovereignty taking place within many developing countries, the status of 
vaccine manufacturers such as Pasteur Institutes have changed. As a result of 
negotiations with the Pasteur Institute in Paris, local institutions have either dissolved, 
remained linked or continued without the Pasteur affiliation (Brès & Chambon, 1982); 
(Milstien et al., 2009). 
2.3. Landscape of recent developments in the vaccine market 
Despite the success of immunisation programs established in the late 1970s, the 
subsequent advances and discoveries of new vaccines have not been equally 
accessible to developing countries. Mahoney and Maynard (1999) and Vandersmissen 
(2001) note that vaccines typically take between 20 – 30 years from first licensing, 
usually in the private market of developed countries, to reach the public markets in the 
developing world. Prior to the last 15 years, NUVs were disproportionately available to 
affluent countries, yet this has now changed thanks to the concerted efforts of public 
health advocates and international organisations.  
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2.3.1. Tiered pricing mechanism for vaccines 
In 2000, WHO called for a movement towards equity pricing based on income level 
classifications developed by the World Bank (WHO, 2001). The aim of this proposal 
was to enable the lowest prices for the poorest countries.  
Conceptually, in a tiered pricing mechanism producers charge different prices for 
different units of the same product, yet not due to the differences in costs.  Economic 
theory suggest that producers are still gaining profit from differentiating prices because 
it allows them to cater for 1) different buyers that are willing to pay a different amount 
for the same product, and 2) a buyer who is willing to pay a different dollar amount for 
different units of the same product. This way, a tiered pricing mechanism allows 
producers to capture some of the consumers' surplus that would otherwise go to buyers 
(Figure 2.2). 
 
Figure 2.2 The economic concept of a tiered pricing mechanism. 
Multiple prices permit a seller to capture consumers’ surplus. As seen in Figure 2.2, 
with differentiated prices, manufacturers may capture more of the consumers' surplus 
compared to a condition where it is only restricted to two different price levels. 
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The operation of tiered pricing is however dependent upon the ability of the producer 
to segment the markets in which different prices are charged. Since vaccines are a 
particular product which require certain conditions in their handling, leakage between 
markets is quite difficult. From an economic efficiency perspective, the more tiers linked 
to different prices and levels of development the better. Administratively however, the 
more complicated the system, the more difficult it will be to police any system and 
prevent parallel importation. 
The use of a tiered pricing system allows licensed vaccines to be accessed by the 
poorest countries without much delay. The rationale is that new vaccines can be made 
available to developing countries reduced prices, because these are offset by higher 
prices charged for the same product in more affluent markets. This way, manufacturers 
can recover their investments while making the product available in developing country 
markets at the same time. 
The development and support for tiered pricing was essential in enabling early 
introduction of newer vaccines in to the developing world. This mechanism was further 
advocated and enforced through a body known as the Global Alliance for Vaccines and 
Immunization (GAVI), which was established in January 2000. This alliance, later 
known as the GAVI Alliance, focused its efforts on supporting countries to introduce 
NUVs as well as support countries in strengthening their immunisation systems in 
coping with the introduction of new vaccines. GAVI procures its vaccines in bulk 
through UNICEF and PAHO’s pooled procurement mechanism. The prices of these 
vaccine are usually already tiered, and tailored to different markets. 
The success of tiered pricing was due to several factors. Firstly, the vaccines procured 
in the 1980s and 1990s were mostly similar across markets, enabling vaccine 
manufacturers to recoup their production costs by way of the tiered/differential pricing 
arrangement whereby they sold the same vaccines at higher prices to developed 
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countries, allowing for cost-recuperation while selling at lower and more affordable 
prices to developing countries. This was done through the coordination of the United 
Nations Children's Fund (UNICEF) and Pan American Health Organization (PAHO) 
(Batson, 2005). Secondly, vaccine manufacturers tended to keep an excess production 
capacity for many of the traditional vaccines, enabling them to supply vaccines at a low 
price to developing countries without having to invest in expanding production capacity. 
Thirdly, until the 1980s, the number of vaccine suppliers was large enough to maintain 
competition, effectively keeping vaccine prices low. Lastly, as described by Plahte 
(2005), tiered pricing, though often mistaken for a subsidy, in fact provides economic 
benefits for all parties involved: consumers in the lower priced market benefit from 
having access to a product that would not have otherwise been available; producers, 
who gain a larger revenue and profit; and consumers in the higher-priced market, who 
benefit from prices being slightly lower than if the tier-price mechanism wasn’t 
introduced.  
2.3.2. Market shaping strategies 
As advances in biotechnology enabled new and more advanced vaccine products, the 
demand for vaccines used in developed and developing countries however started to 
differ, and the dynamics of the market changed even further. Immunization programs 
in developed countries started to demand newer antigens and technology 
advancements on existing vaccines, taking them further from the traditional set of 
vaccines afforded by developing countries (Hausdorff, 1996). 
Tiered pricing is very much dependent on homogenous immunization schedules and 
demand across high and low income countries. Therefore, when vaccine requirements 
differ between developed and developing countries, it becomes difficult to maintain 
excess capacities and economies of scale, and in the end, price tiering becomes even 
more difficult to sustain. This market divergence phenomenon later became more 
prominent in the vaccine market and highlighted the need for new and longer-lasting 
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strategies (Jarrett, 2008; Levine, Kremer, & Albright, 2005; Milstien, 2010; Milstien et 
al., 2006). 
In response to market divergence between high and low-income countries, a number 
of market shaping strategies have been devised under the framework of push and pull 
mechanisms. A push mechanism provides a guarantee (Berkley, 2014) for developers 
to invest in R&D of a new drug; while pull mechanisms ensure that the product 
developed will be purchased.  
Though Kremer (2000) highlighted that there could be many risks to society in regards 
to push mechanisms due to adverse selection and moral hazard, some initiatives that 
have been developed based on the principles of push and pull mechanisms have 
showed a significant influence in the vaccine market. An example with regards to pull 
mechanisms is the advance market commitment (AMC), whereby a market is 
essentially created ahead of time so that vaccine manufacturers are willing to sell their 
vaccines at a price that would only be available at a much later timeframe. This strategy 
has been used to support countries in producing the pneumococcal conjugate vaccine, 
an NUV. The introduction time gap between high and low income countries was around 
five years (Figure 2.3). 
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Figure 2.3. Pneumococcal conjugate vaccine (PCV) introduction: high- and low-income 
markets. International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of 
Public Health. VIEW-hub Global Vaccine Introduction and Implementation Report, June 2016; 
and Batson (2014). 
 
The practices of push mechanisms have also produced significant results, such as 
through the development of the meningococcal strain A vaccine (Men-A) by the Serum 
Institute of India and the more recent dengue vaccine developed by Sanofi Pasteur in 
partnership with the International Vaccine Institute (IVI)’s Pediatric Dengue Vaccine 
Initiative (PDVI) (IVI, 2006; Sanofi Pasteur, 2013). The PDVI receives support from the 
Bill and Melinda Gates Foundation (BMGF), a major financier and investor in public 
health. While the market-shaping strategy for the Men-A vaccine, which was also 
supported by the BMGF, in its tendering process attracted many vaccine 
manufacturers including DCVMs16.  
Vaccines are also procured for the private markets in developing countries. Private 
markets are estimated to account for 5–10% of total vaccine sales in developing 
countries (WHO, 2016d). Private-sector demand mainly consists of more affluent 
                                               
16 Personal communication with SII representative. 
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population segments in developing countries that decide to take on responsibility for 
their own immunization, using preferred presentations not offered by the public sector. 
The private sector plays a generally small role on the demand side of vaccines except 
in some populated countries with rapid economic growth, where demand from middle 
classes for new and non-EPI vaccines can be of significant value. 
In recent decades, the importance of building capacity for vaccine production in 
developing countries has increased, particularly with the re-emergence of a highly 
pathogenic avian influenza (Hendriks et al., 2011). The Fifty-eighth World Health 
Assembly in 2005 (resolution WHA58.5) requested WHO to seek ways that would 
reduce the global shortage of influenza vaccines for both epidemics and pandemics, 
and encourage more R&D into new and improved vaccines (Friede et al., 2011). 
Among the resulting efforts, WHO supported the expansion of global manufacturing 
capability, particularly in developing countries, by creating a hub model for the 
technology transfer of influenza vaccines, which boosted the global capacity in an 
unprecedented timeframe. The Bill and Melinda Gates Foundation, a prominent 
supporter of global health, is in the midst of commissioning studies focusing on 
developing countries’ vaccine production and related costs (Shulman, 2014) (BMGF, 
2014). The Federal Ministry of Education and Research (BMBF) in Germany has also 
invested in developing countries’ vaccine production and capacity building, by 
supporting dengue vaccine production in Brazil and Vietnam (IVI, 2014). In addition, 
preliminary discussions are also underway to review the potential of increasing the 
capacity of local production in disproportionately low vaccine-producing regions, 
through initiatives such as the African Vaccine Manufacturing Initiative (AVMI) (KPMG 
Africa, 2014; UNIDO, 2014).  
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2.4. The economics of local vaccine production 
To fully understand how changes in the vaccine market have taken effect, it is important 
to understand the characteristics that make vaccines distinct from other pharmaceutical 
products. 
Vaccines are a type of pharmaceutical product that are of a biological nature and are 
typically used for disease prevention rather than treatment or cure (Milstien, Batson, & 
Wertheimer, 2005). Widespread use of certain vaccines has eliminated infectious 
diseases such as smallpox, and substantially reduced the incidence and mortality of 
respiratory infections associated with measles and pertussis; vaccines have the 
potential to protect unvaccinated people by reducing the circulation of infectious agents 
through a process called herd immunity.  
The definition of a vaccine provided by the WHO is as follows: “A vaccine is a biological 
preparation that improves immunity to a particular disease. A vaccine typically contains 
an agent that resembles a disease-causing microorganism, and is often made from 
weakened or killed forms of the microbe, its toxins or one of its surface proteins. The 
agent stimulates the body's immune system to recognize the agent as foreign, destroy 
it, and "remember" it, so that the immune system can more easily recognize and 
destroy any of these microorganisms that it later encounters.”  These characteristics of 
vaccines affect their production and the market in which they are supplied, in multiple 
ways.  
First is the vaccine’s biological nature and the fact that it is mainly administered to 
healthy individuals from populations that are often vulnerable17. This poses strong 
imperative on ensuring vaccine safety and efficacy, resulting in strict regulatory 
                                               
17 Such as infants, pregnant mothers and elderly individuals. 
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requirements for license approval that are often more stringent compared to other 
pharmaceutical products18.  
Second, as a public health instrument, the major purchasers of vaccines are usually 
governments. The use of public funds therefore, puts much pressure on the prices at 
which a manufacturer is able to sell its vaccines. These two pressures alone have led 
many manufacturers in the past to find the vaccine market unattractive, and to decide 
to leave the market (M. V. Pauly, 2005), leading to a higher level of market imperfection 
and market concentration (P. Danzon & Pereira, 2005; Hendriks, 2012).  
Third, the capital cost in producing vaccines, similar to other pharmaceuticals, is high; 
while compared to other pharmaceuticals products, the profit margins for vaccines are 
lower. Further, despite the lower dosage usually required for vaccines, the level of 
pricing that can be charged, particularly in developing countries, is significantly lower 
compared to other biologicals (Prifti, 2010; Sinclair, Latham, Wen, Ellis, and Pujar, 
2015). 
Finally, vaccines with different antigens have different markets that often do not overlap 
with one another19 (Arnould & DeBrock, 1996), resulting in high market concentrations 
within individual vaccine markets. Currently licensed vaccines prevent against up to 25 
different diseases, while the number of vaccine products available are much higher 
given that some are combination vaccines while some are formulated for different age 
                                               
18 There is no concept of a true generic product for vaccines. A vaccine made in a new facility 
is treated as a new vaccine and has to undergo rigorous preclinical and clinical studies to be 
approved for use, often requiring a dedicated facility for its manufacturing. Unlike drugs, where 
generics are made and licensed based on chemical equivalence, a simple bioequivalence is 
not adequate proof that a vaccine will be safe and efficacious. The implication of this is that 
producing a copy of an existing vaccine is still expensive and time consuming. 
19 Vaccine product that do not overlap with one another are those catered for distinctive 
diseases such as vaccines for Poliomyelitis and Hepatitis B. However some vaccines may be 
in competition with one another in the case of similar vaccines perceived as using more 
advanced methods, such as the oral poliomyelitis (OPV) and inactivated poliomyelitis (IPV) 
vaccines, also when combination forms are developed such as DTP-Hepatitis B-IPV vaccine. 
48 
 
groups and geographical needs20 (Smith, Lipsitch, & Almond, 2011) most of which 
become individual markets that do not compete with one another. Demand for a 
pentavalent vaccine (DTP, Hepatitis B and Hib) may not be equivalent to the demand 
for a quadrivalent vaccine (DTP and Hepatitis B only). Further, vaccine production 
involves a large range of biological agents, which allows very limited standardization 
of production process and outputs (Wang & Singh, 2013). In manufacturing a vaccine, 
the goal is to develop a process that can consistently produce vaccines that are safe 
and efficacious. This starts at the vaccine discovery stage, and up to the clinical study 
and commercial supply stages in which the requirement is that the vaccine can 
preserve the defined immunological properties from the discovery stage (Pujar et al., 
2014).  
Sinclair et al. (2015) suggest that the capital required to produce vaccines is higher 
than for other pharmaceutical products. They reported that the capital intensity21 of the 
biopharmaceutical industry, calculated as a percentage capital expenditure divided by 
total revenue, was 12.4%, which was much higher than the general pharmaceutical 
sector at 9%. This high capital intensity might explain the high costs of manufacturing 
vaccines, whilst indicating that cost reductions will be difficult to achieve. Sinclair et al. 
(2015) suggested that if manufacturing capital requirements do not change, the capital 
intensity value will increase further as health care providers and competitive products 
put increasing pressure on biopharmaceutical and vaccine pricing. 
Vaccines can be generally differentiated into three different groups, based on their 
market structure and characteristics (Table 2.1). 
 
                                               
20 Examples of vaccines for different age groups are the Pneumococcal conjugate (PCV) 
vaccine for infants and the Pneumococcal polysaccharide (PPS) vaccine for adolescents and 
adults. While examples of vaccines for different geographical needs are the Meningococcal 
strain C (Men-C) vaccine for UK and Australia; and the Meningococcal strain A (Men-A) vaccine 
for the African region. 
21 The level of capital intensity measures the amount of capital required per dollar of revenue 
generated. 
49 
 
Table 2.1. Vaccines categories, based on market structure and characteristics  
 
TRADITIONAL 
VACCINES 
NEW AND 
UNDERUSED 
VACCINES 
VACCINES IN 
DEVELOPMENT 
MARKET 
STRUCTURE AND 
CHARACTERISTIC 
 Typically 'mature' 
vaccines - in the market 
for decades 
 Saturated market 
 Off-patent products,  
 Sold at very low prices  
 Low marginal rates of 
return to producers. 
 Old technology 
 increasingly efficient to 
produce:  
 learning curve (over 
time) 
 economies of scale 
(cost/dose lowers as 
volume increases) 
 Limited incentive for 
R&D investment  
 Producers mostly local 
manufacturers in 
developing countries 
 Advanced version exist 
for a divergent market 
(marketed for 
developed countries 
 
 Slow adoption in 
developing countries, 
despite being available 
in developed countries 
for a long time 
 Though introduced at 
tiered prices, the price 
is higher than 
traditional (EPI) vaccine 
prices 
 Many supply chain 
systems in developing 
countries not yet 
adapted to incorporate 
NUVs 
 Inadequate national 
disease burden data 
 High sunk costs,  
 More advanced 
technology 
 Typically oligopoly (or 
duopoly) 
 Still on patent (‘product-
patent’ not ‘process-
patent’) 
 High incentive for R&D 
investment 
 Producers are mostly 
multinational firms. 
 Potential monopoly for first 
inventors 
 High incentive for R&D 
investment 
 Producers mostly 
multinational firms and 
biotechnology companies 
EXAMPLES  Poliomyelitis (OPV), 
 Tetanus,  
 Diphtheria,  
 Pertussis,  
 Measles, 
 Hepatitis B, 
 Haemophilus 
influenzae type b (Hib), 
 Meningococcal 
meningitis 
 Tuberculosis (BCG),  
 Yellow Fever 
 Cholera 
 Dengue 
 Hepatitis A 
 Hepatitis E 
 Human papillomavirus 
(HPV) 
 Influenza 
 Japanese encephalitis 
 Malaria 
 Mumps 
 Pneumococcal disease 
 Rabies 
 Rotavirus 
 Rubella 
 Tick-borne encephalitis 
 Typhoid 
 Varicella 
 Campylobacter jejuni 
 Chagas Disease 
 Chikungunya 
 Dengue 
 Enterotoxigenic 
Escherichia coli 
 Enterovirus 71 (EV71) 
 Group B Streptococcus 
(GBS) 
 Herpes Simplex Virus 
 HIV-1 
 Human Hookworm Disease 
 Leishmaniasis 
 Malaria 
 Nipah Virus 
 Nontyphoidal Salmonella 
Disease 
 Norovirus 
 Paratyphoid fever 
 Respiratory Syncytial Virus 
(RSV) 
 Schistosomiasis 
 Shigella 
 Staphylococcus aureus 
 Streptococcus pneumoniae 
 Streptococcus pyrogenes 
 Tuberculosis 
 Universal Influenza 
Vaccine 
Source: Adapted from Batson, Glass, and Seiguer (2003), WHO and other sources. 
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Manufacturers in developing countries mostly produce vaccines in the first and second 
category. By contrast, pipeline vaccines in the third category are mostly produced by 
multinational producers and biotechnology firms.  
Economic theory suggests that the supply of a product depends on the market that the 
producer faces. A limited number of multinational pharmaceutical firms dominate the 
global vaccine market (Figure 2.4). The role DCVMs in the global vaccine market is 
relatively small, but it is increasing over time (Figure 2.5). 
 
Figure 2.4.  Global vaccine sales by supplier (value) in 2012. Source: Batson (2014). 
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Figure 2.5.  Supplier origins and values of UNICEF vaccine purchases over time (2001 – 
2014). Source: Reproduced from Batson (2014). 
A huge gap however exists between vaccine markets in industrialised and developing 
countries, where the revenue of vaccine sales is still mainly driven by vaccine markets 
in industrialised or high-income countries (Figure 2.6) yet the majority of disease 
burden and global population in need of vaccines is found in developing countries 
(Figure 2.7). This gap poses a challenge for manufacturers globally, because 
sustainable production needs to be driven by economic incentives (Robbins & Arita, 
1994).  
Figure 2.6. Share of global vaccine markets in 2014. US$ approximate value. Source: 
Reproduced from Batson (2014) 
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Figure 2.7. Comparison of share of global disease burden and population sizes, in 2000 
and 2012. Disease Burden is % of total DALYs for Group I causes (communicable, maternal, 
perinatal and nutritional conditions). WHO data 
 
Sloan (2012) suggested that there may be an endogenous relationship between a 
country’s economic level, which constrains its ability to pay high vaccine prices, and 
the high prevalence of infectious diseases that would inhibit its economic growth. He 
further highlighted the irony that, despite the high social benefit of immunisation 
programmes, development of new vaccines, particularly those that prevent diseases in 
low-income countries, is likely to face underinvestment.  
2.5. Local vaccine production in developing countries 
Hausdorff (1996) suggested that developing countries have three options in obtaining 
new vaccines. They can either 1) procure the vaccine directly; 2) enter into an 
arrangement with a foreign manufacturer by having the new vaccine shipped in bulk 
then bottled and labelled domestically; or 3) make the vaccine entirely locally, perhaps 
after entering into a joint venture arrangement with another manufacturer. 
A survey of policy makers in developing countries conducted by DeRoeck (2004) 
concluded that local producers of vaccines in several countries have had an important 
role in locally influencing the introduction of vaccines either by initiating the 
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development of new vaccines or through the attainment of new technologies in 
vaccinology. Local production is also believed to drive down vaccine prices to a level 
where governments would be encouraged to consider their use (Muraskin, 1995).  
Milstien and Kaddar (2006) noted that an ideal source of R&D for diseases affecting 
developing countries is the countries where the diseases are endemic. Recent 
developments have shown an emergence of disease-specific, public-private 
partnerships stimulating research on vaccines for diseases that disproportionately 
affect people in developing countries. These partnerships have included efforts in basic 
research, vaccine development, joint production and clinical trials. 
Vaccine production has existed in over 55 countries across all income brackets, 
including 36 developing countries (Children's Vaccine Initiative, 1999)22. In 2014 
however, WHO data showed that this number has declined to a total of 33 countries 
that produce vaccines, of which 16 are developing countries, and specifically within the 
middle-income bracket (Plotkin, Orenstein, & Offit, 2013) (Figure 2.8). The decline in 
numbers of vaccine-producing countries has been mainly linked to challenges in 
production management and access to new technologies, as well as in meeting the 
continuously strengthened regulatory requirements for producing vaccines (Milstien et 
al., 2009).  
 
 
                                               
22 The CVI study reported that the vaccine producing countries were: Argentina, Bangladesh, 
Brazil, Bulgaria, Chile, China, Colombia, Croatia, Cuba, Czech Republic, DPRK, Ecuador, 
Egypt, India, Indonesia, Iran, Jordan, Mexico, Myanmar, Nigeria, Pakistan, Philippines, Poland, 
Romania, Russia, Senegal, Serbia, Slovakia, South Africa, South Korea, Thailand, Tunisia, 
Turkey, Uruguay, Venezuela and Vietnam. 
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Figure 2.8. Map of vaccine-producing countries in 2014. 16 developing countries23 that 
produce vaccines are shaded yellow and 17 industrialised countries that produce vaccines are 
shaded blue. 
Local production of vaccines is of particular interest to developing countries. Among 
the different arguments behind a government’s desire to manufacture new vaccines 
locally, securing adequate supply of vaccines is known to be a critical factor, mainly in 
countries with large populations (Munira & Fritzen, 2007; van Noort, 1992). Kaplan and 
Laing (2005) suggested several industrial policy reasons behind a country’s decision 
to invest in production. These are unmet or unavailable quality specifications produced 
elsewhere; design and process secrecy needs; existing supply being unreliable; 
wanting control over production schedules; local employment creation; interest in 
acquiring and upgrading domestic technology capacity; self-sufficiency in public health 
interventions; reduced reliance on imports; managing foreign exchange flow; and the 
desire to enter or expand into export markets.  
The need to increase capacity of local producers has also been discussed in the 
international forums. In 1978, discussions of local production were initiated by the WHO 
during the International Conference on Primary Health Care (WHO, 1978). The United 
Nations (UN) agencies also promoted strategies for local production using technology 
transfer arrangements aimed at acquiring more sophisticated technologies and 
                                               
23 Developing countries with national vaccine production as of 2014 are: Brazil, Bulgaria, China, 
Croatia, Cuba, Egypt, India, Indonesia, Iran, Mexico, Pakistan, Senegal, Serbia, Thailand, 
Tunisia and Vietnam. In 2014, Argentina moved from an Upper Middle Income country to a High 
Income Country.  
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increasing local capacity (UNCTAD, 2002). In 2003, the Commission on Intellectual 
Property Rights, Innovation and Public Health (CIPIH) was established during the 
World Health Assembly. The aims of CIPIH were to “review the interfaces and linkages 
between intellectual property rights, innovation and public health” and to “examine in 
depth how to stimulate the creation of new medicines and other products for diseases 
that mainly affect developing countries” (CIPIH, 2011). In its report in 2006, CIPIH 
discussed local production as a means to have affordable pharmaceutical products 
and to strengthen the bargaining position of developing countries for compulsory 
licencing (WHO, 2006). Some input-related barriers along with potential solutions were 
also highlighted in the report. Following the CIPIH report recommendations, the 
negotiations between WHO member states led to the adoption of the Global Strategy 
and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA-PHI), 
in 2008. Through GSPA-PHI, an emphasis on local production was renewed, that it be 
a “means to contribute to the overall goals of promoting technology transfer, innovation, 
capacity-building and improving access” (WHO, 2011b). 
Local vaccine producers play a crucial role in the establishment and maintenance of 
the WHO Expanded Program on Immunisation (EPI) (Jadhav et al., 2014; Munira & 
Fritzen, 2007). Many local producers, especially those that are publicly owned, often 
have exclusive supply arrangements with their governments, which provide them with 
a captive market in their respective countries (CVI, 1999; Mahoney & Maynard, 1999). 
Nevertheless, local production of vaccines is not an easy task, often faced with much 
scrutiny from the public, particularly with regards to patent issues and quality 
assurance. Mahoney and Maynard (1999) argued that, despite initiatives to stimulate 
vaccine research and development and improve public sector vaccine production in 
developing countries, it is not likely that developing countries will soon become 
significant players in basic and upstream applied vaccine R&D. This is further 
emphasized for the public sector where sources of external funding are spread thinly 
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among many pressing health priorities, and where sources of know-how are becoming 
less freely available. 
A study by McKinsey (2002), commissioned by GAVI and the World Bank, compared 
the choice of sourcing GAVI-programs with vaccines produced by multinational firms 
to those produced by DCVMs. The study findings recommended that GAVI source its 
procurement with readily available vaccines and technologies supplied by 
multinationals. An important assumption was that vaccines produced by emerging 
manufacturers would require a time trade off, because it would take time for these 
suppliers to access technology and establish supplies, including waiting for patent 
expiry on vaccines. The study also reported the lengthy time and high costs related to 
technology transfers of even simple conjugate vaccine technology, involving four to five 
years of technology transfer plus an additional five years to scale up to required 
capacity and obtain expensive raw materials and limited price advantages in 
developing countries. 
2.6. Viability of vaccine production 
Milstien, Batson, and Meaney (1997) published a landmark study on the viability of 
local vaccine production. Based on a series of country assessments, they analysed 
characteristics of viable or successful producers, and established a systematic method 
to evaluate the potential viability of producers in providing a reliable supply of existing 
and new vaccines. This study provided a structured way to analyse vaccine producers 
by identifying seven critical elements for viability, each defined by several factors 
(Table 2.2). Further, the findings refuted two popular assumptions: 1) that a lack of 
funds for state-of-the-art facilities is the primary barrier to viable vaccine production in 
developing countries, and 2) a large captive population is needed for viability. This 
study concluded that the most important factors for viable vaccine production were 
national wealth, or total GNP, and a commitment to invest in local vaccine production 
on the part of the government. 
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Table 2.2. Vaccine viability characteristics 
Viability elements Indicator 
1. Economic/scale  Number of children (population ~50 million) 
 Number of vaccines > 2 
2. Good Manufacturing Process (GMP) / 
consistency of production 
 Percentage of lots failed <5% 
 Consistent number of lots per year 
 Consistent number of doses per lot 
 Maintenance programme and budget 
 Planned, significant capital expenditure 
(CAPEX) per year 
 QA budget and programme 
3. New technology 
 
 Process development budget, programme 
 Research budget and programme 
 Realistic plan to meet national needs 
 Added new technology in last 5 years 
4. Historical performance/quality 
 
 Supply sufficient for national demand 
 Proven scale up in last 5 years 
5. Credibility of quality 
 
 Customer has choice 
 National Regulatory Authority (NRA) with six 
functions 
 NRA independent, with authority 
6. Management structure 
 
 Detailed 3 year economic plan 
 Price covers full cost-per-dose 
 Research on future demand 
 Human resource training plan 
 Appropriate ratio skilled/unskilled staff 
7. Legal status-autonomy 
 
 Control to set salaries 
 Control to hire and fire as necessary 
 Control over revenues, budgets 
 Political stability (number  of Health Ministers 
within last 5 years) 
Source: Excerpt from Milstien et al. (1997) 
The role of DCVMs has evolved over past 30 years. The focus has now shifted from 
developing countries acquiring the ability to manufacture a sustainable and sufficient 
supply of assured quality vaccines (W. Muraskin, 1998) to including viable vaccine 
producers in developing countries as partners in securing the global supply of vaccines.  
58 
 
Figure 2.9. The diversity of developing country manufacturers.  
The graph does not exhaust the list of developing country vaccine manufacturers. Adapted from 
Program for Appropriate Technology in Health (PATH)’s presentation to WHO, 2016 
 
The chart in Figure 2.9 shows the span of current local vaccine manufacturers across 
ownership and markets served24,25. At the present time, the question is no longer 
whether developing country manufacturers are able to produce sustainable and 
sufficient supply of high quality vaccines, because DCVMs are already major suppliers 
of vaccines. In recent decades, natural selection has driven inefficient suppliers out of 
the market. The question now is how to ensure, and assess, the viability of vaccine 
production in developing countries, and to determine whether the viability factors 
assessed previously are still relevant at the present time. Such an assessment will be 
conducted in Chapter 4, where the seven viability factors presented in the paper by 
Milstein and colleagues were assessed amongst several additional factors, in terms of 
their impact on revenue sizes and percent market share.  
                                               
24 The chart has been adapted to include only manufacturers that are not based in high income 
countries 
25 Using World Bank income bracket of GNI/capita below US$12,736. The complete list of the 
World Bank country classification is available in Table 2.1. 
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The global vaccine market witnessed a sharp contraction in the number of vaccine 
suppliers during the 1980s – 1990s due to pressures of liability and unattractive profits 
(Danzon & Pereira, 2011). However, the global vaccine market size has grown more 
rapidly than before (Figure 2.10), and the numbers of manufacturers and vaccine types 
that have achieved the World Health Organization’s (WHO) prequalification (PQ) status 
have also increased. (Figure 2.11).  
 
Figure 2.10. Global vaccine market (2000 – 2015).   
Data derived from Batson (2014), Kaddar (2013) and (Statistista, 2016) 
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Figure 2.11. Global production of prequalified vaccines (1986 – 2012). Data from WHO 
prequalified vaccine list. https://extranet.who.int/gavi/PQ_Web/Default.aspx. Accessed 
11/03/2016 
 
This increase in numbers of vaccines achieving prequalification status is an important 
development in global vaccine supply, because it not only indicates the number of 
vaccines available for public markets globally but also those of assured quality. From 
a manufacturer’s perspective, meeting the requirements of the PQ system provides 
access to the large vaccine market that is managed via bulk procurement by UN 
agencies such as the United Nations Children's Fund (UNICEF), WHO and the Pan 
American Health Organization (PAHO)26 (Figure 2.12).  
                                               
26 PAHO is WHO’s regional office in the Americas, and has established a procurement system 
using a Revolving Fund, operating since 1979 years now. 
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Figure 2.12. Trend of supply to UNICEF vaccine markets. Contract value to developing 
country manufacturers (DCMs) may include those awarded to countries such as South Korea 
which is no longer a developing country. UNICEF Supply Division data, 2015. Accessed 
16/10/2016  
 
A recent study by de los Angeles Cortes, Cardoso, Fitzgerald, and DiFabio (2012) 
noted the global vaccine market to be growing at a rate of 16.52% per annum, and 
highlighted that not all vaccine manufacturers operate on a level playing field, or are 
able to produce successful products. Their study finds that the challenges 
manufacturers face in timely production of efficacious products often stem from the 
biological nature of vaccines. Vaccine production requires more care to ensure stability 
and safety than other pharmaceutical products. The same rigour also applies to non-
originating vaccines27. 
                                               
27 The term non-originating is used in this thesis to differentiate between ‘originating vaccines’ 
that were developed by research-based manufacturers and vaccines produced by non-research 
based manufacturers through technology transfer mechanisms. 
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2.7. Vaccine production costs 
Different from other pharmaceutical products such as drugs, where generic or me-too 
products exist based mainly on bioequivalence28, a ‘generic vaccine’ technically does 
not exist (WHO, 2011a). This is because vaccines are complex biological products (as 
opposed to simple small molecule products which typify drugs). As a result, the actual 
process employed to produce a vaccine can have a significant effect on vaccine 
efficacy. By contrast, with drugs, different processes can be employed and yet still 
result in the same drug product. Therefore, vaccines produced through technology 
transfer processes, even when the originating vaccine’s patents have expired, are still 
required to undergo a clinical trial process or at a minimum, bridging studies where 
applicable29, whenever production is done in a new location or facility. Therefore the 
figures produced in estimating production costs of pharmaceutical products cannot be 
generalised to vaccine products, though some of the basic principles can be adopted.  
A number of published studies have proposed the mean estimates of R&D costs for 
pharmaceutical drugs, and highlight that variations exist across therapeutic areas, firm 
sizes and compound origins (DiMasi, Hansen, & Grabowski, 2003; Mestre-Ferrandiz, 
Sussex, & Towse, 2012; Pronker, Weenen, Commandeur, Osterhaus, & Claassen, 
2011). A study commissioned by the GAVI reviewed vaccine production costs, using 
multinational producers as a benchmark, suggested that similar variations also apply 
to vaccine production (Mercer Managment Consulting, 2002). 
In its 2015 industrial report, the pharmaceutical industry provided an estimate of 
US$2.6 billion as the average cost to develop a drug30. This was reported to be more 
                                               
28 the property where two products with identical active ingredients or two different dosage forms 
of the same product possess similar bioavailability and produce the same effect at the site of 
physiological activity. 
29 Bridging studies are often conducted for vaccine production via technology transfers where 
the vaccine is needed in time-pressing and public health objective, such as in pandemic 
situations. 
30 This estimate includes the cost of failures and is said for the period between 2000s and early 
2010s. 
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than double the cost estimated for the previous decade, which was in turn double the 
cost for two decades prior (PhRMA, 2015). Waye, Jacobs, and Schryvers (2013) in a 
systematic review provided a range of US$800 million to US$1.8 billion as the cost of 
drug development. Their review however suggested that “a similar statistic for vaccines 
is yet to be estimated, and it is unclear whether the cost of vaccines is similar to drug 
development”.  
Studies on vaccine production costs by DCVMs are mostly presented as costs-per-
dose, whilst studies on vaccine production by multinational companies usually focus 
on the capitalised fixed costs or R&D costs in total. Presenting an aggregate estimate 
of capital costs and/or R&D costs is important in that it provides evidence regarding the 
necessity of high prices of newer vaccines (in particular the large difference between 
marginal production costs and vaccine prices) for manufacturers to recoup their R&D 
investments as well as to sustain and motivate innovation in vaccine research.  
Though an industry-wide estimate may not yet exist specifically for vaccines, a number 
of studies have estimated the cost of producing vaccines at an individual product level. 
One of the earliest was the report by Mahoney (1990), who presented an estimate of 
producing a plasma-derived hepatitis B vaccine with an assumed production of four 
million doses. His estimates for the year 1989 showed the cost-per-dose ranged from 
$20 to around $0.10 as the production volume increased from small quantities to 20 
million doses per year. This study highlighted the effect of increasing the scale of 
production on reducing costs-per-dose. Another study by Mahoney et al. (2012) 
analysed the cost of producing a tetravalent dengue vaccine in Brazil and suggested 
that it would not exceed US$ 0.20 per dose in 10 dose vials and US$ 0.70 per dose in 
single dose vials when producing 60 million doses annually.  
In 2014, Chit et al. (2014) reviewed the production costs of a seasonal influenza 
vaccine and estimated that taking the vaccine from preclinical development in 2011 to 
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licensure in 2022 would cost $337–570 M Canadian dollars31. A more recent study by 
Herlihy, Hutubessy, and Jit (2016), which included a review of the producer surplus of 
the human papillomavirus (HPV) vaccine, provides an estimate of the development 
cost of the HPV vaccine of US$2.9billion. This was a much larger estimate than a 
previous study of rotavirus vaccines by Light, Andrus, and Warburton (2009), who 
estimated a cost of around $317–$974 million. However the latter study did not include 
failure rates, which is an important element in calculating the full cost of producing a 
successful vaccine product (Levin, 1983; Struck, 1996). Producer surplus is an 
economic concept that measures the difference between the amount a producer 
receives and the minimum payment it is willing to accept. This difference represents 
the benefit that the producer receives for the good or service it sells in the market. 
Further, a source of economic advantage for a producer can be obtained through 
economies of scale and economies of scope (Galambos & Sewell, 1997). Economies 
of scale occur when a manufacturer’s average costs lowers as a result of increasing 
its production scale of a single product type. In the case of producing vaccines, despite 
having such high fixed costs, an economies of scale can be achieved by increasing its 
batch size (GAVI, 2002). Economies of scope on the other hand, is obtained when 
average costs lower by producing more types of products (Lipsey, Ragan, & Courant, 
1997). For example, adding a new vaccine production line to an existing one may 
reduce the total average costs due to shared costs of administrative overheads for 
each vaccine, compared to the average cost of each vaccine being produced 
separately. Henderson and Cockburn (1996) observed the relationship between 
research productivity in the pharmaceutical with a firm’s size and discovered that larger 
firms were more productive by sustaining economies of scale and in particular due to 
economies of scope through diversifying its portfolios. Good coordination of growing 
                                               
31 At the time of the study the Canadian dollar was close to parity with the US dollar.  
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portfolios however is an important aspect in order to avoid diseconomies of scale 
(Mankiw, 2014).   
In addition to the published literature, a GAVI commissioned study by Mercer 
Management Consulting (2002) suggested that vaccine production costs vary 
significantly, ranging between $0.05 to $3-$4 per dose. The report suggested six 
factors that are main drivers of variation to these costs, among which are presentation, 
scale of production, method of vaccine inputs, location of production, size of vaccine 
batches, and vaccine production characteristics. Vaccine production characteristics 
include the amount of time, labour intensity and testing regimen required to produce a 
given vaccine.  In addition to these, vaccine manufacturing costs also depend on 
whether production is set up on a brownfield or greenfield production site. Brownfield 
production uses facilities built on pre-existing structures, usually involving a lower setup 
cost, depending on the level of refurbishment required and any complications 
associated with it. By contrast, greenfield production sites are built using completely 
new facilities. 
Among the published literature, only the studies by Mahoney (1990) and Mahoney et 
al. (2012) estimated the costs of production by DCVMs. In light of the tendency of 
developing countries to prioritise local production of vaccines, particularly when 
considering new vaccine introduction (see sub-section 2.3), it is important for such 
countries to evaluate the costs associated with establishing new vaccine 
manufacturing facilities. An analysis of cost structures for DCVMs is presented in 
Chapter 3.  
2.8. Vaccine prices 
Vaccine prices can influence a government’s decision to introduce a vaccine into their 
national immunisation programs. Prices of new vaccines, which are typically higher 
than traditional EPI vaccines (Hinman, 1999), are often quoted as a major impediment 
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to vaccine uptake, particularly in developing countries (Milstien, Munira, & McKinney, 
2003). However, vaccine prices often signal to manufacturers the potential revenue 
and profit that they would be able to generate should they choose to produce the 
vaccine locally. Therefore, the market price of a vaccine may influence a government’s 
decision to either source the vaccine locally or import it from external sources.  
Multiple studies have analysed the role of prices in influencing the demand and supply 
of vaccines (Arnould & DeBrock, 1996; Batson et al., 2003; Lee & McGlone, 2010; 
Milstien & Candries, 2000). Arnould and DeBrock (1996) suggested a number of ways 
that prices help indicate vaccine production viability. One is that the structure and 
movement of prices may reflect the “underlying behaviour of the industry and [can help] 
identify the extent and nature of market failure”. They suggest that increases in vaccine 
prices may indicate market imperfections or even monopolistic behaviour.  
In producing vaccines, scale plays a very important role in vaccine viability (Milstien & 
Candries, 2000). Vaccine manufacturers must make investment decisions on their size 
of production well in advance, often without certainty regarding revenue and quantities 
demanded. These decisions influence the prices of vaccines, particularly as a result of 
assumed production sizes and risks. Furthermore, competition has also been 
suggested to influence price (Milstien & Candries, 2000; Muraskin, 1995; Srinivas, 
2006). A study by Jadhav, Datla, Kreeftenberg, and Hendriks (2008) provided some 
examples of how declining prices have occurred as a result of competition from DCVMs 
entering the market. An example given was the Diphtheria-Tetanus-Pertussis-Hepatitis 
B combination vaccines, where prices dropped by 40% due to competition. By contrast, 
prices of Haemophilus-influenza type b (Hib) vaccines did not decline even after 5 
years of GAVI support. The latter was believed to be a result of a near monopoly market 
for the Hib vaccine. 
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Though the prices of vaccines tend to be strongly influenced by market forces, prices 
in domestic markets for local producers are influenced by additional factors. In her book 
chapter, Batson et al. (2003) highlighted findings from a number of field assessments 
of local vaccine producers conducted by WHO on behalf of the Children’s Vaccine 
Initiative (CVI). Based on these assessments, she reported that “vaccine prices were 
often set by the government and in many cases did not cover the full costs of the 
manufacturer, making it difficult for these entities to maintain the facilities, train staff, or 
invest in new vaccine research and development or production.” These requirements 
may affect the viability of local manufacturers.  
2.8.1. The Vaccine Product, Price and Procurement (V3P) project  
Another barrier to vaccine affordability is the presence of asymmetric information32. A 
WHO study by Results for Development (R4D) identified that a key barrier in vaccine 
procurement and pricing is a lack of access to information regarding vaccine products 
and prices from vaccine manufacturers and their procuring countries. In response to 
this, WHO developed a Vaccine Product, Price and Procurement (V3P) project in 2011. 
V3P’s objective was to improve transparency of public sector vaccine prices by creating 
a shared platform where procuring countries provide information regarding prices, 
products and procurement information on vaccines that they have purchased from 
manufacturers. The V3P database compiled information from procuring countries as 
well as from PAHO and UNICEF. As of 20 November 2016, the database included 
1394 transactions and corresponding prices of 55 vaccine products that were produced 
by 43 different vaccine manufacturers. These were located in one low income, 18 upper 
middle-income, 18 lower middle-income and 19 high income countries and included 
procurements over 11 years (2005 – 2015). The data included 9 transactions by a low 
income country, 398 transactions by a lower middle-income country, 423 transactions 
                                               
32 Also known as information failure, asymmetric information occurs when one party has more 
information than the other. This often provides more power towards the one with more 
information. 
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by an upper middle-income country and 564 transactions by a high-income country. 
The average price of vaccines reported by the V3P participating countries was $3.67, 
while the average prices for each vaccine reported to the V3P are shown in Table 2.3. 
The full database, as well as documents relating to vaccine pricing, are available on 
the WHO website: http://www.who.int/immunization/v3p. The project is expected to 
help countries make fully informed decisions when negotiating with vaccine 
manufacturers.  
The V3P dataset captures a subset of all vaccine transactions along with their prices 
and procurement terms and conditions, based on data reported by participating 
countries. To increase the validity of the data provided, WHO provides countries with 
a two-year period to report any necessary changes to the data they have provided. 
Table 2.3. Summary of vaccine prices-per-dose sold by vaccine manufacturers to V3P-
participating countries. 
 
Vaccine 
Weighted average 
price per dose 
(US$) 
Minimum 
price per dose 
(US$) 
Maximum 
price per dose 
(US$) 
Number of 
observations 
BCG 0.27 0.03 15.08 121 
bOPV1,3 0.16 0.13 0.33 9 
Cholera 0.47 0.47 0.47 1 
Diphteria 0.05 0.05 0.05 1 
DT (ped) 0.55 0.01 14.47 38 
DTaP 5.66 2.65 30.97 15 
DTaP-HepB-Hib-IPV 30.56 12.25 59.15 31 
DTaP-Hib 19.07 16.46 41.67 4 
DTaP-Hib-IPV 10.79 7.98 44.49 40 
DTaP-IPV 9.60 6.19 34.36 33 
DT-IPV 8.09 8.09 8.09 1 
DTP 0.15 0.01 3.14 46 
DTP-HepB 3.20 3.20 3.20 1 
DTP-HepB-Hib 2.09 1.19 5.10 69 
DTP-Hib 1.27 1.24 2.80 2 
HepA (adult) 18.61 15.36 34.26 12 
HepA (pediatric) 7.07 6.65 20.55 5 
HepA-HepB 41.22 37.72 45.12 2 
HepB (adult) 1.76 0.17 66.34 40 
HepB (pediatric) 0.86 0.16 11.41 103 
Hib 5.43 0.78 19.90 28 
HPV 22.96 5.00 103.49 41 
Influenza (seasonal - Adult) 4.13 1.12 12.73 49 
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Influenza (seasonal - Ped) 1.95 1.95 5.46 4 
IPV 3.32 0.00 42.18 43 
JE_Inactd 0.59 0.50 1.50 2 
JE_LiveAtd 5.77 0.42 27.27 7 
Measles 0.35 0.14 5.98 37 
MenA,C,Y,W-135 (conjugate) 36.11 14.21 41.99 5 
MenA,C,Y,W-135 (polysaccharide) 7.73 4.65 42.72 7 
MenA+C 9.29 9.29 9.29 1 
MenB 78.09 73.94 88.46 2 
MenC 17.30 8.98 82.19 19 
MMR 4.35 0.50 15.34 101 
MMRV 28.83 26.07 31.19 2 
mOPV3 0.23 0.22 1.31 2 
MR 0.73 0.52 1.73 20 
Mumps 0.71 0.71 0.71 1 
PCV 18.30 3.30 72.89 90 
Pneumo ps 12.26 7.52 21.23 20 
Rabies 5.30 2.86 101.91 15 
Rota 3.79 2.06 61.00 39 
Rubella 0.43 0.43 8.29 4 
TBE (adult) 3.95 2.93 17.86 5 
TBE (pediatric) 15.55 14.10 16.86 2 
Td (Adult) 2.43 0.00 26.51 74 
Tdap (booster) 12.38 4.21 24.04 25 
Tdap-IPV (booster) 8.82 8.72 22.97 6 
Td-IPV 13.58 12.54 15.01 3 
tOPV 0.17 0.01 7.67 77 
TT 0.15 0.00 7.65 55 
Typhoid 1.16 0.49 17.51 9 
Varicella 18.77 16.52 50.46 11 
YF 1.61 0.59 82.92 14 
Source: Data based on vaccine prices reported to WHO (2005 – 2015), based on 
transactions between V3P-participating countries and manufacturers from industrialised and 
developing countries. N = 1394. Last accessed 20/11/2016 
Though procuring vaccines at very low prices may be desirable for countries, it is also 
noted that prices need to be at a level that still encourages innovation and production 
of vaccines (Lieu, McGuire, & Hinman, 2005). The ability of vaccine manufacturers to 
recoup their investments and gain enough profit will help ensure the vaccines market 
retains and sustains adequate, viable suppliers. This in turn may help secure the global 
supply of vaccines.  
This thesis focuses on the prices that DCVMs set for their vaccines. An analysis of the 
determining factors of these prices is presented in Chapter 5. 
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2.9. Conclusions 
DCVMs play and important role in ensuring that the aims of immunisation programs in 
developing countries continue to be achieved. Building capacity for new vaccine 
production in developing countries is crucial to secure global supply of vaccines. Gaps 
in the existing literature regarding local vaccine production include: quantification of 
industry-wide production costs of vaccines manufactured in developing countries; 
quantification of the factors contributing to the viability of vaccine production by these 
manufacturers in the public health market; and the quantification of procurement 
factors’ influences on vaccine prices offered by DCVMs. These gaps are analysed in 
Chapters 3–5 of the thesis.  
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2.10. Appendices 
Appendix 2.1. World Bank country classifications 
Year: 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Low income (L) <= 875 <= 905 <= 935 <= 975 <= 995 <= 1,005 <= 1,025 <= 1,035 <= 1,045 <= 1,045 <= 1,025 
Lower middle income 
(LM) 
876-3,465 906-3,595 936-3,705 976-3,855 996-3,945 1,006-3,975 1,026-4,035 1,036-4,085 1,046-4,125 1,046-4,125 1,026-4,035 
Upper middle income 
(UM) 
3,466-10,725 3,596-11,115 3,706-11,455 3,856-11,905 3,946-12,195 3,976-12,275 4,036-12,475 4,086-12,615 4,126-12,745 4,126-12,735 4,036-12,475 
High income (H) > 10,725 > 11,115 > 11,455 > 11,905 > 12,195 > 12,275 > 12,475 > 12,615 > 12,745 > 12,735 > 12,475 
            
Afghanistan L L L L L L L L L L L 
Albania LM LM LM LM UM UM LM UM UM UM UM 
Algeria LM LM LM UM UM UM UM UM UM UM UM 
American Samoa UM UM UM UM UM UM UM UM UM UM UM 
Andorra H H H H H H H H H H H 
Angola LM LM LM LM LM LM UM UM UM UM UM 
Antigua and Barbuda H H H H UM UM UM H H H H 
Argentina UM UM UM UM UM UM UM UM UM H UM 
Armenia LM LM LM LM LM LM LM LM LM LM LM 
Aruba H H H H H H H H H H H 
Australia H H H H H H H H H H H 
Austria H H H H H H H H H H H 
Azerbaijan LM LM LM LM UM UM UM UM UM UM UM 
Bahamas, The H H H H H H H H H H H 
Bahrain H H H H H H H H H H H 
Bangladesh L L L L L L L L L LM LM 
Barbados UM H H H H H H H H H H 
Belarus LM LM UM UM UM UM UM UM UM UM UM 
Belgium H H H H H H H H H H H 
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Belize UM UM UM LM LM LM LM UM UM UM UM 
Benin L L L L L L L L L L L 
Bermuda H H H H H H H H H H H 
Bhutan L LM LM LM LM LM LM LM LM LM LM 
Bolivia LM LM LM LM LM LM LM LM LM LM LM 
Bosnia and 
Herzegovina 
LM LM LM UM UM UM UM UM UM UM UM 
Botswana UM UM UM UM UM UM UM UM UM UM UM 
Brazil LM UM UM UM UM UM UM UM UM UM UM 
British Virgin Islands .. .. .. .. .. .. .. .. .. .. H 
Brunei Darussalam H H H H H H H H H H H 
Bulgaria LM UM UM UM UM UM UM UM UM UM UM 
Burkina Faso L L L L L L L L L L L 
Burundi L L L L L L L L L L L 
Cabo Verde LM LM LM LM LM LM LM LM LM LM LM 
Cambodia L L L L L L L L L L LM 
Cameroon LM LM LM LM LM LM LM LM LM LM LM 
Canada H H H H H H H H H H H 
Cayman Islands H H H H H H H H H H H 
Central African 
Republic 
L L L L L L L L L L L 
Chad L L L L L L L L L L L 
Channel Islands H H H H H H H H H H H 
Chile UM UM UM UM UM UM UM H H H H 
China LM LM LM LM LM UM UM UM UM UM UM 
Colombia LM LM LM UM UM UM UM UM UM UM UM 
Comoros L L L L L L L L L L L 
Congo, Dem. Rep. L L L L L L L L L L L 
Congo, Rep. LM LM LM LM LM LM LM LM LM LM LM 
Costa Rica UM UM UM UM UM UM UM UM UM UM UM 
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Côte d'Ivoire L L L LM LM LM LM LM LM LM LM 
Croatia UM UM UM H H H H H H H H 
Cuba LM LM UM UM UM UM UM UM UM UM UM 
Curaçao .. .. .. .. .. H H H H H H 
Cyprus H H H H H H H H H H H 
Czech Republic UM H H H H H H H H H H 
Denmark H H H H H H H H H H H 
Djibouti LM LM LM LM LM LM LM LM LM LM LM 
Dominica UM UM UM UM UM UM UM UM UM UM UM 
Dominican Republic LM LM LM UM UM UM UM UM UM UM UM 
Ecuador LM LM LM LM LM UM UM UM UM UM UM 
Egypt, Arab Rep. LM LM LM LM LM LM LM LM LM LM LM 
El Salvador LM LM LM LM LM LM LM LM LM LM LM 
Equatorial Guinea UM UM H H H H H H H H UM 
Eritrea L L L L L L L L L L L 
Estonia UM H H H H H H H H H H 
Ethiopia L L L L L L L L L L L 
Faeroe Islands H H H H H H H H H H H 
Fiji LM LM UM UM UM LM LM UM UM UM UM 
Finland H H H H H H H H H H H 
France H H H H H H H H H H H 
French Polynesia H H H H H H H H H H H 
Gabon UM UM UM UM UM UM UM UM UM UM UM 
Gambia, The L L L L L L L L L L L 
Georgia LM LM LM LM LM LM LM LM LM LM UM 
Germany H H H H H H H H H H H 
Ghana L L L L L LM LM LM LM LM LM 
Gibraltar .. .. .. .. H H .. .. .. .. H 
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Greece H H H H H H H H H H H 
Greenland H H H H H H H H H H H 
Grenada UM UM UM UM UM UM UM UM UM UM UM 
Guam H H H H H H H H H H H 
Guatemala LM LM LM LM LM LM LM LM LM LM LM 
Guinea L L L L L L L L L L L 
Guinea-Bissau L L L L L L L L L L L 
Guyana LM LM LM LM LM LM LM LM LM LM UM 
Haiti L L L L L L L L L L L 
Honduras LM LM LM LM LM LM LM LM LM LM LM 
Hong Kong SAR, China H H H H H H H H H H H 
Hungary UM UM H H H H H UM UM H H 
Iceland H H H H H H H H H H H 
India L L LM LM LM LM LM LM LM LM LM 
Indonesia LM LM LM LM LM LM LM LM LM LM LM 
Iran, Islamic Rep. LM LM LM LM UM UM UM UM UM UM UM 
Iraq LM LM LM LM LM LM LM UM UM UM UM 
Ireland H H H H H H H H H H H 
Isle of Man H H H H H H H H H H H 
Israel H H H H H H H H H H H 
Italy H H H H H H H H H H H 
Jamaica LM LM UM UM UM UM UM UM UM UM UM 
Japan H H H H H H H H H H H 
Jordan LM LM LM LM LM UM UM UM UM UM UM 
Kazakhstan LM UM UM UM UM UM UM UM UM UM UM 
Kenya L L L L L L L L L LM LM 
Kiribati LM LM LM LM LM LM LM LM LM LM LM 
Korea, Dem. Rep. L L L L L L L L L L L 
Korea, Rep. H H H H H H H H H H H 
Kosovo .. .. .. LM LM LM LM LM LM LM LM 
Kuwait H H H H H H H H H H H 
Kyrgyz Republic L L L L L L L L LM LM LM 
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Lao PDR L L L L L LM LM LM LM LM LM 
Latvia UM UM UM UM H UM UM H H H H 
Lebanon UM UM UM UM UM UM UM UM UM UM UM 
Lesotho LM LM LM LM LM LM LM LM LM LM LM 
Liberia L L L L L L L L L L L 
Libya UM UM UM UM UM UM UM UM UM UM UM 
Liechtenstein H H H H H H H H H H H 
Lithuania UM UM UM UM UM UM UM H H H H 
Luxembourg H H H H H H H H H H H 
Macao SAR, China H H H H H H H H H H H 
Macedonia, FYR LM LM LM UM UM UM UM UM UM UM UM 
Madagascar L L L L L L L L L L L 
Malawi L L L L L L L L L L L 
Malaysia UM UM UM UM UM UM UM UM UM UM UM 
Maldives LM LM LM LM LM UM UM UM UM UM UM 
Mali L L L L L L L L L L L 
Malta H H H H H H H H H H H 
Marshall Islands LM LM LM LM LM LM LM UM UM UM UM 
Mauritania L L L L L LM L LM LM LM LM 
Mauritius UM UM UM UM UM UM UM UM UM UM UM 
Mexico UM UM UM UM UM UM UM UM UM UM UM 
Micronesia, Fed. Sts. LM LM LM LM LM LM LM LM LM LM LM 
Moldova LM LM LM LM LM LM LM LM LM LM LM 
Monaco H H H H H H H H H H H 
Mongolia L L LM LM LM LM LM LM LM UM LM 
Montenegro .. UM UM UM UM UM UM UM UM UM UM 
Morocco LM LM LM LM LM LM LM LM LM LM LM 
Mozambique L L L L L L L L L L L 
Myanmar L L L L L L L L L LM LM 
Namibia LM LM LM UM UM UM UM UM UM UM UM 
Nauru .. .. .. .. .. .. .. .. .. .. H 
Nepal L L L L L L L L L L L 
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Netherlands H H H H H H H H H H H 
New Caledonia H H H H H H H H H H H 
New Zealand H H H H H H H H H H H 
Nicaragua LM LM LM LM LM LM LM LM LM LM LM 
Niger L L L L L L L L L L L 
Nigeria L L L LM LM LM LM LM LM LM LM 
Northern Mariana 
Islands 
UM UM H H H H H H H H H 
Norway H H H H H H H H H H H 
Oman UM UM H H H H H H H H H 
Pakistan L L L LM LM LM LM LM LM LM LM 
Palau UM UM UM UM UM UM UM UM UM UM UM 
Panama UM UM UM UM UM UM UM UM UM UM UM 
Papua New Guinea L L L LM LM LM LM LM LM LM LM 
Paraguay LM LM LM LM LM LM LM LM LM UM UM 
Peru LM LM LM UM UM UM UM UM UM UM UM 
Philippines LM LM LM LM LM LM LM LM LM LM LM 
Poland UM UM UM UM H H H H H H H 
Portugal H H H H H H H H H H H 
Puerto Rico H H H H H H H H H H H 
Qatar H H H H H H H H H H H 
Romania UM UM UM UM UM UM UM UM UM UM UM 
Russian Federation UM UM UM UM UM UM UM H H H UM 
Rwanda L L L L L L L L L L L 
Samoa LM LM LM LM LM LM LM LM LM LM LM 
San Marino H H H H H H H H H H H 
São Tomé and Principe L L L LM LM LM LM LM LM LM LM 
Saudi Arabia H H H H H H H H H H H 
Senegal L L L L LM LM LM LM LM LM L 
Serbia .. UM UM UM UM UM UM UM UM UM UM 
Seychelles UM UM UM UM UM UM UM UM UM H H 
Sierra Leone L L L L L L L L L L L 
Singapore H H H H H H H H H H H 
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Sint Maarten (Dutch 
part) 
.. .. .. .. .. H H H H H H 
Slovak Republic UM UM H H H H H H H H H 
Slovenia H H H H H H H H H H H 
Solomon Islands L L L LM L LM LM LM LM LM LM 
Somalia L L L L L L L L L L L 
South Africa UM UM UM UM UM UM UM UM UM UM UM 
South Sudan .. .. .. .. .. .. LM L LM L L 
Spain H H H H H H H H H H H 
Sri Lanka LM LM LM LM LM LM LM LM LM LM LM 
St. Kitts and Nevis UM UM UM UM UM UM H H H H H 
St. Lucia UM UM UM UM UM UM UM UM UM UM UM 
St. Martin (French part) .. .. .. .. .. H H H H H H 
St. Vincent & the 
Grenadines 
UM UM UM UM UM UM UM UM UM UM UM 
Sudan L L LM LM LM LM LM LM LM LM LM 
Suriname LM LM UM UM UM UM UM UM UM UM UM 
Swaziland LM LM LM LM LM LM LM LM LM LM LM 
Sweden H H H H H H H H H H H 
Switzerland H H H H H H H H H H H 
Syrian Arab Republic LM LM LM LM LM LM LM LM LM LM LM 
Taiwan, China H H H H H H H H H H H 
Tajikistan L L L L L L L L L LM LM 
Tanzania L L L L L L L L L L L 
Thailand LM LM LM LM LM UM UM UM UM UM UM 
Timor-Leste L L LM LM LM LM LM LM LM LM LM 
Togo L L L L L L L L L L L 
Tonga LM LM LM LM LM LM LM UM UM UM LM 
Trinidad and Tobago UM H H H H H H H H H H 
Tunisia LM LM LM LM LM UM UM UM UM UM LM 
Turkey UM UM UM UM UM UM UM UM UM UM UM 
Turkmenistan LM LM LM LM LM LM UM UM UM UM UM 
Turks and Caicos 
Islands 
.. .. .. .. H H H H H H H 
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Tuvalu .. .. .. .. LM LM UM UM UM UM UM 
Uganda L L L L L L L L L L L 
Ukraine LM LM LM LM LM LM LM LM LM LM LM 
United Arab Emirates H H H H H H H H H H H 
United Kingdom H H H H H H H H H H H 
United States H H H H H H H H H H H 
Uruguay UM UM UM UM UM UM UM H H H H 
Uzbekistan L L L L LM LM LM LM LM LM LM 
Vanuatu LM LM LM LM LM LM LM LM LM LM LM 
Venezuela, RB UM UM UM UM UM UM UM UM UM H UM 
Vietnam L L L L LM LM LM LM LM LM LM 
Virgin Islands (U.S.) H H H H H H H H H H H 
West Bank and Gaza LM LM LM LM LM LM LM LM LM LM LM 
Yemen, Rep. L L L L LM LM LM LM LM LM LM 
Zambia L L L L L LM LM LM LM LM LM 
Zimbabwe L L L L L L L L L L L 
Note: GNI per capita in US$ (Atlas methodology). Changes in classification indicated in light green. Presentation is limited to years relevant to thesis: 2005 – 
2015. Source: World Bank historical country classification, 2016 
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 The cost structure of establishing new 
vaccine manufacturing facilities in developing 
countries 
3.1. Introduction 
As outlined in the previous chapter, a review of the literature found that research on 
individual vaccine production costs is limited and that published studies that have 
quantified and characterised industry-wide vaccine production costs in developing 
countries are still lacking. (Mahoney, 1990; Mahoney et al., 2012; Oliver Wyman, 2007; 
Pronker et al., 2011). An assessment of cost structure and cost behaviour is important 
to understand whether developing countries can produce and offer vaccines at an 
affordable price. It is also important information to justify whether such investments are 
sustainable. This is especially necessary because local vaccine production often 
involves public funds in developing countries, where budgets are particularly 
constrained, and vaccine production competes with numerous other investment 
priorities. Therefore, a careful analysis is required on whether local vaccine production 
is suitable for each country that expresses interest. 
Local production is known to be an important consideration for governments when 
seeking access to new vaccines (Clemens, 2003; Hendriks, Liang, & Zeng, 2010; 
Munira & Fritzen, 2007; W. Muraskin, 1996; Woodle, 2000). A study commissioned by 
the World Health Organization (WHO) and the CVI 33 surveyed local vaccine 
manufacturers to understand their motivations. They discovered that the primary 
motivations are based on political and strategic objectives, and that economic 
inefficiencies alone may unlikely result in a decision to cease production (Blanc & 
Brewer, 1999). The need to secure sufficient supply of vaccines is critical to ensure the 
                                               
33 Now defunct 
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success of immunisation programs. However such investments must meet certain 
measures of cost efficiency in order to be justified. 
In general, establishing vaccine production in a country comprises of different step. 
Firstly is the establishment of a facility and acquisition of equipment, followed by 
upstream processes involving pre-clinical and clinical trials at the start of a new 
production; these components are called the Clinical Development stage. This process 
depends on whether the vaccine technology used is novel or reinvented from 
originating/existing products. Once completed, there are two manufacturing phases - 
bulk vaccine production and filling processes, which are known as the Bioprocess 
Development stage. An assay development stage is done afterwards where different 
testing are conducted, including tests for purity, stability and potency (Figure 3.1).  
  
 
Figure 3.1.  Process of vaccine development. Adapted from various sources; including 
Plotkin, Orenstein, and Offit (2013), H. L. Levine (2010); and Technology Transfer Initiative, 
WHO. Note: In some instances, vaccine manufacturers establish bulk manufacturing 
construction prior to Phase III clinical trials but after Phase I and Phase II clinical trials show 
promising results.   
 
Many countries have approached the WHO indicating their interest in establishing new 
vaccine facilities. There is a common perception within the public sector that local 
production of health products will ensure a country’s self-sufficiency, less dependency 
on foreign currency and means of enhancing capacity in the science and technology 
sector. An earlier study by the CVI however found that these perceptions are often 
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unfounded (Milstien, 1999). For example, in cases where raw materials are imported, 
capital expenditures may be higher due to high interest rates on loans, and lower-cost 
facilities and poorer regulatory process may pose challenges in achieving standards of 
good manufacturing processes (GMP). 
For a newly built vaccine production facility to be sustainable, the output and revenue 
must generate returns that can justify the investment. Investors, either governments or 
funding agencies, must be able to have a clear plan as to how long subsidies, if any, 
will be required and at what scale. An understanding of the costs to research and 
develop a vaccine will help countries estimate the required size of investments involved 
and evaluate the appropriateness of the prices achieved for vaccines produced. 
Lang and Wood (1999) argue that vaccine costs-per-dose is a primary driver in 
predicting the adoption of new EPI vaccines, and assessments should be made at each 
stage from research to production and delivery of vaccines to identify whether the 
potential cost-per-dose ensures production is competitive in the current market. 
Milstien and Batson (1998) discussed a joint WHO/UNICEF commissioned report by 
Mercer Management Consulting in 1993, which presented an economic model of 
vaccine production highlighting that the number of doses produced by a vaccine 
manufacturer was inversely related to the cost-per-dose.  
Only two studies, by the same group of authors, have quantified cost-per-dose of 
vaccines produced in a developing country (Mahoney, 1990; Mahoney et al., 2012). 
These papers evaluated 1) the cost of producing an existing plasma-derived hepatitis 
B vaccine by an unidentified manufacturer (Mahoney, 1990) and 2) a candidate vaccine 
which is the live attenuated dengue vaccines developed by Instituto Butantan, Sao 
Paulo, Brazil (Mahoney et al, 2012). In the first study, a hypothetical 50-million 
population country was assumed with the production done in two distinct facilities, one 
for producing the bulk antigen without adjuventing, and the other for the adjuventing 
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process, sterile filling, and vaccine packaging. The results of the first study found that 
the vaccine can be sold at US$0.50 per dose packed in10-dose vials, if about 4 million 
doses per year were procured, with a condition that about 8% of total production is sold 
in the private sector for a profit. The study also identified the need for an initial capital 
investment of around US$3.7 million (1990 prices). The study also found that if the 
model was extended to the quantity of 10 to 20 million doses per year, the vaccine can 
be sold for less than US$0.10 per dose, similar to other EPI vaccines. The study 
concluded that the hepatitis B vaccine would be viable when large-scale procurement 
is undertaken by governments and international donor agencies. 
The second paper assess a candidate tetravalent vaccine which was in the later stages 
of development. The economic analysis used a standard industrial methodology, 
applying accepted accounting practices, originally developed at the US National 
Institutes of Health (National Institute of Allergy and Infectious Diseases). The direct 
costs of materials, direct costs of personnel and labor, indirect costs, and depreciation 
were all determined, and assumed a production of 60 million doses per year. The study 
was not aimed at identifying the price of the final licensed vaccine, and concluded that 
the vaccine could be made available at a price affordable to governments in developing 
countries.  
This chapter adopts a similar approach to assessing cost drivers as these two studies, 
but for a larger number of countries and vaccine types. The aims of this chapter were 
firstly, to calculate the costs-per-dose of establishing local vaccine production in 
developing countries based on data provided by existing vaccine producers; and 
secondly, quantify the variability of these costs across different driving factors, namely 
production scale and scope, as well as vaccine technology and formulation types. The 
findings will allow non-producing developing countries to inform their plans to establish 
new vaccine manufacturing facilities, by estimating the cost required to establish a new 
vaccine facility and to bring a vaccine to market. 
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This chapter is organised as follows: the production cost data used in the analysis are 
described in section 3.2, followed by the results of the cost structures, patterns and 
comparison to vaccine market prices in both developing and industrialised country 
markets in section 3.3. A secondary analysis on the economic benefits of fill-finish 
mechanisms in comparison to procuring finished products is also presented in section 
3.3, followed by a discussion, study limitations and conclusions in section 3.4. 
3.2. Methods 
Cost production data, as in any industry, are of a sensitive nature and are proprietary 
information. This is especially the case in the vaccines industry, where competition is 
high because the number of companies in the industry is limited and the entry and exit 
barriers are high. Given the commercial sensitivity of the data from manufacturers, this 
study uses a questionnaire for data collection rather than accessing actual cost data. 
The data were collected based on self-reporting of cost figures in the form of ranges, 
where the range options were based on existing assumptions in the discipline (Friede, 
2013; Mahoney, 1990; Mahoney et al., 2012) The questionnaire was sent to ten 
manufacturers, in which nine manufacturers provided data and of these, eight were 
DCVMs. The questionnaire included questions 11-15 to identify manufacturers in case 
this information was accidently missed during the colelction. The answers for these 
questions however were not reported to maintain the respondents’ annonymousity.  
3.2.1. Data collection 
The questionnaire was developed under close supervision of two senior vaccine 
experts in WHO, based on the existing literature and industrial practice regarding 
vaccine cost estimations (Friede, 2013; Mahoney, 1990; Mahoney et al., 2012). An 
early draft of the questionnaire was reviewed in consultation with eight experts in 
vaccine production and costing (Table 3.1). This involved three rounds of pretesting 
before the final version was created.  
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Table 3.1. List of experts consulted on questionnaire development 
Expert 1 Senior vaccine economist, former WHO staff 
Expert 2 Vaccine economist, former WHO staff 
Expert 3 Senior pharmaceutical industry expert, UNIDO 
Expert 4 Pharmaceutical industry expert, UNIDO consultant 
Expert 5 Vaccine expert, PATH 
Expert 6 Senior vaccine expert, former WHO staff 
Expert 7 Senior vaccine expert, WHO staff 
Expert 8 Senior vaccine expert, WHO staff 
 
By using hypothetical scenarios of different production scales and scope that 
respondents are asked to provide their expert judgement on, the questionnaire was 
designed to ensure comparability of the data collected across different companies. This 
is important given that different cost accounting methods are used in different 
companies and different tax policies exist in different countries34. The questionnaire is 
presented in Appendix 3.1. 
Ten vaccine producers with senior management positions were contacted by a senior 
vaccine expert in WHO during an annual meeting of the DCVMN. The data were 
collected during this meeting to maximise efficiency. The completion of the 
questionnaire were unsupervised and followed up via face to face and postal method 
for clarification and confirmation of responses. Nine of the ten respondents provided 
responses, and eight respondents qualified as a developing country vaccine 
manufacturer. The respondents were later contacted to clarify the answers provided 
and to ask for any mission information in their responses to the questionnaire. A 
presentation showing preliminary results from the questionnaire was made to the 
respondents in a subsequent DCVMN-related meeting, where respondents along with 
other DCVMs were present. During the meeting, the respondents were also 
approached again to clarify any unclear responses from the questionnaire.  
                                               
34 Personal communication with Kristopher Howard, vaccine industry expert and UNIDO 
consultant 
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Each respondent was asked to consider a specific vaccine product upon which they 
based their responses and was asked to estimate three types of cost associated with 
production of that vaccine. The first was fixed costs associated with facility and 
equipment costs; the second was development costs which are semi-fixed costs; and 
the third was variable costs related to bulk-dose release and fill-finish costs for a single 
unit of vaccine produced. 
Fixed costs 
Economics theory defines fixed costs as indirect costs or overheads that are spent at 
the onset of production and are not dependent on the level of goods or services 
produced (Solberg, 1982). The respondents were asked to indicate, based on their 
experiences with fixed costs, estimates for three different hypothetical scenarios of 
production of scale and scope, assuming greenfield production, where building 
facilities are set up on completely new infrastructure. These scenarios were:  
Scenario A: A production scale of 20 million doses per year, producing 1 vaccine. 
Scenario B: A similar set up as in Scenario A, but producing 5 vaccines instead of 1. 
This scenario allowed assessment of shared costs from producing more vaccines in a 
single facility. 
Scenario C: A much larger production scale of 100 million doses per year, for the same 
number of vaccines as Scenario B (5 vaccines). This allowed estimation of the potential 
cost savings of a much larger production scale than in scenario B. 
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In estimating fixed costs, manufacturers were asked to provide figures that included 
buildings, equipment, quality control (QC) laboratories, utilities, administration and 
offices. The scenarios above are only applied to fixed cost estimations35. 
In addition to the three greenfield scenarios, an additional Scenario D was presented 
to respondents in which estimates were generated. This scenario assumes brownfield 
production, where facilities are built on pre-owned and existing infrastructure. In this 
scenario, the production scale was for 100 million doses of one additional vaccine. This 
scenario did not provide a direct comparison with the production scale and scope of 
the other scenarios, therefore the estimates will be presented independently as a fixed 
cost figure (Figure 3.2), but not included in the observation of economies of scale and 
economies of scope. 
Semi fixed costs 
Semi-fixed costs are defined as costs that contain components of both fixed and 
variable costs (Solberg, 1982). Fixed costs are costs that are spent irrespective of the 
level of output, while variable costs increase proportionally to production levels. Semi-
fixed costs in vaccine production are costs that are not dependent on the number of 
vaccine vials produced but are spent each time a new vaccine type is manufactured in 
the facility. R&D costs would fall under this category. DCVMs however, do not typically 
expend R&D costs to the level of novel vaccines, where very large sums of money are 
spent on preclinical studies. In the context of local vaccine production in developing 
countries, semi fixed costs are usually spent on validation batches and/or technical 
transfer costs.  
The R&D costs required in local vaccine production depend on whether the vaccine is 
an originating or non-originating product, with the latter being more common for 
                                               
35 The fixed cost estimations under each Scenario assumptions is reflected in the resulting 
annualised capital costs and total average costs-per-dose. 
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developing country manufacturers. R&D costs in non-originating vaccines are based 
on the costs of validation batches, whereas for novel vaccines, the costs would include 
preclinical and clinical trials. In the case of vaccines produced through technology 
transfer arrangements, R&D costs would also depend on the stage in which the 
technology transfer arrangement was conducted. Technology transfer vaccines 
provided at a more ready or advanced stage may not require all three clinical trials and 
have lower failure rates but may incur higher transactional fees given the lower risk of 
the product.36 
For this expense, respondents were asked to provide estimates for the R&D cost of 
bringing a vaccine product to market. This includes costs on personnel, pre-clinical and 
Phase I, II, III clinical trials and supplies. Respondents were also asked to estimate the 
average failure rates associated with such a development. These failure rates are 
important to economically estimate the contribution of attrition costs to the full cost of 
production. 
Variable costs 
Within the context of vaccine production, variable costs are expenditures related to 
downstream processes, including: fill and finishing of each vaccine batch produced 
(Appendix 3.1). For this component, respondents were asked to provide two different 
variable costs, relevant to downstream processes. The first question asked for the cost 
of goods required for vaccine manufacturing, estimated per bulk dose released. These 
costs only included running costs such as labour, materials and maintenance, with no 
account of R&D, buildings or equipment. In the second question, respondents were 
asked to provide estimates of the costs of filling. These were comprised of costs of 
vials or syringes, stoppers, labels, QC, and release.  
                                               
36 Personal communication with biotechnological expert, Ines Atmosukarto.  
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Given the variability of vaccine formulation presentations, respondents were also asked 
to identify costs based on four common vaccine presentations, these are: multi-dose 
vial (in this case a 10-vial dose), single-dose vials, pre-filled syringes and a lyophilised 
(or freeze dried) dose. 
Economic benefit of fill-finish mechanisms versus procuring finished vaccines  
Respondents were asked to estimate, based on their experiences, the economic 
benefit of procuring antigens as bulk doses in comparison to procuring finished 
vaccines for both traditional and modern vaccines. This economic benefit was 
estimated by the differences reported between the two procurement methods, by 
different vaccine technologies (traditional and modern vaccines) and production scale 
(1-5 million doses and 10–20 million doses)37 (see question number 10 in Appendix 
3.1).  
Comparison to vaccine market prices 
To assess how the estimated costs generated in this analysis would perform in both 
developing country and industrialised country markets, a comparison was made with 
market prices of vaccines in both markets. Vaccine market price data were obtained 
from a WHO database for the Vaccine Product, Price and Procurement (V3P) project38. 
These data, reported by countries, included prices of vaccines procured by low, middle 
and high income countries over 11 years (2005 – 2015). For the purpose of this 
analysis, the market price data used were for 2014. The data for 2014 included prices 
for 48 vaccine types, produced by 31 vaccine manufactures, procured and reported by 
41 different countries. A separate analysis on vaccine prices is presented in Chapter 
5. 
                                               
37 An example was provided to the responded as follows: if procuring finished vaccine costs 
$10 for a vial but fill-finish vaccine costs $4 ($3 for bulk purchase + $1 for filling) the benefit 
would be 60%. 
38 Data as of 15 August 2016 
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To have a comparable analysis, the price data from the V3P database were aggregated 
by similar cost drivers applied to the questionnaire data. These were: vaccine 
formulation presentations (i.e.: multi-dose, single-dose, prefilled syringe and 
lyophilised) and vaccine technology types (i.e.: all, bacterial, viral, combination, 
recombinant and conjugate vaccines). The vaccine price data included additional 
estimates for vaccines using lyophilised with pre-filled formulations, which will be 
presented though not compared to the cost data, which did not include information for 
this vaccine type. A price index from the V3P data was constructed and compared to 
the cost index, across comparable cost drivers. 
Given that manufacturers face two different vaccine markets: those of industrialised 
and developing countries; the comparison was presented for both markets separately. 
3.2.2. Analysis 
The assumptions used in the analysis were adopted from studies by Mercer 
Management Consulting (2002), Mercer Management Consulting (2006), Mahoney 
(1990), and Mahoney et al. (2012). The analysis in this chapter however differed from 
these studies in that it included opportunity costs, by incorporating the cost of failure 
rates and an annualisation factor (Levin, 1983; Pronker et al., 2011). Opportunity costs 
were included to ensure that the total economic costs of production were accounted 
for and represented in the vaccine costs-per-dose estimations. This annualisation 
factor(𝑎), takes into account the depreciation and interest rate on the remaining or 
undepreciated value, for which the following factors need to be quantified: the 
replacement cost and lifespan of the capital, and the rate of interest that is foregone by 
investing in vaccine production rather than any other alternative investment (Levin, 
1983). Life year assumptions were applied to each fixed and semi-fixed cost 
component: buildings, equipment and validation batches. These assumptions were 
adopted from Mahoney et al. (2012) as follows: buildings and equipment were 
assumed to have 25 and 10 year lifespans respectively. For semi-fixed costs of 
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validation batch production, the analysis used the life-year applied to equipment (10 
years) with the assumption that validation batches are required when a new piece of 
equipment and/or facility is used.  
To calculate the cost-per-dose, all three components were added as follows: fixed 
costs and semi-fixed costs both annualised and averaged over total doses produced, 
together with variable costs, also as an average cost-per-dose. The analysis did not 
differentiate between bulk doses produced in-house and those that were imported. The 
currency of analysis was US dollars. Where a different currency was provided in the 
questionnaire response, an exchange rate at the time of data collection was used39. 
From the estimates obtained, three main comparisons were conducted:  
 To establish the effect of increases in production scale on cost-per-dose, scenarios 
B and C were compared, where production increased from 20 million doses to 100 
million doses annually, with five vaccines produced in each facility. This 
comparison was labelled as (A1).  
 To establish the effect of an increase in production scope on cost-per-dose, 
scenarios A and B were compared, where production scale was the same but the 
scope, or number of vaccine types produced, increased. This comparison was 
labelled as (B1). 
  A comparison between the production scale effect to that of the production scope 
effect was conducted (A1 versus B1). 
Annualised fixed cost-per-dose 
The annualised fixed cost-per-dose was calculated by adopting the following formula 
(Butler, 1990; Levin, 1983): 
𝑪𝒂 = (𝑽 − 𝑹)𝒂        Equation 3.1 
                                               
39 The exchange rate was based on an online currency converter service (http://www.xe.com/).  
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where 𝐶𝑎 is the annualised capital cost of equipment, obtained by multiplying the 
acquisition cost of the equipment V, after deducting its estimated residual value R, by 
an annualisation factor a.   
Further, the annualisation factor was calculated as follows: 
𝒂 =
𝒓(𝟏+𝒓)𝒏
(𝟏+𝒓)𝒏−𝟏
        Equation 3.2   
              
where r is the annual interest rate and n is the life of the equipment (in years) and the 
residual value R is assumed to be zero. Using standard industry practices40, the interest 
rates for buildings was 10%, while for equipment it was 5%. The reference for life years 
of buildings and equipment used by Mahoney et al. (2012) was adopted and fixed costs 
were assumed to be made up of two-thirds of facility costs and one-third of equipment 
costs. These were then divided by the total number of doses produced in each 
production setting. 
Annualised capital costs 
Annualised capital costs consist of annualised fixed costs-per-dose41 and annualised 
semi-fixed costs-per-dose (Mahoney, 1990). Each of these components was 
calculated using the assumptions mentioned earlier. 
Variable costs 
For the variable costs of the bulk-dose released and fill-finish processes, estimates 
were taken from the different questionnaire responses and followed up with 
respondents to clarify and complete the dataset. Following the study by Mahoney 
(1990), factory overheads were calculated as 15% of the total of direct materials and 
inputs, plus direct manpower and labour; while administrative overheads were 
                                               
40 Reference to (classified) Hexavalent vaccine proposals to WHO from manufacturers 
41 Termed “depreciation” in Mahoney (1990). 
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assumed to be 5% of that same total. The variable costs were presented as variable 
costs-per-dose. 
Total average cost-per-dose 
The total average cost was obtained by the summation of the fixed cost-per-dose, 
semi-fixed cost-per-dose and variable cost-per-dose, for each vaccine observed, as 
described below (Equation 3.3)  
Fixed costs per dose        a 
Semi-fixed costs per dose       b___+ 
Capital costs per dose     a+b 
Variable costs per dose       c___+ 
Total average costs per dose (a+b)+c  Equation 3.3    
As in Mahoney (1990), the estimates were summarised as follows:  
 Raw Materials & Direct Labour, equalled the fill and finish costs; 
 Assay Costs, equalled the bulk-dose release costs; 
 Indirect costs, equalled 15% of the total of the two costs above as factory overhead, 
plus 5% of the same total for administrative overheads;  
 Depreciation, which was the annualised capital cost-per-dose; and  
 Total cost-per-dose, the sum of all of the above. 
Further, to analyse the cost behaviour of vaccines, an index was constructed using the 
total average cost-per-dose as the index base (1.00). All other costs-per-dose were 
compared against this figure, to display metrics of the cost drivers relative to the overall 
average (Oliver Wyman, 2007). 
To address the uncertainty in the data and assumptions used in the analysis, a 
sensitivity analysis was conducted on the cost-range of the fixed cost responses, range 
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of success rates responses, as well as the assumptions used for the annualisation 
factor.  
3.3. Results 
3.3.1. Cost structures 
Fixed costs 
On average, fixed costs based on the 12 observed vaccines were respectively 
US$ 47.5 million, US$ 80 million and US$ 147.1 million for Scenarios A, B and C, 
respectively. Further, the average estimate provided for Scenario D was US$ 18 
million. (Figure 3.2).  
 
 
Figure 3.2. Calculations of fixed costs for vaccine facilities in developing countries, 
based on four hypothetical scenarios. Scenario A: 20 million annual doses – 1 vaccine 
(Greenfield); Scenario B: 20 million annual doses – 5 vaccines (Greenfield); Scenario C: 100 
million annual doses – 5 vaccines (Greenfield); Scenario D: 100 million annual doses – 1 
vaccine (Brownfield) 
 
Theoretically, fixed costs are generally not influenced by the number or volume of 
outputs produced. However, all of the responses indicated that as production scale and 
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production scope increased, fixed costs in vaccine production have a step-costs 
pattern, where higher fixed costs are required when the current production surpasses 
a certain threshold.  
Semi-fixed costs 
R&D costs in bringing a vaccine to market were estimated to be an average of $16.9 
million, with vaccine type-specific estimates of between $7.5 million (combination 
vaccines) and $80 million (novel vaccines). One respondent provided an estimated 
figure ranging between US$ 500 million to US$ 1 billion, however as this was assumed 
to be taken from the existing literature (DiMasi et al., 2003; Pronker et al., 2011), rather 
than being an empirical observation, this estimate was excluded from the analysis.  
The respondents estimated the success rates to be an average of 75%, ranging from 
55% (novel vaccines) to 98% (combination vaccines). This was inversely correlated 
with the R&D costs reported above. The novel vaccines included in this chapter 
analysis, which showed the lowest success rates, were produced under technology-
transfer arrangements. These are shown in Figure 3.3. 
Figure 3.3. Estimations of R&D costs and success rate of vaccine production in 
developing countries. Estimations are based on eight DCVM responses. 
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Annualised capital costs 
The annualised capital costs (Figure 3.4) were on average US$ 0.37, US$ 0.11 and 
US$ 0.040 per dose across scenarios A, B and C, respectively. Capital costs-per-dose 
were found to be lower as production scale and scope increased.  
 
Figure 3.4. Estimations of annualised capital cost-per-dose for vaccine produced in 
developing countries. Based on information provided by eight DCVMs on 12 vaccine 
examples. Figures are based on four hypothetical scenarios. Scenario A: 20 million annual 
doses – 1 vaccine (Greenfield); Scenario B: 20 million annual doses – 5 vaccines (Greenfield); 
Scenario C: 100 million annual doses – 5 vaccines (Greenfield); Scenario D: 100 million annual 
doses – 1 vaccine (Brownfield). 
Variable costs 
The average variable cost-per-dose were US$ 1.77 for a one million dose production, 
and US$ 1.74 and US$ 1.15 respectively for 20 million and 100 million dose 
productions (Figure 3.5).  
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Figure 3.5. Estimations of variable costs of vaccine production in developing countries. 
Information based on 12 vaccine examples provided by eight DCVMs. 
Average costs-per-dose 
The overall average costs-per-dose were found to be US$ 2.3 (Scenario A), US$ 2.02 
(Scenario B) and US$ 1.82 (Scenario C). The costs lowered as production scale and 
scope increased (from Scenario A – C). This was also consistent across both observed 
cost drivers: vaccine technology types and formulation presentation (Table 3.2 and 
Figure 3.6).  
Table 3.2. Estimations of average cost-per-dose for vaccines produced in developing 
countries, with standard deviations.  
Categories Scenario A  
(SD) 
Scenario B 
(SD) 
Scenario C 
(SD) 
Technology All $ 2.30 
(0.91) 
$ 2.02 
(0.86) 
$ 1.82 
(0.78) 
Bacterial $ 2.32 
(0.97) 
$ 2.02 
(0.87) 
$ 1.82 
(0.77) 
Viral $ 2.26 
(0.83) 
$ 2.02 
(0.85) 
$ 1.83 
(0.80) 
Recombinant $ 2.56 
(1.16) 
$ 2.18 
(0.99) 
$ 1.72 
(0.63) 
Conjugate $ 2.06 
(0.63) 
$ 1.77 
(0.63) 
$ 1.72 
(0.63) 
$1.77 
$2.32 
$1.94 
$1.20 
$3.17 
$1.56 
$9.60 
$0.38 
$2.12 
$3.11 
$2.79 
$1.74 
$3.60 
$1.77 
$1.20 
$3.60 
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Novel $ 4.58 
- 
$ 3.80 
- 
 
Formulation Multi-dose $ 1.26 
(0.38) 
$ 0.99 
(0.38) 
$ 0.92 
(0.39) 
Single-dose $ 2.24 
(0.36) 
$ 1.97 
(0.36) 
$ 1.90 
(0.36) 
Pre-filled 
syringe 
$ 2.59 
(1.07) 
$ 2.26 
(0.89) 
$ 1.93 
(0.74) 
Lyophilised $ 3.04 
(0.36) 
$ 2.81 
(0.38) 
$ 2.54 
(0.52) 
Note: Data based on 12 vaccine examples provided by eight DCVMs. Estimations based on 
three hypothetical scenarios. Scenario A: 20 million annual doses – 1 vaccine; Scenario B: 20 
million annual doses – 5 vaccines; Scenario C: 100 million annual doses – 5 vaccines. 
 
 
Figure 3.6. Estimations of average cost-per-dose for vaccines produced in developing 
countries. Data based on 12 vaccine examples provided by eight DCVMs. Estimations based 
on three hypothetical scenarios. Scenario A: 20 million annual doses – 1 vaccine; Scenario B: 
20 million annual doses – 5 vaccines; Scenario C: 100 million annual doses – 5 vaccines. 
3.3.2. Cost patterns 
In comparing production scenarios A, B and C (Figure 3.6), two observations can be 
made; first, that average costs-per-dose were lower as production scale and production 
scope increased. This was consistent across all vaccine technology categories. 
Second, across vaccine formulations, the average cost-per-dose increased (in 
ascending order): from multi-dose to single-dose, pre-filled syringe and lyophilised 
vaccine formulation. The cost index also showed similar results for formulation types, 
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while for technology types, production was most costly for novel and recombinant 
vaccines, whereas technologies such as viral, and conjugate vaccines were less costly 
(Table 3.3). 
Table 3.3.  Cost index of vaccine production in developing countries, based on three 
hypothetical scenarios 
Cost drivers Categories Scenario A Scenario B Scenario C 
Technology 
All 1.00 1.00 1.00 
Bacterial 1.01 1.00 1.00 
Viral 0.99 1.00 1.00 
Recombinant 1.12 1.08 0.95 
Conjugate 0.90 0.88 0.95 
Novel 2.00 1.89 0.00 
Formulation 
Multi-dose 0.55 0.49 0.51 
Single-dose 0.98 0.97 1.04 
Pre-filled 
syringe 
1.13 1.12 1.06 
Lyophilised 1.33 1.39 1.39 
Note: Average cost-per-dose was used as the base index (1.00) and values shown are 
multiples of the base index. 
Economies of scale 
Economies of scale (A1) occur when the cost-per-dose decreases as the volume size 
(production scale) increases. This was observed in the study by comparing Scenario 
B to Scenario C. The results show that the economies of scale for all vaccine types 
was an average of 9.5%, meaning that  increasing the production scale from Scenario 
B to C (from 20 million doses to 100 million doses) will reduce the cost-per-dose of the 
vaccine by 9.5% (Figure 3.7). The economies of scale, across vaccine technology 
types, were highest in recombinant vaccines (20.9%) and lowest in conjugate vaccines 
(2.8%). The economies of scale for novel vaccines were not observable because 
responses for novel vaccines in Scenario C were not available. Across vaccine 
formulations, the highest economies of scale were found in pre-filled syringe vaccines 
(14.7%) and lowest in single-dose vaccines (3.3%).   
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Figure 3.7. Estimations of economies of scale and economies of scope for costs-per-
dose of vaccines produced in developing countries. A1: Economies of scale; B1: 
Economies of scope. Data based on three hypothetical scenarios. Scenario A: 20 million annual 
doses – 1 vaccine; Scenario B: 20 million annual doses – 5 vaccines; Scenario C: 100 million 
annual doses – 5 vaccines. 
Economies of scope 
Economies of scope (B1) occur when cost-per-dose lowers due to multi-product 
manufacturing, and was observed by comparing Scenarios A and B. Figure 3.7 shows 
that economies of scope were present in general and across all cost drivers at an 
average of 12.2%. Among vaccine technology types, economies of scope were highest 
in recombinant vaccines (14.9%) and lowest in viral vaccines (11.1%). For vaccine 
formulations, the economies of scope were highest in multi-dose vaccines (21.7%) and 
lowest in lyophilised vaccines (7.7%).  
Comparing economies of scale to economies of scope (A1 vs B1) 
A comparison between economies of scale and economies of scope show that though 
the economies of scale and economies of scope for costs-per-doses were both positive 
across all vaccines observed; on average, the economies of scope were higher than 
the economies of scale (12.2% versus 9.5%). Further, the economies of scope had a 
smaller range (7.7% to 21.7%) than economies of scale (2.8% to 20.9%). With the 
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exception of recombinant vaccines and prefilled syringe vaccines, the economies of 
scope were higher than economies of scale for the different vaccine technology types 
and formulation presentations (Figure 3.7). 
3.3.3. Market price comparisons 
Comparison in industrialised-country markets 
Figure 3.8 shows the comparison between costs-per-dose in Scenarios A, B and C and 
the price-per-dose of vaccines, within the industrialised-country market. The costs-per-
dose estimated from the analysis was much lower than the vaccine price-per-doses 
reported being procured in industrialised vaccine markets. This suggests a producer 
surplus can be gained in this market (Herlihy et al., 2016). 
 
Figure 3.8. A comparison of estimated developing country vaccines’ costs-per-dose 
based on hypothetical Scenarios A, B and C to prices-per-dose paid by industrialised 
countries. Costs based on scenarios: Scenario A: 20 million annual doses – 1 vaccine; 
Scenario B: 20 million annual doses – 5 vaccines; Scenario C: 100 million annual doses – 5 
vaccines; Price data for industrialised countries from V3P database, WHO (2014). 
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Figure 3.9 shows that the pattern of the costs-per-dose index was similar to that of the 
price-per-dose index in industrialised-country markets, with the exception of pre-filled 
syringes, lyophilised vaccines and recombinant vaccines. Cost-per-dose data were not 
available for combination vaccine types nor lyophilised with pre-filled syringe vaccines 
formulations, therefore a comparison to the price index could not be made. 
 
Figure 3.9. A comparison of estimated developing country vaccines’ cost index based 
on hypothetical Scenarios A, B and C to price index for industrialised country vaccine 
markets. Costs based on scenarios: Scenario A: 20 million annual doses – 1 vaccine; Scenario 
B: 20 million annual doses – 5 vaccines; Scenario C: 100 million annual doses – 5 vaccines; 
Price data for industrialised countries from V3P database, WHO (2014). Index base (1.00) for 
cost and price indexes used average of all vaccines. 
 
Comparison in developing-country markets 
A similar comparison was made for the developing-country markets. Figure 3.10 shows 
that the overall average costs-per-dose was relatively lower than the vaccine prices-
per-dose in developing-country markets. Vaccine categories where the reported prices 
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were lower than the estimated costs were recombinant vaccines, multi-dose vaccines 
and (only slightly) lyophilised vaccines.  
 
Figure 3.10. A comparison of estimated developing country vaccines’ costs-per-dose 
based on hypothetical Scenarios A, B and C to prices-per-dose paid by developing 
countries. Costs based on scenarios: Scenario A: 20 million annual doses – 1 vaccine; 
Scenario B: 20 million annual doses – 5 vaccines; Scenario C: 100 million annual doses – 5 
vaccines; Price data for developing countries from V3P database, WHO (2014). 
 
Figure 3.11 shows the pattern of the costs-per-dose index to be similar to the price-
per-dose index in developing-country markets. The only differences were in 
recombinant vaccines and pre-filled syringes and lyophilised vaccine presentation 
types. There were also no comparable cost index estimates for the price index of 
combination vaccines and lyophilised with pre-filled syringe vaccines. 
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Figure 3.11. A comparison of estimated developing country vaccines’ cost index  based 
on hypothetical Scenarios A, B and C to price index paid by developing countries. Costs 
based on scenarios: Scenario A: 20 million annual doses – 1 vaccine; Scenario B: 20 million 
annual doses – 5 vaccines; Scenario C: 100 million annual doses – 5 vaccines; Price data for 
industrialised countries from V3P database, WHO (2014). Index base (1.00) for cost and price 
indexes used average of all vaccines. 
 
3.3.4. Economic benefit of fill finish mechanisms versus procuring finished 
vaccines 
Six of the eight respondents provided estimates of the economic benefits of vaccines 
procured as a finished product as opposed to establishing a fill and finish mechanism 
for bulk material, as shown in Figure 3.12. Overall, the economic benefit was reported 
to be higher when vaccines are procured as antigen and filled locally, for high volume 
procurement and in modern vaccines. 
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Figure 3.12. Estimated economic benefit of procuring antigens and filling compared to 
procuring finished vaccines. Data based on six DCVMs, e.g: if procuring finished vaccine 
costs $10 for a vial but fill-finish vaccine costs $4 ($3 for bulk purchase + $1 for filling) the benefit 
would be 60%. 
 
3.3.5. Sensitivity analyses 
Using the lower bound of the fixed cost ranges provided by the respondents, the results 
showed a similar pattern of step fixed costs, yet the difference was that fixed cost 
estimates for recombinant, conjugate and novel vaccine technologies were 
considerably lower in Scenario B where the production scope increased from one 
vaccine to five vaccines. Yet the annualised capital cost which is made of fixed costs 
and semi fixed costs per dose, lowered as the production scale and scope increased 
maintained a similar patter to the original analysis. Similarly for total average costs-per-
dose, there were no differences. The results from using the upper bound did not 
present any significant difference in regards to the cost structures. The comparison 
between costs and market prices in developing country markets also showed a similar 
pattern to the original analysis. Using the lower bound for success rates also did not 
show any significant difference in cost structures. Economies of scale and economies 
of scope were found in all the sensitivity analyses conducted. Lowering the discount 
0%
10%
20%
30%
40%
50%
60%
70%
A B C D E F
Traditional vaccines - 1 – 5 M doses/year
Traditional vaccines - 10 – 20 M doses/year
Modern vaccines - 1 – 5 M  doses/year
Modern vaccines - 10 – 20 M doses/year
 
 
 
40 -60% 
  
 
 
 
   
20-40% 
 
 
 
 
 
0 – 20% 
105 
 
rates (5% for building and 1% for both equipment and validation batches) and life years 
(10 years for building and 5 years for both equipment and validation batches) did not 
show any significant differences to the original analysis. 
3.4. Discussion 
The study found that the overall average cost-per-dose of establishing new vaccine 
facilities in developing countries were reported to be highest for Scenario A, followed 
by Scenarios B and C respectively, indicating both economies of scale and scope. The 
estimated costs-per-dose across all cost drivers ranged between US$ 0.92 (Scenario 
C for multi-dose vaccines) and US$ 4.40 (Scenario A for novel vaccines). These 
estimates are in agreement with the costs suggested in the report by Mercer 
Management Consulting (2002), which used a multinational manufacturer as its 
benchmark and found costs ranging between $0.05 to $3-$4 per dose. The study also 
showed that the estimated cost-per-dose by formulation types followed the pattern 
typically found in industrial practices42, that is the average cost-per-dose increased (in 
ascending order) from multi-dose to single-dose, pre-filled syringe and lyophilised 
vaccine formulation. 
Under the three hypothetical scenarios, costs-per-dose of vaccines produced by 
developing countries were on average 47% lower than vaccine prices in developing-
country markets and 84% lower than prices in industrialized country markets. This 
suggests that a producer surplus may be attainable for both markets, in which the 
difference will allow for profit that can support sustainable production.  
Comparing the potential price-cost margin for specific vaccine types, the result show 
that DCVMs have the potential to obtain producer surpluses in vaccine technology 
types such as bacterial and conjugate vaccines for the developing-country markets, 
and conjugate and novel vaccines for industrialised markets. The potential producer 
                                               
42 Personal communication, vaccine production expert Jan Hendriks. 
106 
 
surplus in developing country markets can be obtained for pre-filled syringe vaccines. 
As for industrialised country markets, the potential for producer surplus would be in 
multi-dose and single-dose vaccines. 
A comparison of the cost index and price index for industrialised vaccine markets 
showed a similar pattern between the two, with the exception of pre-filled syringes, 
lyophilised vaccine formulations and recombinant vaccine types. For developing-
country markets, the pattern was similar, with the exception of recombinant vaccine 
types and formulations with pre-filled syringes and lyophilised vaccines.  
A general observation of the fixed costs was that there are an economies of scale and 
economies of scope in the vaccine costs-per-dose across the different scenarios 
examined. However, the fixed costs required across these different scenarios suggest 
a pattern of step fixed costs in establishing new vaccine manufacturing facilities in 
developing countries. These step fixed costs occur whereby, upon passing a certain 
production threshold43, a higher fixed costs is required, mainly due to the equipment 
capacity used for manufacturing vaccines in these different settings. The presence of 
this step cost feature emphasises the importance of demand forecasting for vaccine 
manufacturers. Uncertainties exist in demand forecasting, particularly in developing 
countries as well as in the case of pandemics, which poses a great problem for 
manufacturers. This step cost feature however also implies that the cost estimates 
generated in this Chapter may not be applicable to production scale and scope settings 
that are different from the ones used in the analysis. 
Economies of scale and economies of scope were found to exist across vaccine 
production scenarios. The lowest economies of scale were found in the conjugate 
vaccine category while the highest were in recombinant vaccines. By formulation 
                                               
43 i.e.: from single to multiple vaccine facilities, or production scales of 20 million doses to 100 
million doses, or the combination of these. 
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category, the lowest economies of scale were found in single-dose vaccines and the 
highest in pre-filled syringes. Economies of scope however, were lowest in bacterial 
vaccines and highest in recombinant vaccines. By formulation category, the lowest 
economies of scope were in lyophilised vaccines and highest in multi-dose vial 
vaccines. These findings suggest that despite the high fixed-cost requirements in 
establishing new vaccine manufacturing facilities (Sloan, 2012), setting a production 
scale at 20 million annual doses and above as well as establishing a multiproduct 
facility can reduce the final costs-per-dose.  
Though results from this study suggested that local vaccine production, which involves 
mainly the production of pre-existing vaccines, would have fixed costs that are lower 
than those of manufacturing pipeline vaccines, large scale and scope of production are 
still required in order to maintain costs-per-dose at a level close to the marginal costs.  
Vaccine facilities of these scenario sizes however may not be attainable or sustainable 
for many countries, including those wanting to invest in local vaccine production. This 
is especially true given that vaccine manufacturers would normally need to first secure 
and sustain their domestic market before expanding into export markets, where 
competition and regulatory requirements are more challenging44.   
The failure rates of developing country manufacturers were an average of 
approximately 25% (range 3% – 55%). This range was significantly lower than what 
was found by Pronker et al. (2011) who found a wide variety of figures across different 
studies, ranging from 7% to 78%. Their study however covered originating vaccines or 
new chemical entities where success rates are notoriously low (Struck, 1996). 
This is not entirely surprising given that vaccines produced by developing country 
manufacturers are mostly developed through technology transfer arrangements that 
                                               
44 Personal communication with vaccine industry expert in WHO, Martin Friede 
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have passed some if not all of the development and preclinical steps. Additionally, the 
R&D costs in developing countries were found to be much lower and to have higher 
success rates than those of drug products and vaccines produced by multinational 
companies. This is also not surprising given that the R&D required in vaccine 
production by developing countries is usually done in a technology transfer context. 
Given that several (or all) clinical trial phases might be required, the success rates for 
novel vaccine production would be much lower and certainly more costly than for other 
vaccine types (Pronker et al., 2011; Struck, 1996). 
The cost estimations under Scenarios A, B and C compared to the V3P price data 
suggest that our estimates were lower than prices reported in industrialised country 
vaccines markets. Given the divergence market phenomenon45, whereby vaccine 
demand is increasingly divergent between different geographical regions and income 
levels, manufacturers in developing countries that are interested in supplying to the 
vaccines markets in industrialised-countries may encounter a different set of 
epidemiological demands and needs than current clientele in developing country 
markets (Jarrett, 2008; Pauly & Cleff, 1996). 
This chapter used the 2014 data from the V3P database as an indication of market 
prices of vaccines. The figures show that the vaccine prices in industrialised and 
developing country markets are structured differently across the different vaccine 
technology types. Prices for some technology categories between these two markets, 
relative to their respective overall average price, are either different (i.e.: higher in 
industrialised markets but lower in developing country markets) or are in the same 
direction yet more pronounced. The most notable differences would be in the 
categories of bacterial vaccines (higher than the average in developing countries yet 
lower than the average in industrialised countries) and combination vaccines (higher 
                                               
45 Please refer to Chapter 2, section 2.3 
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than average in both markets but more pronounced in the industrialised market). For 
formulation types, differences are pronounced for single-dose vaccines (close to 
overall average in developing country markets and more than double in the 
industrialised market), prefilled syringes (significantly higher than average in 
developing country markets, yet not in industrialised markets) and lyophilised with 
prefilled syringe vaccines (opposite to that found in prefilled syringe vaccines). These 
differences may affect the cost – price comparison between the two markets, therefore 
the comparisons are treated separately. Also important to note is that these vaccine 
prices are likely to include subsides available through market access initiatives by 
agencies such as GAVI. However, the prices that developing country vaccine 
manufacturers must compete against in the market are those that are reported in the 
V3P database. Further, to assess the affordability of vaccines produced by developing 
countries would require a budget impact analysis which assess the affordability of a 
certain product or treatment while taking into account the resources and budget 
constraints in context. 
With regards to the difference in cost for brownfield and greenfield production, the fixed 
costs for brownfield facilities (Scenario D) were as low as US$ 18 million compared to 
scenarios using greenfield facilities (US$ 48 million, US$ 80 million and US$147 million 
for Scenarios A, B and C respectively) (Figure 3.2). However there was no direct 
comparison for the production scale and scope in the scenario for brownfield (scenario 
D) to the other scenarios using greenfield production (Scenarios A, B and C), without 
making some assumptions about the applicability of the findings from the other 
scenarios to the brownfield scenario. Such comparisons could form the basis of future 
research.  
With regards to the economic benefits observed by local vaccine manufacturers 
between the options of procuring finished vaccines and procuring antigens to then be 
filled locally, the results suggest that the economic benefit of the latter is higher for 
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new/modern vaccines and for vaccines procured in larger volumes (10 – 20 million 
annual doses compared to 1 – 5 million doses). These results confirm the findings by 
Mestre-Ferrandiz et al. (2012) that type (viral, bacterial or combination vaccine), and 
technology (new or traditional) are driving factors in the cost of vaccine production. 
The findings in this study also complement those of Mercer Management Consulting 
(2002), Mahoney (1990) and Mahoney et al. (2012), who highlighted that capital 
expenditure constitutes a large proportion of the cost; and that the size of capital 
expenditure plays a big role in determining the cost-per-dose. Cost-per-dose is highly 
volume sensitive and becomes lower when more vaccines are produced in one facility. 
However, this study has also found that at production sizes as large as 20 million and 
100 million doses annually, the cost-per-dose becomes largely driven by variable costs. 
This is further supported by the findings in the sensitivity analyses where using the 
upper bound of the fixed cost range did not present any significant difference in regards 
to the average cost-per-dose, suggesting the determining role of variable costs at 
production scales above 20 million annual doses. 
3.4.1. Limitations 
A number of constraints were faced in generating the data, which are largely a result 
of the sensitivity of commercial cost data. Ideally direct observation would be made, 
where disaggregate cost estimations are generated based on each respondents’ actual 
vaccine production scale and scope. However, such an approach may not easily 
generate a large number of respondents or case studies. Further, given the structural 
differences in cost accounting methods across companies and countries, cost 
estimates may not necessarily be comparable across different countries or 
manufacturers.  
In relation to the data sensitivity mentioned above, the cost-analysis mostly relied on 
information provided by the respondents, which may be subject to selection bias. 
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Efforts to minimise this risk was made as much as possible, by randomly selecting the 
respondents, yet the options were limited to those attending the DCVMN meeting 
where the data collection process was conducted. In order to maximise the opportunity 
of attracting respondents, the questionnaire was designed to be as easy as possible 
for respondents to answer, therefore multiple-choice answers were provided, where 
possible. The figures in the multiple-choice however were based on existing literature 
and industrial practice of vaccine cost estimations (Friede, 2013; Mahoney, 1990; 
Mahoney et al., 2012) and were consulted to eight vaccine experts (Table 3.1).  
Another potential selection bias may arise from the small number of experts 
interviewed in the questionnaire. Though the number may be limited, these experts 
however were all well experienced vaccine experts with long standing international 
exposure, with many years of experience working with vaccine manufacturers, 
including those in developing countries. Their judgement and feedback therefore, can 
be assumed to be fair and representative of the practical knowledge regarding 
developing country vaccine manufacturers. 
Further, some improvements can be made to the questionnaire. Among the questions 
posed to respondents, two questions were noted as ambiguous. These are: question 
4, which asks about the cost of brownfield production for an additional one vaccine that 
is produced once a five vaccine production is running; and question seven which asks 
for information on the R&D costs of five vaccines. Though Scenario D is presented in 
the results, a comparison could have been made if Scenario D had the same 
production scale and scope to the baseline greenfield scenarios (Scenarios A, B or C).  
Finally, though economies of scale is generally calculated by analysing the change in 
average costs-per-dose, the dataset does not support the identification of the point at 
which scale efficiency is likely to be achieved. Comparing marginal costs for different 
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output levels with average cost estimates from the same data set would have allowed 
the diagnosis of economies or diseconomies of scale. 
3.4.2. Conclusions 
At an annual production of 20 million doses of one vaccine, increasing the scale and 
scope of production will result in a lower cost-per-dose. Cost-per-dose, though mainly 
driven by fixed costs, becomes driven by variable costs at production scales over 20 
million doses. This is an advance on the current literature because other vaccine cost 
studies have focused mainly on the contributions of fixed costs. Under the three 
hypothetical scenarios used to analyse and compare respondents, costs-per-dose of 
vaccines produced by developing countries were on average 47% lower than vaccine 
prices in developing country markets and 84% lower than prices in industrialized 
country markets. In developing country markets, local producers would gain most 
producer surplus in bacterial, and conjugate technology type vaccines and in pre-filled 
syringe formulations. With regards to industrialised country markets, these 
manufacturers have the potential to gain higher producer surplus when producing 
conjugate and novel technology vaccines as well as in multi-dose single-dose vaccine 
formulations. For local vaccine producers to access industrialised country markets 
however, they must consider changes to their current portfolio and production 
processes, including additional public health needs to cater for, and required upgrades 
to their existing manufacturing processes, to comply with regulatory requirements in 
industrialised countries.  
In conclusion, local producers can produce vaccines that are economically viable in 
both developing country and industrialised country markets and also gain producer 
surpluses in these markets, when production is made at a scale that is over 20 million 
annual doses. For this, manufacturers should ideally have facilities that produce 
multiple vaccines. 
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3.5. Appendices 
Appendix 3.1 Questionnaire on the cost structure of vaccine production in developing 
countries 
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 A multilevel modelling analysis of 
viability factors for vaccine production in developing 
countries 
4.1. Introduction 
Vaccinations and immunisation programs are known for being highly cost-effective 
public health interventions, with the need to maintain and secure the global supply of 
vaccines being high on the public health agenda. However, technological 
developments and changes in standards have constantly posed challenges to vaccine 
manufacturers globally (Danzon & Pereira, 2011), making it necessary for 
manufacturers to find ways to cope with these changes and remain viable. The term 
viability, commonly used in the financial or corporate sector, is indicative rather than 
specific. Viability is best described as survivability, or the ability of an entity to perform 
its objective/task. Commercial viability can be defined as a company’s ability to 
generate sufficient income for its operations and to cope with changes in the long run, 
and is closely linked to financial performance and position (ATO, 2013). Viability was 
introduced into the local vaccine production context by a series of studies based on 
country assessments conducted by the CVI in the early 1990s.  
Within a similar context, that is for pharmaceutical companies, a commissioned study 
by the British Government’s Department for International Development (DFID) states 
that financial viability of pharmaceutical companies is dependent on percent market 
share and prices of raw materials (Guimier, Lee, & Grupper, 2004). In a more general 
context, Buzzell, Gale, and Sultan (1975) studied 57 companies and suggested that 
there is a close link between percent market share and returns on investment, 
identifying percent market share as the main determinant of business profitability.  
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The global vaccines market has dramatically evolved over the past 30 years. The 
vaccines industry has often been considered the ‘poor cousin’ of the pharmaceutical 
industry with only 2-3% market share of the whole pharmaceutical industry. However, 
this share has tripled in value over the last decade, from US$5 billion in 2000 to almost 
US$24 billion in 2013, with even higher numbers projected in the next 10 years 
(Kaddar, 2013). Further, there are over 120 new products in the vaccine development 
pipeline, and half of these are important to the developing world. Vaccines are now 
considered to be an engine for the pharmaceutical industry, with an anticipation of new 
business models expected to emerge (Kaddar, 2013).  
An industry report on the global vaccine market outlook (Research & Markets, 2014) 
compared the pharmaceutical industry (excluding vaccines) and the vaccines industry 
and suggested that pharmaceuticals are facing declining prospects due to lower rates 
of research and productivity, whereas vaccines have been highly profitable as a result 
of advances in genomics and manufacturing technologies and from the increasing 
demand in emerging economies. 
Emerging manufacturers that mainly originated as an arm of Pasteur institutes in their 
respective developing countries, and are known to be the main suppliers of traditional 
vaccines, are now transitioning from being ‘suppliers of local markets’ to ‘suppliers of 
global markets’ (Jadhav, Datla, Kreeftenberg, & Hendriks, 2008).  Figure 4.1 shows the 
proportion of vaccine doses supplied by both industrialised and developing countries, 
and indicates that in the last few decades a growing proportion of the global vaccine 
market represented by UNICEF and PAHO has been sourced from emerging 
manufacturers.  Figures 4.2 and 4.3 which illustrate the proportion of vaccines supplied 
by manufacturing country type, show that emerging country manufacturers make up 
nearly two-thirds of UNICEF and PAHO procurement volumes in 2014 and about 40% 
of its total value. 
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Figure 4.1 Quantity share of UNICEF vaccine supply by manufacturing country type. 
Reproduced from UNICEF (2014). 
 
Figure 4.2. Source of vaccines supplied to UNICEF & PAHO (2014). Calculated based on 
country reporting to WHO/UNICEF’s Joint Reporting Form. 
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Figure 4.3. Volume of vaccines supplied to UNICEF & PAHO by vaccine and 
manufacturing country type (2014). Calculated based on country reporting to 
WHO/UNICEF’s Joint Reporting Form 
 
The majority of the human population and disease burden can be found in developing 
countries, and 16 of the 33 countries worldwide that manufacture vaccines are 
developing countries (Figure 4.4). However, the greatest share of vaccine 
manufacturing revenue is generated by multinational companies in industrialised 
country markets (Kaddar, 2013; WHO, UNICEF, & World Bank, 2009). This poses 
considerable challenges for vaccine producers in developing countries to remain 
viable.  
Figure 4.4 Vaccine production worldwide (2013). Note: Vaccine production as reported by 
WHO member countries and defined by Douglas and Samant (2013). All vaccine producing 
countries in colour. Vaccine production in low and middle income countries in yellow (16 
countries: Argentina, Brazil, Bulgaria, China, Cuba, Egypt, India, Indonesia, Iran, Mexico, 
Pakistan, Senegal Serbia, Thailand, Tunisia, Vietnam). 
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Industrial organization theories state that the decision to locally produce is generally 
taken when the price of purchasing a good is higher than the cost to manufacture it or 
when one is not able to rely on existing suppliers (Belleflamme & Peitz, 2010). 
However, this decision assumes that local producers possess the required skills and 
infrastructure to meet their needs and standards. Many developing country authorities 
consider local vaccine production as a panacea that will enable vaccine self-
sufficiency, and provide a foundation to develop and further advance their national 
science and research base (Milstien et al., 1997).  
A limited number of studies have reviewed the viability of vaccine production. These 
include studies conducted by the UN agency for Industrial Development (UNIDO), 
which assessed the cost and benefit of local manufacturing of vaccines (UNIDO, 1986), 
as well as a more recent study by the WHO (WHO, 2011a). Some of these studies 
have also identified determinant factors, such as Rautiainen (2001), who identified 
several internal and external factors46 that are critical in determining success of the 
biopharmaceutical industry. Internal factors included human resources, products, 
networking and company climate, whereas external factors included agglomeration of 
firms47 infrastructure and national polices. A series of country assessments conducted 
by WHO in 1992 as part of a Task Force on Situation Analysis of the Children’s Vaccine 
Initiative reported that the quality, cost and reliability of vaccine producers, which at the 
time existed in over 55 countries, ranged from the very good to very poor (Milstien, 
1999) (Milstien et al., 1997). Seven critical elements were identified by these authors 
as viable characteristics of successful vaccine producers: economies of scale48, 
consistency of production, access to new technologies, historical performance to meet 
demand and scale up production, credibility of quality, management structure and legal 
                                               
46 Rautiainen (2001) suggests that internal factors are those affected by the company itself; 
while external factors are defined as those not influenced by company activities and often 
depend on the company’s location. 
47 Geographic concentration of interconnected firms 
48 In this chapter, this element is further divided into economies of scale and economies of 
scope. 
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status. These seven elements were used as the basis for evaluation of DCVM viability 
in this Chapter.  
This chapter aims to identify and quantify the effect of factors determining the viability 
of production by DCVMs. This chapter does not aim to grade the viability of individual 
producers or vaccines. Five outcomes were investigated that included revenue sizes 
and percent market shares for global markets, and specifically for domestic and export 
markets given the trend of DCVMs expanding into vaccine export markets. These 
outcomes were used as proxies for viability. The goal was to provide evidence for 
developing countries and public health advocates to develop policies and strategies 
that can further ensure the quality and supply of global vaccines.  
This chapter is organised as follows: the description of the variables used in the 
analysis and the econometric methods are presented in section 4.2. Section 4.3 
presents the results of the regression model of determinants of vaccine producer 
viability in developing countries, followed by a discussion, summary, study limitations 
and conclusions in section 4.3. 
4.2. Methods 
4.2.1. Data management and inclusion and exclusion criteria  
The data for the variables used in this chapter were collected from various sources, 
including the WHO, World Bank and the Vaccine Information Management System 
(VIMS) database from John Hopkins Bloomberg School of Public Health.  
A dataset was compiled with identifiers for country, vaccine type, and year. The 
compilation used the Joint Reporting Form (JRF) data as an anchor, where each 
manufacturer’s vaccine sales were listed by procuring country. Once relevant 
indicators were joined to the matching procuring and producing country, the data were 
collapsed by manufacturer, vaccine product and year. Some indicators were created 
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to allow for specific calculations, such as an identifier of transaction frequency per 
manufacturer vaccine product and how many of these procurements were conducted 
through bulk-procurement mechanisms. The total number of vaccine doses procured 
globally was identified for each vaccine type, and was used to calculate each vaccine 
manufacturer’s revenue size and percent market share.  
Inclusion and exclusion criteria were adopted in selecting observations for the 
regression. The inclusion criteria were vaccine doses procured from local vaccine 
manufacturers owned by developing countries49. Production by industrialised country 
manufacturers acquired by a developing country50 were also included in the analysis. 
The exclusion criteria were vaccines that did not have corresponding vaccine price 
information from the Vaccine Product, Price and Procurement (V3P) database. This 
resulted in exclusion of five data points of a total 323 observations. For data where 
procurement was reported as being from multiple sources, volumes procured were 
divided equally amongst the reported manufacturers. This was to avoid selection bias 
from excluding data on potential competition in domestic vaccine sources. Developing 
country manufacturers identified as subsidiaries of multinational companies were 
considered as multinational manufacturers in this analysis and were excluded. 
Production under joint ventures between local producers and foreign or multinational 
companies was not excluded. 
The analysis focused on five aspects of viability: revenue sizes from global, domestic 
and export markets (the latter two being subsets of the former), along with percent 
market shares for global and export markets. Percent market share for domestic 
markets was not included in the analysis, because the percent market shares found in 
                                               
49 Developing countries based on classification by the World Bank. For countries where over 
the three years of observation have experienced changes in their country classification, only 
the vaccines produced during the years in which they are classified as either low and or middle 
income countries are included.  
50 This includes Bilthoven, a Netherlands vaccine manufacturer, acquired by Serum Institute of 
India in 2012 
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the domestic markets were consistently above 95% (shown in Table 4.5.). Data on 
revenue sizes and percent market shares used in this chapter were calculated based 
on data from the JRF database and V3P database. The data were based on sales of 
DCVM vaccine products to immunisation programs globally between 2012 – 2014. 
The JRF is a key tool and includes the most comprehensive data for immunisation that 
WHO member countries complete on an annual basis. The JRF mechanism has 
collected data from WHO member countries on its immunization financing indicators 
since 1998, to measure health system performances and trends. The indicators 
collected through the JRF tries to capture the expenditure on routine immunization 
programs, vaccine procurement, and government financing and planning for 
procurement of vaccines and injection supplies. 
The data on percent market share were calculated by dividing the revenue of each 
vaccine sold by manufacturers by the total revenue for each respective vaccine. The 
revenue was calculated by multiplying the number of doses of each vaccine sold by 
manufacturers, by its estimated vaccine price. The vaccine prices were estimated 
based on data from WHO’s V3P database. The vaccine price reference used from the 
V3P database used a weighted average price that was summarised by vaccine type, 
procurement method and income level of procuring country. The official 
UNICEF/PAHO price list could not be used as reference, because the V3P database 
shows that vaccine prices procured through UNICEF and PAHO tend to differ in its 
transactions. 
Markets shares were determined in two ways: 1) for global market shares, the 
denominator was the total revenue of the respective vaccine’s sales globally, 2) for 
export markets, the denominator was the total vaccine export revenue. Global market 
share indicates a product’s profitability, while export market share measures the 
degree of importance of a country within the total export market. A country may lose 
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export market share not only from declining exports but also if its exports are not 
growing at the same rate as world exports, causing its relative position at the global 
level to deteriorate (Eurostat, 2013).  
In estimating revenue sizes and percent market shares, the dataset was structured by 
vaccine type, manufacturer and originating country. Though most of the data collected 
through the JRF questionnaire were available on the WHO and UNICEF websites, 
specific information on vaccine procurement and its sources were not available to the 
public. For the purpose of this chapter, data on vaccine source were obtained for the 
years 2012, 2013 and 2014. 
Three sensitivity analyses were performed: the first one excluded vaccine procurement 
data that were reported as having multiple producers; the second sensitivity analysis 
categorised the vaccine technology types by two groups: traditional and modern 
(binary: 0, 1) instead of the original four groups: pre-GAVI, Phase I, Phase II and Phase 
III GAVI vaccines (category: 0,1,2,3); while the third sensitivity analysis was for each 
vaccines’ target market, where instead of using the number of doses administered, the 
immunization programs’ target doses were used instead. 
4.2.2. Explanatory variables 
There were seven characteristics of viable producers identified by Milstien et al. (1997). 
This chapter uses these characteristics to define domains for the explanatory variables, 
as follows: 
1. Economies of scale and scope 
a. Birth cohort/surviving infants 
In the case of national immunisation programs, which mainly target children, 
the number of surviving infants, referred to as birth cohort, drives the number 
of vaccines needed by countries. A larger birth cohort size would work positively 
for vaccine sales in two ways. First is that if a captive market is possible, then 
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the larger the birth cohort, the larger the number of potential sales. Secondly, a 
larger domestic sales base would assist manufacturers to establish 
sustainability in the lead up to accessing the global market. This will be 
identified as economies of scale. The number of surviving infants (per 1000 live 
births) was calculated as follows:  
𝑺𝑰𝒏𝒇𝒊,𝒕 = 𝑷𝒐𝒑𝒊,𝒕 ∗ 𝑪𝑩𝑹𝒊,𝒕 ∗ (𝟏 − 𝑰𝑴𝑹𝒊,𝒕)          Equation 4.1 
Where: 
𝑆𝐼𝑛𝑓𝑖,𝑡:  Number of surviving infants 
𝑃𝑜𝑝𝑖,𝑡:  Total population  
𝐶𝐵𝑅𝑖,𝑡:  Crude birth rates 
𝐼𝑀𝑅𝑖,𝑡:  Infant mortality rates 
b. Number of vaccine products produced by a single manufacturer (nominal).  
This variable identifies the number of different vaccine products that the 
manufacturer produces. The data were obtained from the DCVMN Directory 
(2014) and each of the manufacturers’ company websites. Different vaccines 
are identified by antigens and technology used. For the purpose of this 
research, similar vaccines with different presentation types were not considered 
to be different products. This variable will be able to address the question of 
whether a larger portfolio dictates a larger revenue. Though Milstien et al. 
(1997) identified this variable as economies of scale, this chapter will further 
specify this variable as economies of scope, where multiple products may lower 
costs-per-dose from a number of shared costs and not necessarily by the scale 
of production. 
2. Consistency of Production/Annual capital expenditure 
c. Consistent number of doses per year. 
Milstien et al. (1997) highlighted the importance of having consistent and 
reliable supply of vaccines. The indicators used in their study were production-
process specific, such as number of failed lots, consistency of lots and doses 
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per lot per year. Given the unavailability of such data for this thesis, this chapter 
instead measures the consistency of production by measuring the number of 
years that each vaccine was sold within the three years. Vaccines with sales 
missing in 2012 or 2013 were further assessed as to whether they were in fact 
new products launched in either 2013 or 2014. For such newly launched 
products, the codes were adjusted to identify as ‘consistent production’. 
3. New technology 
d. Vaccine technology type produced. 
This variable captures the manufacturer’s ability to access new technology. 
Vaccines were categorised by traditional and modern vaccines based on WHO 
and GAVI’s classification of vaccine priorities and market-shaping strategies for 
developing countries51. The first category, traditional vaccines, are those 
introduced through the initial EPI program, prior to GAVI’s establishment. These 
vaccines include diphtheria, tetanus, wholecellular pertussis (wP), rabies, 
influenza, smallpox, measles, OPV and BCG vaccines. The next categories are 
for modern vaccines, also known as new and underused vaccines (NUVs). 
These modern vaccines are further divided by GAVI’s phases of support to 
developing countries. The second category, which was based on GAVI’s Phase 
I, included vaccines for hepatitis B, acellular pertussis (aP), yellow fever, 
haemophilus type B (Hib) and pentavalent vaccine. The third category based 
on GAVI’s Phase II included HPV, rotavirus, and pneumococcal vaccines. The 
fourth category based on GAVI’s Phase III included meningitis A, measles 
rubella (MR), IPV, cholera and Japanese encephalitis vaccines. Influenza 
vaccines however were reclassified into category 3 because the technology 
transfer to DCMs was only facilitated in 2007. The categorical variable was 
structured as follows: 0 for pre-GAVI vaccines, 1 for Phase I vaccines, 2 for 
                                               
 51 Phase I (2000-06), Phase II (2007-10), Phase III (2011-15) and Phase IV (2016-20), please 
refer to: http://www.gavi.org/about/strategy/  
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Phase II vaccines and 3 for Phase III vaccines. Though GAVI has a Phase IV, 
there weren’t any vaccines in the dataset that were part of Phase IV. The order 
of these categories indicates access to more advanced technology.  
Whilst it has been suggested that vaccines are categorised by year of 
development (Plotkin et al., 2013), vaccine technologies accessible to 
developing countries are not necessarily chronologically ordered with the time 
in which they were developed. Developing countries often lag far behind the 
curve of vaccine adoption in developed country markets (Vandersmissen, 
2001). Figure 4.3 shows that traditional EPI vaccines were supplied mainly by 
DCVMs (78%), but a much smaller proportion of the NUVI vaccines supply was 
from DCVMs (41%). 
4. Historical performance/quality 
e. Supply sufficiency for global demand. (%) 
Vaccine sufficiency is defined as the ability to provide a sustainable supply of 
high-quality vaccines to meet demand. (Towse, Keuffel, Kettler, & Ridley, 2012) 
suggested that sufficient demand determines whether or not a vaccine is 
deemed viable. In this chapter supply sufficiency was derived in two steps. First 
was the identification of the target market (defined below), and secondly by 
whether vaccine sales fulfilled the total need of immunisation programs 
(classified as a binary variable, 1 = fulfilled and 0 = did not fulfil the total need). 
In their paper, Milstien et al. (1997) analysed supply sufficiency from a national 
perspective, however this chapter takes the perspective of sufficiency in meeting global 
demand. Sufficient supply for global demand is measured by comparing the number of 
vaccine doses sold relative to the targeted market. This was done by measuring the 
targeted market of each vaccine, obtained by multiplying the program cohort size52  in 
                                               
52 Program cohort size refers to the number of people receiving the vaccine. In cases where the 
immunisation program coverage is lower than the total number of people within the target 
coverage, the program cohort size will reflect those receiving the vaccine only, as reported by 
countries to WHO.  
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each procuring country by the number of doses required in each country’s 
immunisation schedule. The total number of doses sold for each vaccine was 
measured as a proportion of this targeted market. Not only was this variable indicative 
of the sufficiency of supply, it may also have provided an indication of each 
manufactures’ percent market share for the vaccines it produced.       
Some vaccines are known to have significantly high wastage rates and so some 
vaccines are procured in much larger doses than required by the birth cohort size. 
These were subsequently reclassified to reflect a 100 percent sufficiency.  
Vaccine target market 
The size of the target market is a measure of the potential market for a given vaccine. 
Most vaccines in the dataset were paediatric vaccines procured for national 
immunisation programmes. Two factors are known to determine the potential size of 
the paediatric vaccines market, these are: annual birth cohort and the number of 
vaccines administered to a child (Institute of Medicine, 1993).  Though the Institute of 
Medicine (1993) defined the annual birth cohort by live births per year, this definition 
was refined in the current chapter to be numbers of surviving infants, who are the 
members of the birth cohort specifically receiving the vaccine. Surviving infants are 
used as indicators in the WHO – UNICEF Joint Reporting form for the target group 
receiving early-life vaccines such as BCG or first dose of DPT vaccine. This chapter 
calculated the market for each vaccine as the product of the total number of surviving 
infants and the number of doses required in the procuring countries’ immunisation 
schedule. This can be observed in Equation 4.2 below. 
𝒗𝒙𝒎𝒂𝒓𝒌𝒆𝒕𝒊,𝒕 = 𝒔𝒊𝒏𝒇𝒂𝒏𝒕𝒊,𝒕 ∗ 𝒅𝒐𝒔𝒆𝒇𝒓𝒆𝒒𝒊,𝒕                          Equation 4.2 
 
Where: 
𝑣𝑥𝑚𝑎𝑟𝑘𝑒𝑡: potential market for 𝑜𝑏𝑠𝑖,𝑡 
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𝑠𝑖𝑛𝑓𝑎𝑛𝑡𝑖,𝑡 : number of surviving infants in vaccine manufacturer’s country 
𝑑𝑜𝑠𝑒𝑓𝑟𝑒𝑞𝑖,𝑡 : number of vaccine doses required for 𝑜𝑏𝑖,𝑡 in procuring country 
𝑜𝑏𝑠𝑖,𝑡 : unit of observation, i.e. the vaccine product produced by developing country 
manufacturer 
For vaccines that had not been introduced universally in a country’s immunisation 
schedule at the time of the study, either being phased in, targeted for risk groups, or 
regional areas or where the above calculation was not applicable, the target market 
was assumed to be based on the number of vaccine doses procured in a given year.  
Two versions of this variable were calculated, the first using target doses and the 
second using doses administered. The latter takes into consideration countries where 
immunisation coverages were low for certain vaccines. 
5. Credibility of quality/ regulatory infrastructure 
f. Fully functional National Regulatory Authority (NRA) (binary: 0, 1).  
To ensure the quality of vaccines procured through UN agencies on behalf of 
member countries, WHO established six main functions for which national 
regulatory authorities are assessed. Producing countries must fulfil all six of 
these functions to be allowed to export vaccines to other countries, while 
procuring countries must fulfil a minimum of four functions (Table 4.1). 
Table 4.1. NRA functions depending on source of vaccines 
Vaccine-specific NRA 
functions needed 
Areas of activity by NRA (or WHO) depending on 
source of vaccines 
Vaccine 
procured by  
United Nations 
agency 
Vaccine 
procured by 
NRA 
Vaccine 
manufactured 
in country 
FUNCTION 1 
Marketing authorization and 
licensing activities 
   
FUNCTION 2 
AEFI surveillance    
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Vaccine-specific NRA 
functions needed 
Areas of activity by NRA (or WHO) depending on 
source of vaccines 
Vaccine 
procured by  
United Nations 
agency 
Vaccine 
procured by 
NRA 
Vaccine 
manufactured 
in country 
FUNCTION 3 
NRA lot release 
NRA functions 
undertaken by 
WHO on behalf of 
United Nations 
agencies or 
producing 
countries. 
  
FUNCTION 4 
Laboratory access   
FUNCTION 5 
Regulatory inspections NRA functions 
undertaken by 
producing 
country. 
 
FUNCTION 6 
Oversight of clinical trials  
Source: http://vaccine-safety-training.org/functions-depending-on-the-source-of-vaccines.html 
g. Prequalified vaccine (binary: 0, 1) 
The prequalification process for vaccines is an established procedure that WHO 
conducts as a service to UN procuring agencies such as UNICEF. 
Prequalification determines that the vaccines procured by UNICEF and GAVI 
on behalf of countries meet certain standards required. Information regarding 
each vaccine’s prequalification status in each period was requested through 
WHO for the corresponding years.  
6. Type of ownership 
h. Public or private (binary: 0, 1) 
This variable classifies each vaccine manufacturer by type of ownership vis-a-
vis their management structure, whether it is publicly or privately owned. Public 
manufacturers are associated with management structures that are not as 
flexible as those in the private sector, particularly in regards to hire and fire-
ability of staff, an important element that helps companies maintain efficiency 
(CVI & WHO, 1999; Mahoney & Maynard, 1999; Milstien et al., 1997). Because 
the dataset included only three observations that fall under a public-private 
partnership status, these observations have been reclassified as private, with 
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the assumption that their management structure would be more flexible than a 
typical public entity.  
7. Legal status-autonomy 
i. Political stability/number of Ministers of health in the last five years 
Frequent changes at the health minster level is a potential indicator of health 
sector stability particularly regarding changes in policies and structures. 
Instances where ministers stepped down or were replaced and caretakers were 
appointed, were added to the count because an additional level of change was 
assumed.  
In addition to the characteristics above, this chapter also included additional factors not 
considered by Milstein and colleagues, which are known to be drivers of vaccine 
demand. These factors were: 
8. Purchasing power (GNI/cap) (US$) 
If the total gross national income represents the size of a country’s economy, 
the GNI per capita provides an indicator of a country’s purchasing power. This 
variable measures the income level of the producing country and investigates 
how increases in a country’ purchasing power would affect its viability in 
producing vaccines. 
9. Proportion of export sales (%) 
Most manufacturers differ their vaccine sales destinations, where some have 
primarily domestic sales, some have a mix of both domestic and export sales, 
and some have primarily export sales. The proportion of export sales compared 
to domestic sales will allow a better understanding of the impact on market 
strategy towards viability factors given the growing tendency of local vaccine 
producers towards producing for export markets.  
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4.2.3. Statistical analysis 
Five outcome variables were identified, and used as proxies of viability. These 
outcomes were calculated based on sales by vaccine manufacturers to immunisation 
programs, for each respective vaccine. These outcome variables are: 
 Revenue size for global market (Model 1) 
 Revenue size for domestic market (Model 2) 
 Revenue size for export market (Model 3) 
 Percent market share for global market (Model 4) 
 Percent market share for export market (Model 5) 
Because the outcome variables were a continuous variables, linear regression was 
used. All five outcome variables were logarithmically transformed to deal with the 
skewed data and to ensure that these outcome variables have constant variance, so 
that the data conformed more closely to a normal distribution (Figure 4.5).  
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           (3a)     (3b)
  
            (4a)     (4b)
            
            (5a)      (5b) 
Figure 4.5. Logarithmic transformations of outcome variables for vaccines produced by 
developing country manufacturers. Note: (1a) revenue size of global market; (1b) revenue 
size of global market – log transformed; (2a) revenue size of domestic market; (2b) revenue 
size of domestic market – log transformed; (3a) revenue size of export market; (3b) revenue 
size of export market – log transformed; (4a) percent market share of global market; (4b) 
percent market share of global market – log transformed; (5a) percent market share of export 
market; (5b) percent market share of export market – log transformed 
 
Some explanatory variables varied across different levels (vaccine, manufacturer and 
country), whilst others varied across both levels and time. Numbers of surviving infants 
and GNI per capita were log transformed to normalise their skewed distributions 
(Figure 4.6). 
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          (1a)      (1b)
 
          (2a)      (2b) 
Figure 4.6. Logarithmic transformations of several explanatory variables for vaccines 
produced by developing country manufacturers. Note: (1a) Surviving infant (million); (1b) 
Surviving infant – log transformed; (2a) GNI per capita; (2b) GNI per capita – log transformed 
 
Data were imported to STATA 14.0 (Stata Corporation, College Station, Texas) where 
each observation was linked to its corresponding vaccine type-, manufacturer- and 
country level explanatory variable. Multicollinearity was investigated using Pearson’s 
correlation coefficients. No pairs of explanatory variables had a Pearson’s correlation 
coefficient >|0.6| (Table 4.2) and therefore no variables were excluded for reasons of 
multicollinearity. Heteroscedasticity was also tested using Breusch-Pagan / Cook-
Weisberg (Table 4.3). 
In building the model, a univariable analysis was conducted, where a high significance 
threshold of P>0.2 was used for subsequent variable selection for multivariable 
analysis, to avoid potential exclusions of false positives.  
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Table 4.2. Correlation matrix of explanatory variables associated with revenue sizes and percent market share of vaccines produced by developing 
country vaccine manufacturers 
 Surviving 
Infants (log) 
GNI per 
capita 
(log) 
Number of 
vaccines 
products 
Consistent 
production 
supply 
Vaccine 
technology 
Sufficient supply 
against demand 
NRA 
Vaccine 
PQ status 
Manufacture 
status 
Number of 
MOH, last 5 
years 
Proportion of 
export sales 
Surviving Infants 
(log) 
1.000           
GNI per capita (log) - 0.595 1.000          
Number of vaccines 
products 
0.578 - 0.501 1.000         
Consistent 
production supply 
- 0.079 - 0.042 0.082 1.000        
Vaccine technology 0.119 0.078 0.074 - 0.193 1.000       
Sufficient supply 
against demand 
- 0.097 0.213 - 0.098 0.199 0.066 1.000      
NRA 0.362 - 0.008 0.194 0.043 0.176 0.136 1.000     
Vaccine PQ status 0.206 - 0.275 0.379 0.334 - 0.066 -  0.210 0.026 1.000    
Manufacture status 0.565 - 0.522 0.381 - 0.014 0.112 -  0.034 0.196 0.244 1.000   
Number of MOH, 
last 5 years 
- 0.462 0.219 - 0.253 0.056 - 0.257 -  0.039 
- 
0.336 
- 0.011 - 0.210 1.000  
Proportion of export 
sales 
0.278 - 0.349 0.532 0.014 0.041 -0.103 
-
0.045 
0.322 0.359 -0.066 1.000 
Note: None of the correlation estimations exceeded the correlation coefficient threshold of |0.6|, therefore there are no observed multicollinearity in the model  
Table 4.3. Breusch-Pagan / Cook-Weisberg test for heteroscedasticity  
Ho   Constant variance 
Variables  logvxrev logsurvinf loggnipercap vxnumb continue vxtech vxsuff vxpq status moh vxtrade 
chi2(11)  0.87 
Prob > chi2   0.3519 
Note: the test statistic has a p-value above 0.05, therefore the null hypothesis of homoscedasticity cannot be rejected.
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Multivariable multilevel linear regression models were developed by using a backward 
stepwise variable selection method, with vaccine type, manufacturer and country level 
random effects to account for clustering. This was done by using the “stepwise pr(0.2)” 
command in STATA, where variables were dropped from the models if P>0.2.  
Selecting variables for regression analysis involves two contrasting objectives, where 
the model needs to be as comprehensive and realistic as possible (Darlington, 1968), 
yet it must include the least numbers of relevant variables (principle of parsimony), 
because irrelevant variables decrease the precision of the coefficients and predicted 
values.  
Though variables adopted from the paper by Milstien, Batson, and Meaney (1997) 
provides a general direction as to which explanatory variables should be included into 
the model, the actual set of explanatory variables used in the regression is determined 
by the analysis of the data (Conger, 1974). Though multiple variable selection methods 
exist, the backward stepwise was selected where the model starts with the seven 
proposed viability characteristic (Milstien et al., 1997), and tests the removal of each 
variable using a chosen model fit criterion until variables cannot be deleted without a 
statistically significant loss of fit. 
The form of the final models were: 
Model 1 (Revenue size for global market): 
𝑳𝒐𝒈(𝑳𝑷𝑽𝒊𝒋𝒌𝒕) = 𝜷𝟎𝒋𝒌 + 𝜷𝟏𝒋𝒌𝑳𝒐𝒈(𝑺𝑰𝒏𝒇𝒌𝒕) + 𝜷𝟐𝑳𝒐𝒈(
𝑮𝑵𝑰
𝒄𝒂𝒑𝒌𝒕
) + 𝜷𝟑𝑽𝒙𝑵𝒖𝒎𝒃𝒋𝒌𝒕 +
𝜷𝟒𝑪𝒐𝒏𝒔𝒊𝒋𝒌𝒕 + 𝜷𝟓𝑽𝒙𝑻𝒆𝒄𝒉𝒊𝒋𝒌 + 𝜷𝟔𝑺𝒖𝒇𝒇𝒊𝒋𝒌𝒕 + 𝜷𝟕𝑺𝒕𝒂𝒕𝒖𝒔𝒋𝒌 + 𝜷𝟖𝑴𝑶𝑯𝒌𝒕 + 𝜷𝟗𝑻𝒓𝒂𝒅𝒆𝒊𝒋𝒌𝒕 +
∈𝒊,𝒋,𝒌,𝒕                      Equation 4.3 
Model 2 (Revenue size for domestic market): 
𝑳𝒐𝒈(𝑳𝑷𝑽𝒊𝒋𝒌𝒕) = 𝜷𝟎𝒋𝒌 + 𝜷𝟏𝒋𝒌𝑳𝒐𝒈(𝑺𝑰𝒏𝒇𝒌𝒕) + 𝜷𝟐𝑳𝒐𝒈(
𝑮𝑵𝑰
𝒄𝒂𝒑𝒌𝒕
) + 𝜷𝟑𝑽𝒙𝑵𝒖𝒎𝒃𝒋𝒌𝒕 +
𝜷𝟒𝑪𝒐𝒏𝒔𝒊𝒋𝒌𝒕 + 𝜷𝟓𝑽𝒙𝑻𝒆𝒄𝒉𝒊𝒋𝒌 + 𝜷𝟔𝑺𝒖𝒇𝒇𝒊𝒋𝒌𝒕 + 𝜷𝟕𝑺𝒕𝒂𝒕𝒖𝒔𝒋𝒌 +∈𝒊,𝒋,𝒌,𝒕  
Equation 4.4 
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Model 3 (Revenue size for export market): 
𝑳𝒐𝒈(𝑳𝑷𝑽𝒊𝒋𝒌𝒕) = 𝜷𝟎𝒋𝒌 + 𝜷𝟏𝒋𝒌𝑳𝒐𝒈(𝑺𝑰𝒏𝒇𝒌𝒕) + 𝜷𝟐𝑳𝒐𝒈(
𝑮𝑵𝑰
𝒄𝒂𝒑𝒌𝒕
) + 𝜷𝟑𝑪𝒐𝒏𝒔𝒊𝒋𝒌𝒕 +
𝜷𝟒𝑽𝒙𝑻𝒆𝒄𝒉𝒊𝒋𝒌 + 𝜷𝟓𝑺𝒖𝒇𝒇𝒊𝒋𝒌𝒕 + 𝜷𝟔𝑽𝒙𝑷𝑸𝒊𝒋𝒌𝒕 + 𝜷𝟕𝑺𝒕𝒂𝒕𝒖𝒔𝒋𝒌 + 𝜷𝟖𝑴𝑶𝑯𝒌𝒕 +∈𝒊,𝒋,𝒌,𝒕                 
 Equation 4.5    
Model 4 (Percent market share for global market): 
𝑳𝒐𝒈(𝑳𝑷𝑽𝒊𝒋𝒌𝒕) = 𝜷𝟎𝒋𝒌 + 𝜷𝟏𝒋𝒌𝑳𝒐𝒈(𝑺𝑰𝒏𝒇𝒌𝒕) + 𝜷𝟐𝑳𝒐𝒈(
𝑮𝑵𝑰
𝒄𝒂𝒑𝒌𝒕
) + 𝜷𝟑𝑽𝒙𝑵𝒖𝒎𝒃𝒋𝒌𝒕 +
𝜷𝟒𝑪𝒐𝒏𝒔𝒊𝒋𝒌𝒕 + 𝜷𝟓𝑽𝒙𝑻𝒆𝒄𝒉𝒊𝒋𝒌 + 𝜷𝟔𝑺𝒖𝒇𝒇𝒊𝒋𝒌𝒕 + 𝜷𝟕𝑽𝒙𝑷𝑸𝒊𝒋𝒌𝒕 + 𝜷𝟖𝑻𝒓𝒂𝒅𝒆𝒊𝒋𝒌𝒕 +∈𝒊,𝒋,𝒌,𝒕   
                  Equation 4.6 
                       
Model 5 (Percent market share for export market): 
𝑳𝒐𝒈(𝑳𝑷𝑽𝒊𝒋𝒌𝒕) = 𝜷𝟎𝒋𝒌 + 𝜷𝟏𝒋𝒌𝑳𝒐𝒈(𝑺𝑰𝒏𝒇𝒌𝒕) + 𝜷𝟐𝑳𝒐𝒈(
𝑮𝑵𝑰
𝒄𝒂𝒑𝒌𝒕
) + 𝜷𝟑𝑪𝒐𝒏𝒔𝒊𝒋𝒌𝒕 +
𝜷𝟒𝑽𝒙𝑻𝒆𝒄𝒉𝒊𝒋𝒌 + 𝜷𝟓𝑺𝒖𝒇𝒇𝒊𝒋𝒌𝒕 + 𝜷𝟔𝑽𝒙𝑷𝑸𝒊𝒋𝒌𝒕 + 𝜷𝟕𝑺𝒕𝒂𝒕𝒖𝒔𝒋𝒌 + 𝜷𝟖𝑴𝑶𝑯𝒌𝒕 +∈𝒊,𝒋,𝒌,𝒕 
                    
Equation 4.7 
Where:   
 𝐿𝑜𝑔(𝐿𝑃𝑉𝑖𝑗𝑘𝑡), the outcome variable, is revenue size or percent market share (as 
defined for each model), for vaccine i, manufacturer j, country k and year t; 
 𝐿𝑜𝑔(𝑆𝐼𝑛𝑓), denotes number of surviving infants, in log form; 
 𝐿𝑜𝑔(
𝐺𝑁𝐼
𝑐𝑎𝑝
), denotes gross national income per capita, in log form; 
 𝑉𝑥𝑁𝑢𝑚𝑏, denotes number of vaccines produced by each company; 
 𝐶𝑜𝑛𝑠, denotes consistency of production of each vaccine (coded 0=interrupted 
supply, 1=consistent supply); 
 𝑉𝑥𝑇𝑒𝑐ℎ, denotes vaccine technology level, in categorical form (coded 0=pre-GAVI, 
1=GAVI Phase I, 2=GAVI Phase II, 3=GAVI Phase II); 
 𝑆𝑢𝑓𝑓, denotes vaccine sufficiency level; 
 𝑁𝑅𝐴, denotes whether the NRA is fully functional in binary form (coded 1=fully 
functional, 0=not); 
 𝑉𝑥𝑃𝑄, denotes prequalification status of vaccines, in binary form (coded 
1=prequalified, 0=not prequalified); 
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 𝑆𝑡𝑎𝑡𝑢𝑠, denotes firm ownership status, in binary form (coded 0=public, 1=private); 
 𝑀𝑂𝐻, denotes number of Ministers of Health over last five years; 
 𝑀𝑎𝑟𝑘𝑒𝑡, denotes proportion of export sales compared to domestic sales. 
4.3. Results 
4.3.1. Descriptive analysis and correlation analysis 
Overall, the dataset had 318 observations that represented 5.13 billion vaccine doses 
(Table 4.4). The total summed to US$5.83 billion. There were 38 different vaccine types 
produced by 35 local manufacturers in 16 developing countries.
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Table 4.4 Revenue sizes and percent market shares of public vaccine markets supplied by developing country vaccine manufacturers (2012 – 2014). 
Country Vaccine Manufacturer 
Revenue Size, global 
(US$ million) 
Revenue Size, domestic 
(US$ million) 
Revenue Size, export 
(US$ million) 
Percent market share, global (%) Percent market share, export (%) 
2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 
Argentina Influenza_Adult Sinergium - 11.60 51.58 - 11.60 51.58 - - - - 4.41 21.86 - - - 
Argentina Influenza_Pediatric Sinergium - 3.44 10.94 - 3.44 10.94 - - - - 11.95 31.72 - - - 
Mexico HepB_adult Probiomed 0.93 - 0.40 0.93 - 0.40 - - - 2.25 - 0.89 - - - 
Mexico HepB_pediatric Probiomed 3.27 - 5.18 3.27 - 5.18 - - - 4.85 - 6.92 - - - 
Pakistan Measles NIH Pakistan - 0.11 - - 0.11 - - - - - 0.23 - - - - 
Pakistan TT NIH Pakistan - 0.02 0.14 - 0.02 0.14 - - - - 0.06 0.44 - - - 
Senegal OPV IP Dakar - 0.05 - - - - - 0.05 - - 0.03 - - - - 
Senegal YF IP Dakar - 6.62 1.64 - - 0.36 - 6.62 1.27 - 9.19 1.96 - - 1.53 
Serbia BCG Torlak - - 0.03 - - - - - 0.03 - - 0.05 - - - 
Serbia Td Torlak - - 0.05 - - - - - 0.05 - - 0.02 - - - 
Serbia TT Torlak - - 0.01 - - - - - 0.01 - - 0.03 - - - 
Serbia DT Torlak - - 0.01 - - - - - 0.01 - - 0.02 - - - 
Serbia DTwP Torlak - - 6.0 x 10^-4 - - - - - 6.0 x 10^-4 - - 2.2 x 10^-3 - - - 
Thailand HepB_pediatric GPO-Merieux 0.39 0.39 0.62 0.39 0.39 0.62 - - - 0.58 0.46 0.83 - - - 
Thailand Influenza_Adult GPO-Merieux 5.68 6.90 6.09 5.68 6.90 6.09 - - - 2.53 2.62 2.58 - - - 
Thailand OPV GPO-Merieux 1.48 1.48 1.16 1.48 1.48 1.16 - - - 1.05 0.75 0.66 - - - 
Thailand JE_Inactd GPO-Merieux 1.15 1.45 3.00 1.15 1.45 3.00 - - - 17.29 27.65 49.34 - - - 
Thailand YF GPO-Merieux - - 0.03 - - - - - 0.03 - - 0.04 - - - 
Thailand MR Masu - - 2.48 - - 2.48 - - - - - 10.14 - - - 
Thailand Td Masu 12.15 27.62 24.30 12.15 27.62 24.30 - - - 9.57 11.81 12.40 - - - 
Thailand DTwPHepB Masu 7.68 7.68 8.64 7.68 7.68 8.64 - - - 6.98 11.73 100.00 - - - 
Tunisia BCG IP Tunis 0.27 0.18 0.30 0.27 0.18 0.30 - - - 0.55 0.30 0.57 - - - 
Vietnam BCG IVAC 0.42 0.42 0.42 0.42 0.42 0.42 - - - 0.85 0.72 0.81 - - - 
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Country Vaccine Manufacturer 
Revenue Size, global 
(US$ million) 
Revenue Size, domestic 
(US$ million) 
Revenue Size, export 
(US$ million) 
Percent market share, global (%) Percent market share, export (%) 
2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 
Vietnam TT IVAC 0.54 0.63 0.63 0.54 0.63 0.63 - - - 2.28 2.12 1.99 - - - 
Vietnam DTwP IVAC 0.36 0.42 0.28 0.36 0.42 0.28 - - - 1.69 1.99 1.05 - - - 
Vietnam OPV Polyvac 1.62 1.37 1.33 1.62 1.37 1.33 - - - 1.14 0.69 0.76 - - - 
Vietnam Measles Polyvac 1.00 0.96 2.07 1.00 0.96 2.07 - - - 1.07 1.98 2.83 - - - 
Vietnam HepB_pediatric Vabiotech 0.46 0.34 0.27 0.46 0.34 0.27 - - - 0.68 0.40 0.36 - - - 
Vietnam Cholera Vabiotech - 0.09 0.09 - 0.09 0.09 - - - - 85.63 95.87 - - - 
Vietnam JE_Inactd Vabiotech 1.25 1.25 2.00 1.25 1.25 2.00 - - - 18.86 23.85 32.89 - - - 
Vietnam Typhoid DAVAC - 0.15 0.15 - 0.15 0.15 - - - - 1.87 2.05 - - - 
Brazil Hib Fiocruz - 0.18 0.18 - 0.18 0.18 - - - - 3.01 8.44 - - - 
Brazil OPV Fiocruz 4.46 - 5.80 4.00 - 5.80 0.46 - - 3.14 - 3.30 0.33 - - 
Brazil IPV Fiocruz 41.25 56.25 48.75 41.25 56.25 48.75 - - - 77.83 86.81 76.53 - - - 
Brazil MMR Fiocruz 94.82 107.75 39.89 94.82 107.75 39.89 - - - 40.70 38.07 11.53 - - - 
Brazil MMRV Fiocruz - - 73.17 - - 73.17 - - - - - 86.80 - - - 
Brazil Pneumo_conj Fiocruz 237.88 201.29 450.05 237.88 201.29 450.05 - - - 19.18 12.05 15.85 - - - 
Brazil Rotavirus Fiocruz - 33.35 37.35 - 33.35 37.35 - - - - 20.59 14.94 - - - 
Brazil Varicella Fiocruz - 18.32 - - - - - 18.30 - - 9.90 - - - - 
Brazil YF Fiocruz - 46.62 39.04 - 43.57 38.94 - 3.05 0.09 - 64.66 46.81 - 10.69 0.21 
Brazil MenC_conj FUNED - 207.58 - - 207.58 - - - - - 99.80 - - - - 
Brazil BCG Butantan 0.08 0.04 - - - - 0.08 0.04 - 0.17 0.07 - 0.18 0.07 - 
Brazil HepB_adult Butantan 21.80 21.80 32.14 21.80 21.80 32.14 - - - 53.04 71.71 70.94 - - - 
Brazil HPV Butantan - - 195.15 - - 195.15 - - - - - 55.28 - - - 
Brazil Influenza_Adult Butantan 113.25 89.32 109.62 113.25 89.32 109.62 - - - 50.33 33.96 46.45 - - - 
Brazil OPV Butantan - 0.21 - - - - - 0.21 - - 0.11 - - - - 
Brazil Rabies Butantan - 7.61 - - 7.61 - - - - - 52.13 - - - - 
Brazil Td Butantan 4.60 20.65 - - 20.65 - 4.60 - - 3.62 8.83 - - - - 
142 
 
Country Vaccine Manufacturer 
Revenue Size, global 
(US$ million) 
Revenue Size, domestic 
(US$ million) 
Revenue Size, export 
(US$ million) 
Percent market share, global (%) Percent market share, export (%) 
2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 
Brazil DT Butantan 1.7 x 10^-3 1.7 x 10^-3 - 1.7 x 10^-3 1.7 x 10^-3 - - - - 4.9 x 10^-9 4.9 x 10^-9 - - - - 
Brazil DTwP Butantan 0.06 1.47 - - 1.44 - 0.06 0.03 - 0.30 6.96 - - 0.14 - 
Brazil BCG FAP 3.90 3.90 3.90 3.90 3.90 3.90 - - - 7.88 6.67 7.54 - - - 
Bulgaria BCG BB-NCIPD 1.73 10.42 8.97 0.11 0.10 0.11 1.62 10.30 8.86 3.50 17.81 17.35 3.28 17.67 17.18 
Bulgaria DTwPHibHepB BB-NCIPD - 0.02 - - - - - 0.02 - - 4.4 x 10^-9 - - - - 
Bulgaria Td BB-NCIPD 5.53 35.68 57.54 1.17 0.85 0.73 4.37 34.80 56.80 4.36 15.25 29.36 3.47 14.94 29.10 
Bulgaria TT BB-NCIPD 0.68 2.21 1.67 - - - 0.68 2.21 1.67 2.86 7.44 5.30 - - - 
Bulgaria DT BB-NCIPD 0.46 0.43 0.30 - - - 0.46 0.43 0.30 1.35 0.81 0.97 - - - 
Bulgaria DTwP BB-NCIPD 0.05 - 0.03 - - - 0.05 - 0.03 0.25 - 0.11 - - - 
China HepA Sinovac 1.61 4.05 2.95 - - - 1.61 4.05 2.95 3.68 2.91 1.19 - - - 
China Influenza_Adult Sinovac 0.07 0.08 - - - - 0.07 0.08 - 0.03 0.03 - - - - 
China JE_LiveAtd Chengdu 108.52 157.09 394.23 - - - 109.00 157.00 394.00 126.04 126.69 124.76 - - - 
China Influenza_Adult Changchun 11.05 6.54 2.65 - - - 11.00 6.54 2.65 4.91 2.49 1.12 - - - 
China Influenza_Pediatric Changchun 0.06 0.04 0.07 - - - 0.06 0.04 0.07 0.27 0.14 0.19 - - - 
Cuba Td Finlay 1.68 - - - - - 1.68 - - 1.32 - - - - - 
Cuba TT Finlay 1.00 1.00 1.00 1.00 1.00 1.00 - - - 4.22 3.37 3.16 - - - 
Cuba Typhoid Finlay - 2.71 2.71 - 2.71 2.71 - - - - 34.44 37.73 - - - 
Cuba DT Finlay 0.10 0.09 0.09 0.10 0.09 0.09 - - - 0.29 0.16 0.28 - - - 
Cuba DTwP Finlay 0.06 0.04 0.05 0.03 0.04 0.04 0.03 - 0.01 0.30 0.17 0.19 0.14 - 0.06 
Cuba DTwPHibHepB CIGB 12.96 26.72 24.34 1.39 1.39 1.39 11.60 25.30 22.90 3.47 6.61 5.19 3.11 6.29 4.91 
Cuba HepB_adult CIGB 2.71 2.19 4.41 - - - 2.71 2.19 4.41 6.59 7.21 9.72 - - - 
Cuba HepB_pediatric CIGB 4.19 4.11 6.33 0.05 0.13 0.13 4.14 3.98 6.20 6.22 4.83 8.45 6.15 4.69 8.29 
Cuba Hib CIGB 0.26 0.37 0.39 0.26 0.37 0.39 - - - 12.45 6.01 18.09 - - - 
Cuba DTwPHepB CIGB 4.80 - - - - - 4.80 - - 4.36 - - - - - 
Egypt Td Vacsera - - 7.23 - - 7.23 - - - - - 3.69 - - - 
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Country Vaccine Manufacturer 
Revenue Size, global 
(US$ million) 
Revenue Size, domestic 
(US$ million) 
Revenue Size, export 
(US$ million) 
Percent market share, global (%) Percent market share, export (%) 
2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 
Egypt TT Vacsera - - 0.28 - - 0.28 - - - - - 0.90 - - - 
Egypt DT Vacsera - - 0.03 - - 0.03 - - - - - 0.08 - - - 
Egypt DTwP Vacsera - - 0.18 - - 0.18 - - - - - 0.68 - - - 
India OPV Haffkine 22.03 23.12 9.42 11.88 - - 10.20 23.10 9.42 15.52 11.73 5.35 8.68 14.39 - 
India HepB_pediatric Immunologicals - - 28.50 - - 28.50 - - - - - 38.05 - - - 
India TT Immunologicals - - 13.03 - - 13.03 - - - - - 41.24 - - - 
India DTwP Immunologicals 0.96 1.44 - - - - 0.96 1.44 - 4.57 6.82 - 10.55 20.28 - 
India DTwPHibHepB Panacea 1.88 - 20.92 - - - 1.88 - 20.90 0.50 - 4.46 0.52 - 5.16 
India OPV Panacea 12.26 0.38 - 11.88 - - 0.38 0.38 - 8.63 0.19 - 0.32 0.24 - 
India HepB_adult Bharat 7.34 0.01 - - - - 7.34 0.01 - 17.87 0.03 - - - - 
India HepB_pediatric Bharat 1.5 x 10^-3 - - - - - 1.5 x 10^-3 - - 2.2 x 10^-3 - - - - - 
India OPV Bharat - 36.21 - - 34.61 - - 1.60 - - 18.38 - - 1.00 - 
India Rabies Bharat - - 1.24 - - - - - 1.24 - - 45.46 - - - 
India TT Bharat - - 0.00 - - - - - 0.00 - - 0.00 - - 0.01 
India Typhoid Bharat - - 0.11 - - - - - 0.11 - - 1.57 - - - 
India BCG IP India - 1.0 x 10^-5 - - - - - 1.0 x 10^-5 - - 1.7 x 10^-5 - - 2.1 x 10-5 - 
India DTwP IP India 5.97 - 18.90 5.97 - 18.90 - - - 28.42 - 70.79 - - - 
India BCG SII 14.54 22.35 17.13 4.39 11.12 10.66 10.10 11.20 6.47 29.38 38.21 33.13 24.93 23.71 15.79 
India DTwPHibHepB SII 149.98 196.88 195.19 15.92 - 63.62 134.00 197.00 132.00 40.10 48.73 41.62 37.44 - 32.45 
India HepB_adult SII 2.0 x 10^-3 0.45 0.50 - - - 9.7 x 10^-3 0.45 0.50 4.9 x 10^-3 1.47 1.10 - - - 
India HepB_pediatric SII 2.19 19.33 0.64 - 13.98 - 2.19 5.35 0.64 3.25 22.71 0.85 - 9.37 1.37 
India Hib SII 0.34 0.42 0.22 - - - 0.34 0.42 0.22 16.26 6.93 10.00 - - - 
India OPV SII 2.36 3.93 7.14 - - - 2.36 3.93 7.14 1.66 1.99 4.06 2.02 2.45 - 
India IPV SII 0.01 0.15 3.02 - - - 0.01 0.15 3.02 0.01 0.23 4.75 - - - 
India Measles SII 61.34 24.54 46.14 44.96 - 28.15 16.40 24.50 18.00 65.89 50.59 62.95 34.07 - 39.81 
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Country Vaccine Manufacturer 
Revenue Size, global 
(US$ million) 
Revenue Size, domestic 
(US$ million) 
Revenue Size, export 
(US$ million) 
Percent market share, global (%) Percent market share, export (%) 
2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 
India MenA SII 1.17 8.40 1.19 - - - 1.17 8.40 1.19 100.00 100.00 100.00 - - - 
India MMR SII 46.50 47.62 80.35 - - - 46.50 47.60 80.40 19.96 16.83 23.22 - - - 
India MR SII 13.81 33.65 19.50 - - - 13.80 33.70 19.50 72.31 101.37 79.59 - - - 
India Dip SII 0.11 - - - - - 0.11 - - 89.98 - - - - - 
India Mumps SII - 0.04 - - - - - 0.04 - - 4.07 - - - - 
India Pneumo_conj SII - - 2.56 - - - - - 2.56 - - 0.09 - - - 
India Rabies SII - - 0.04 - - - - - 0.04 - - 1.46 - - - 
India Rotavirus SII - - 0.51 - - - - - 0.51 - - 0.20 - - - 
India Rubella SII 4.2 x 10^-3 0.01 1.2 x 10^-3 - - - 4.2 x 10^-3 0.01 1.2 x 10^-3 13.11 20.17 9.32 - - - 
India Td SII 69.30 50.29 55.22 - - - 69.30 50.30 55.20 54.57 21.49 28.17 - - - 
India TT SII 6.96 8.77 3.34 - - - 6.96 8.77 3.34 29.35 29.53 10.56 40.78 39.38 17.93 
India Typhoid SII - 0.06 - - - - - 0.06 - - 0.73 - - - - 
India DT SII 2.30 0.90 2.14 - - - 2.30 0.90 2.14 6.82 1.70 6.96 - - - 
India YF SII - 0.60 4.76 - - - - 0.60 4.76 - 0.83 5.71 - - - 
India DTaPHibHepB SII - 2.00 0.88 - - - - 2.00 0.88 - 10.19 16.80 - - - 
India DTIPV SII - 1.62 1.38 - - - - 1.62 1.38 - 100.00 100.00 - - - 
India DTwP SII 3.41 1.20 4.34 - - - 3.41 1.20 4.34 16.22 5.69 16.24 37.43 16.91 55.58 
India DTwPHepB SII 10.52 - - - - - 10.50 - - 9.56 - - - - - 
India DTwPHib SII 0.08 4.14 5.88 - - - 0.08 4.14 5.88 0.72 26.91 88.81 - - - 
India BCG Green Signal 4.39 0.17 - 4.39 - - - 0.17 - 8.87 0.29 - - 0.35 - 
India DTwP CRI Kasauli 5.97 - - 5.97 - - - - - 28.42 - - - - - 
India DTwPHibHepB Biological E. 27.20 59.20 98.31 - - - 27.20 59.20 98.30 7.27 14.65 20.96 7.60 - 24.25 
India HepB_pediatric Biological E. - 13.98 - - 13.98 - - - - - 16.43 - - - - 
India OPV Biological E. - - 0.47 - - - - - 0.47 - - 0.27 - - - 
India Td Biological E. - - 0.01 - - - - - 0.01 - - 0.01 - - - 
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Country Vaccine Manufacturer 
Revenue Size, global 
(US$ million) 
Revenue Size, domestic 
(US$ million) 
Revenue Size, export 
(US$ million) 
Percent market share, global (%) Percent market share, export (%) 
2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014 
India TT Biological E. 7.21 9.07 2.35 6.64 7.43 - 0.57 1.64 2.35 30.43 30.53 7.43 3.34 7.37 12.63 
India DTaPHibHepB Biological E. - - 4.38 - - - - - 4.38 - - 83.20 - - - 
India DTwP Biological E. - 14.00 - - 14.00 - - - - - 66.35 - - - - 
Indonesia BCG Bio Farma 4.78 3.90 3.88 4.77 3.86 3.88 0.02 0.04 - 9.67 6.67 7.50 0.04 0.08 - 
Indonesia DTwPHibHepB Bio Farma - 4.21 47.88 - 4.14 45.16 - 0.06 2.72 - 1.04 10.21 - 0.02 0.64 
Indonesia HepB_pediatric Bio Farma - 1.79 1.16 - 1.79 1.16 - - - - 2.11 1.54 - - - 
Indonesia OPV Bio Farma 9.75 9.01 10.21 5.92 5.09 4.93 3.83 3.91 5.28 6.87 4.57 5.80 2.82 2.04 3.09 
Indonesia Measles Bio Farma 13.16 13.90 14.45 8.50 9.04 10.26 4.66 4.85 4.19 14.14 28.66 19.71 5.51 12.30 6.66 
Indonesia Td Bio Farma 1.16 68.55 18.44 - 64.59 7.08 1.16 3.96 11.40 0.91 29.29 9.41 - 2.34 6.01 
Indonesia TdaP Bio Farma 24.77 - - - - - 24.80 - - 99.87 - - - - - 
Indonesia TT Bio Farma 1.62 2.86 2.66 - 0.45 1.28 1.62 2.41 1.37 6.82 9.64 8.41 - 8.25 4.53 
Indonesia DT Bio Farma 24.13 46.10 13.10 23.83 45.80 12.80 0.30 0.30 0.30 71.61 86.98 42.66 3.00 4.13 1.66 
Indonesia DTwP Bio Farma 3.38 1.92 1.68 - - - 3.38 1.92 1.68 16.08 9.12 6.30 - - - 
Indonesia DTwPHepB Bio Farma 79.56 41.52 - 79.24 41.52 - 0.32 - - 72.33 63.39 - 1.04 - - 
Iran BCG IP Iran 1.95 1.56 1.95 1.95 1.56 1.95 - - - 3.94 2.67 3.77 - - - 
Iran HepB_adult IP Iran 2.18 1.09 2.18 2.18 1.09 2.18 - - - 5.30 3.59 4.81 - - - 
Iran HepB_pediatric IP Iran 3.22 3.22 4.60 3.22 3.22 4.60 - - - 4.78 3.78 6.14 - - - 
Iran OPV Razi 3.40 2.00 3.30 3.40 2.00 3.30 - - - 2.39 1.02 1.88 - - - 
Iran Measles Razi 0.21 0.35 0.28 0.21 0.35 0.28 - - - 0.23 0.72 0.38 - - - 
Iran MMR Razi 8.62 17.24 12.28 8.62 17.24 12.28 - - - 3.70 6.09 3.55 - - - 
Iran Rubella Razi 4.2 x 10^-2 - 0.01 4.2 x 10^-2 - 0.01 - - - 13.29 - 90.68 - - - 
Iran Td Razi 13.37 14.58 14.58 13.37 14.58 14.58 - - - 10.52 6.23 7.44 - - - 
Iran DT Razi 0.13 0.13 0.13 0.13 0.13 0.13 - - - 0.39 0.25 0.43 - - - 
TOTAL – by year 1,393.79 1,962.16 2,476.81 827 1,179.44 1,460.4 567.23 782.57 1016.57       
GRAND TOTAL 5,832.76 3,466.84 2,366.37       
Note: N = 318 observations; 5.13 billion vaccine doses
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Among domestic sales of vaccines, 95% of the suppliers had at least 95% of market 
share for those markets. This is shown in Table 4.5. The total revenue from vaccine 
sales in global markets was US$5.83 trillion, where domestic revenue amounted to 
US$ 3.47 trillion and export market revenue was US$ 2.37 trillion. While on average, 
DCVM production revenue from vaccine sales was US$ 18.3 million for global markets, 
US$ 18.1 million for domestic markets, and US$ 13.4 million for export markets. Total 
market shares were 18.4% for global markets and 10.2% in export markets. Within the 
three-year study period, local vaccine producers were mostly state-owned enterprises 
(58%), in countries with a fully functional NRA (91%), had consistent supply to global 
immunisation programs (61%), produced around 8 different vaccines, produced 
traditional vaccine technology types (50%), and produced vaccines that were not of 
prequalified status (63%). These are shown in Tables 4.6 and 4.7. Results of the 
univariate analyses are shown in Table 4.8. 
Table 4.5 Percent market share of developing country vaccine manufacturers in 
domestic markets (2012-2014) 
COUNTRY VACCINE MANUFACTURER 
YEAR 
2012 2013 2014 
ARGENTINA Influenza_Adult Sinergium - 100.02 99.97 
ARGENTINA Influenza_Pediatric Sinergium - 100.00 100.40 
MEXICO HepB_adult Probiomed 100.00 - 100.00 
MEXICO HepB_pediatric Probiomed 100.00 - 100.00 
PAKISTAN Measles NIH Pakistan - 100.00 - 
PAKISTAN TT NIH Pakistan - 100.00 100.00 
SENEGAL YF IP Dakar - - 100.00 
THAILAND HepB_pediatric GPO-Merieux 100.00 100.00 100.00 
THAILAND Influenza_Adult GPO-Merieux 100.00 100.00 88.24 
THAILAND OPV GPO-Merieux 100.00 100.00 100.00 
THAILAND JE_Inactd GPO-Merieux 100.00 100.00 100.00 
THAILAND MR Masu, Thailand - - 100.00 
THAILAND Td Masu, Thailand 99.59 100.09 100.00 
THAILAND DTwPHepB Masu, Thailand 100.00 100.00 100.00 
TUNISIA BCG IP Tunis 100.00 100.00 100.00 
VIETNAM BCG IVAC Vietnam 100.00 100.00 100.00 
VIETNAM TT IVAC Vietnam 100.00 100.00 100.00 
VIETNAM DTwP IVAC Vietnam 100.00 100.00 100.00 
VIETNAM OPV Polyvac Vietnam 95.00 95.00 95.00 
VIETNAM Measles Polyvac Vietnam 100.00 100.00 100.00 
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VIETNAM HepB_pediatric Vabiotech 100.00 100.00 100.00 
VIETNAM Cholera Vabiotech - 100.00 100.00 
VIETNAM JE_Inactd Vabiotech 100.00 100.00 100.00 
VIETNAM Typhoid DAVAC - 100.00 100.00 
BRAZIL Hib Fiocruz - 100.00 100.00 
BRAZIL OPV Fiocruz 100.00 - 100.00 
BRAZIL IPV Fiocruz 99.88 99.91 99.90 
BRAZIL MMR Fiocruz 100.02 99.77 99.98 
BRAZIL MMRV Fiocruz - - 99.96 
BRAZIL Pneumo_conj Fiocruz 99.95 100.14 100.01 
BRAZIL Rotavirus Fiocruz - 99.85 99.87 
BRAZIL YF Fiocruz - 99.94 100.11 
BRAZIL MenC_conj FUNED - 99.80 - 
BRAZIL HepB_adult Butantan 100.00 100.00 100.12 
BRAZIL HPV Butantan - - 100.08 
BRAZIL Influenza_Adult Butantan 100.22 100.02 99.65 
BRAZIL Rabies Butantan - 100.00 - 
BRAZIL Td Butantan - 99.77 - 
BRAZIL DT Butantan 100.00 100.00 - 
BRAZIL DTwP Butantan - 100.00 - 
BRAZIL BCG FAP 100.00 100.00 100.00 
BULGARIA BCG BB-NCIPD 100.00 100.00 100.00 
BULGARIA Td BB-NCIPD 100.00 100.00 100.00 
CUBA TT Finlay 100.00 100.00 100.00 
CUBA Typhoid Finlay - 100.00 100.00 
CUBA DT Finlay 100.00 100.00 100.00 
CUBA DTwP Finlay 100.00 100.00 100.00 
CUBA DTwPHibHepB CIGB Cuba 100.00 100.00 100.00 
CUBA HepB_pediatric CIGB Cuba 100.00 100.00 100.00 
CUBA Hib CIGB Cuba 100.00 100.00 100.00 
EGYPT Td Vacsera - - 100.00 
EGYPT TT Vacsera - - 100.00 
EGYPT DT Vacsera - - 100.00 
EGYPT DTwP Vacsera - - 100.00 
INDIA OPV Haffkine 47.50 - - 
INDIA HepB_pediatric Immunologicals - - 100.00 
INDIA TT Immunologicals - - 100.24 
INDIA OPV Panacea 47.50 - - 
INDIA OPV Bharat - 95.07 - 
INDIA DTwP IP India 50.15 - 100.00 
INDIA BCG SII 50.00 100.15 99.60 
INDIA DTwPHibHepB SII 100.13 - 100.03 
INDIA HepB_pediatric SII - 49.92 - 
INDIA Measles SII 99.90 - 100.16 
INDIA BCG Green Signal 50.00 - - 
INDIA DTwP CRI Kasauli 50.15 - - 
INDIA HepB_pediatric Biological E. - 49.92 - 
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INDIA TT Biological E. 100.00 100.00 - 
INDIA DTwP Biological E. - 100.00 - 
INDONESIA BCG Biofarma 100.00 100.00 100.00 
INDONESIA DTwPHibHepB Biofarma - 100.00 99.92 
INDONESIA HepB_pediatric Biofarma - 100.00 100.00 
INDONESIA OPV Biofarma 95.00 95.00 95.00 
INDONESIA Measles Biofarma 100.00 100.00 99.57 
INDONESIA Td Biofarma - 99.98 100.00 
INDONESIA TT Biofarma - 100.00 100.00 
INDONESIA DT Biofarma 100.14 100.01 99.99 
INDONESIA DTwPHepB Biofarma 100.05 100.05 - 
IRAN BCG IP Iran 100.00 100.00 100.00 
IRAN HepB_adult IP Iran 100.00 100.00 100.00 
IRAN HepB_pediatric IP Iran 100.00 100.00 100.00 
IRAN OPV Razi 100.00 100.00 100.00 
IRAN Measles Razi 100.00 100.00 100.00 
IRAN MMR Razi 100.00 100.23 99.87 
IRAN Rubella Razi 100.00 - 100.00 
IRAN Td Razi 99.74 99.87 99.87 
IRAN DT Razi 100.00 100.00 100.00 
Source: calculated based on JRF and V3P data for 2012 - 2014
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Table 4.6 Summary and definition of outcome and explanatory variables 
Viability factor Variable Definition Indicator Mean 
(Standard Deviation) 
Data source Date of 
access 
2012 - 2014 2012 2013 2014 
Proxy of viability Revenue size 
(US$) 
 
Revenue of vaccine doses sold Model 1. Revenue 
size, 
global (US$ million) 
18.34 
(47.82) 
N=318 
14.83 
(35.30) 
N=94 
18.17 
(39.25) 
N=108 
21.35 
(61.98) 
N=116 
JRF and V3P data, 2012 - 2014 17/01/2017 
Model 2. Revenue 
size, 
domestic (US$ 
million) 
18.06 
(47.39) 
N=192 
15.04 
(38.11) 
N=55 
17.87 
(39.41) 
N=66 
20.57 
(59.60) 
N=71 
JRF and V3P data, 2012 - 2014 17/01/2017 
Model 3. Revenue 
size, 
export (US$ million) 
13.44 
(40.14) 
N=176 
10.12 
(24.73) 
N=56 
13.27 
(33.86) 
N=59 
16.66 
(54.85) 
N=61 
JRF and V3P data, 2012 - 2014 17/01/2017 
Market share 
(%) 
Revenue of vaccine doses sold 
as percentage of total revenue of 
all manufacturers selling the 
same vaccine type. 
Model 4. Percent 
market share, global 
18.42 
(27.79) 
N=318 
16.78 
(26.24) 
N=94 
18.46 
(27.94) 
N=108 
19.72 
(29.00) 
N=116 
JRF and V3P data, 2012 - 2014 17/01/2017 
Model 5. Percent 
market share, exports 
10.20 
(12.68) 
N=73 
9.87 
(13.66) 
N=24 
8.43 
(9.55) 
N=26 
12.56 
(14.77) 
N=23 
JRF and V3P data, 2012 - 2014 17/01/2017 
Economies of Scale Surviving 
Infants 
(per 1,000 live 
births) 
Birth cohort targeted under 
immunisation programs, 
calculated based on crude 
mortality rates and infant mortality 
rates 
Surviving infants 
(per 1000 live births) 
9.70 
(10.73) 
N=318 
10.03 
(10.87) 
N=894 
9.69 
(10.64) 
N=108 
9.45 
(10.79) 
N=116 
World Development 
Indicator/World Bank and UN 
Statistical Division, 2012 - 2014 
20/11/2016 
Economies of Scope Number of 
vaccines 
produced 
Number of vaccines produced by 
manufacturer 
Number of vaccines 
produced by 
manufacturer 
8.38 
(5.21) 
N=318 
8.46 
(5.24) 
N=94 
8.36 
(5.27) 
N=108 
8.35 
(5.19) 
N=116 
JRF database,  
2012 – 2014; Manufacturers’ 
websites, DCVMN Directory 
(2014); and Kaddar, Milstien, 
and Schmitt (2014) 
20/11/2016 
Historical 
performance/quality 
Supply 
sufficiency for 
global demand 
(%) 
Proportion of vaccine doses sold 
by each manufacturer to the 
global market for a particular 
vaccine 
Supply sufficiency for 
global demand 
88.43 
(24.94) 
N=318 
90.25 
(20.69) 
N=318 
89.26 
(25.89) 
N=318 
86.17 
(27.13) 
N=318 
JRF database,  
2012 – 2014 
17/01/2017 
Legal status/autonomy Number of MoH 
in last five years 
Number of ministers of health 
within last 5 years 
Number of Ministers 
of Health over the last 
5 years 
3.22 
(1.58) 
N=318 
2.99 
(1.32) 
N=94 
2.98 
(1.66) 
N=108 
3.63 
(1.63) 
N=116 
Country-related  websites 06/08/2016 
Purchasing power 
of producing country 
National 
Income level 
(US$ 
Gross national income, 
converted to U.S. dollars using 
the World Bank Atlas method, 
divided by the midyear 
population. 
Gross national 
income (GNI) per 
capita, Atlas method 
(current US$) 
5031.20 
(3,687.04) 
N=318 
4931.80 
(3503.45) 
N=94 
5222.83 
(4006.78) 
N=108 
4933.33 
(3543.60) 
N=116 
World Development 
Indicator/World Bank, 2012 -
2014 
11/02/2016 
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Table 4.7 Summary and definition of categorical explanatory variables 
Viability factor Variable Definition Indicator 
2012 – 2014 2012 2013 2014 
Data source 
Date last 
access N % N % N % N % 
Consistency of 
Production/Annual 
capital expenditure 
Consistent 
production 
(binary: 0= 
inconsistent, 1= 
consistent) 
Whether vaccine was 
procured in global 
market over the study 
period 
Consistent 195/318 61.32 65/94 69.15 65/108 60.19 65/116 56.03 
JRF data, 2012 - 
2014 
17/01/2017 
Inconsistent 123/300 38.68 29/94 30.85 43/108 39.81 51/116 43.97 
New technology 
Vaccine technology 
type 
(categorical: 0: pre-
GAVI vaccines; 
1: Phase I vaccines; 
2: Phase II vaccines; 
3: Phase III) 
Whether the vaccine is 
a traditional EPI 
vaccine or a modern 
one 
 
Pre-GAVI vaccine types 158/318 49.69 50/94 53.19 52/108 48.15 56/116 48.28 
Vaccines introduced 
in each GAVI Phase, 
as stated in GAVI 
website. 
17/01/2017 
Phase I GAVI vaccines 84/318 26.42 26/94 27.66 28/108 25.93 30/116 25.86 
Phase II GAVI vaccines 46/318 14.47 12/94 12.77 16/108 14.81 18/116 15.52 
Phase III GAVI vaccines 30/318 9.43 6/94 6.38 12/108 11.11 12/116 10.34 
Credibility of quality/ 
Regulatory 
infrastructure 
 
Fully functional 
National Regulatory 
Authority (NRA) 
National Regulatory 
Authorities (NRA) that 
fulfil six critical 
functions as identified 
and assessed by 
WHO53. 
Fully functional 290/318 91.19 80/94 85.11 101/108 93.52 109/116 93.97 
Interview with 
Regulatory team at 
WHO/HQ 
12/12/2014 
 Not fully functional 28/318 8.81 14/94 14.89 7/108 6.48 7/116 6.03 
 Vaccine 
prequalification 
status 
(binary: 
0=Prequalified, 1=not 
prequalified) 
Whether vaccine 
produced has a 
prequalified status 
Prequalified 117/318 36.79 36/94 38.30 39/108 36.11 42/116 36.21 
Vaccine 
prequalification 
database, WHO 
 
 Not prequalified 201/318 63.21 58/94 61.70 69/108 63.89 74/116 63.79 20/11/2016 
                                               
53 WHO establishes six functions that a national regulatory authority must fulfil to be fully functional, a requirement for the corresponding country’s vaccine 
manufacturer to be allowed to export its vaccine production to other countries. These six NRA functions are: (1) a published set of requirements for licensing; (2) 
surveillance of vaccine field performance; (3) system of lot release; (4) use of laboratory when needed; (5) regular inspections for GMP; and (6) evaluation of 
clinical performance. 
151 
 
Table 4.8. Univariate hierarchical linear regression of factors associated with revenue sizes and percent market share of vaccines produced by 
developing country vaccine manufacturers  
 Model 1 
(n=318) 
Model 2 
(n=192) 
Model 3 
(n=73) 
Model 4 
(n=318) 
Model 5 
(n=73) 
Explanatory 
variable 
β (95% CI) P β (95% CI) P β (95% CI) P β (95% CI) P β (95% CI) P 
Constant 14.45   14.67   0.99   1.37   0.99   
Surviving Infants 
(log) 
0.21 0.05–0.37 0.008* 0.73 0.53–0.92 0.000* 0.03 -0.24–0.30 0.812 0.25 0.11–0.38 0.000* 0.03 -0.24–0.30 0.812 
GNI per capita (log) 0.41 0.04–0.79 0.029* 0.45 0.01–0.89 0.046* -0.64 -1.40–0.11 0.096* -0.04 -0.37–0.29 0.831 -0.64 -1.40–0.11 0.096* 
Number of 
vaccines products 
0.47 -0.01–0.10 0.105* 0.16 0.08–0.25 0.000* 0.20 0.08–0.32 0.001* 0.10 0.05–0.15 0.000* 0.20 0.08–0.32 0.001* 
Consistent 
production supply 
1.27 0.67–1.86 0.000* -0.23 -0.93–0.46 0.348 0.40 1.93–4.06 0.000* 1.04 0.51–1.57 0.000* 2.99 1.93–4.06 0.000* 
Vaccine 
technology 
0.38 0.08–0.68 0.014* 0.19 -1.11–1.49 0.773 0.017 -0.00–0.04 0.110* 0.67 0.42–0.93 0.000* 0.19 -1.11–1.49 0.773 
Sufficient supply 
against demand 
0.34 -0.33–1.01 0.315 0.37 -0.40–1.14 0.348 0.40 -0.73–1.54 0.486 0.58 -0.01–1.17 0.052* 0.40 -0.73–1.54 0.486 
NRA 2.00 0.97–3.02 0.000* 1.92 0.78–3.05 0.001* -0.75 -2.97–1.48 0.511 2.04 1.14–2.94 0.000* -0.75 -2.97–1.48 0.511 
Vaccine PQ status 0.78 0.17–1.39 0.013* 0.35 -0.39–1.10 0.350 2.88 1.92–3.83 0.000* 1.13 0.60–1.66 0.000* 2.88 1.92–3.83 0.000* 
Manufacture status 0.24 -0.37–0.84 0.438 1.18 0.43–1.92 0.002* 1.58 0.51–2.65 0.004* 0.46 -0.66–0.99 0.086* 1.58 0.51–2.65 0.004* 
Number of MOH, 
last 5 years 
-0.10 -0.29–0.09 0.310 -0.16 -0.37–0.05 0.141* 0.17 -0.16–0.50 0.322 -0.120 -0.36– -0.03 0.019* 0.17 -0.16–0.50 0.322 
Proportion of 
export sales 
-0.01 -0.01 - -0.00 0.009* -0.00 -0.00–0.00 0.540 0.14 -0.00–0.03 0.058* -0.01 -0.01– -0.00 0.016* 0.014 -0.00–0.03 0.058* 
* p value ≤ 0.2. Note: Model 1: Revenue size for global market; Model 2: Revenue size for domestic market; Model 3: Revenue size for export market; Model 4: 
Percent market share for global market; Model 5: Percent market share for export market. 
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4.3.2. Multivariate regression 
Determinants of viability in global markets: Revenue size (Model 1) 
In the vaccine market, revenue sizes were estimated to increase as a result of a one 
percent increase in the following factors: the number of surviving infants (0.4%54) and 
the national income level of the producing country (0.83%). Existence of the following 
factors influence an increase in revenue sizes in global markets: consistent production 
(122.2%) and the ability to sufficiently meet the need of immunisation programs in 
procuring countries (2%). Companies with a higher proportion of export sales 
compared to their domestic sales were associated with 2% lower revenue sizes. The 
number of vaccine products produced by a manufacturer as well as the rate of changes 
within the health ministry did not significantly influence global market revenues. 
Determinants of viability in domestic markets: Revenue size (Model 2) 
Revenue sizes in domestic markets were found to increase in association with the 
number of surviving infants (0.92%), and national income levels (0.66%). Having 
consistent production, later stage GAVI vaccines and the ability to sufficiently meet the 
need of immunisation programs in procuring countries were all positively associated 
with revenue size in domestic markets at varying degrees: 80%, 64%, and 1%. The 
number of vaccine products produced by a manufacturer as well as a vaccine’s 
prequalification status were not determinant factors for revenue sizes in domestic 
markets.  
Determinants of viability in export markets: Revenue size (Model 3) 
Export market revenue was positively associated with a one percent increase in 
national income levels (2.37%). Consistency in production supply, as well as the ability 
                                               
54 Percentages in brackets represent the percentage change in the outcome variable associated 
with a one-unit change in the explanatory variable. For instance, if the number of surviving 
infants changes by one percent, the dependent variable is expected to change by 0.4 percent. 
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to meet the demand of immunisation programs in procuring countries was associated 
with increases in export market revenue by 201% and 2%. Prequalified vaccine status 
and private ownership were positively associated with export market revenue by 139% 
and 661%, respectively. Changes within the health ministry were also associated with 
increasing revenues in export markets by 49%. The producer country’s birth cohort as 
well as the technology level of vaccines were not found to be determining factors for 
revenue sizes in export markets. 
Determinants of viability in global markets: Percent market share (Model 4) 
Percent market share in global vaccine markets was positively associated with one 
percent increase in the producing country’s birth cohort (0.24%) and number of 
vaccines produced by a single manufacturer (14%). The consistency in production 
supply and later stage GAVI vaccines were all positively associated with market share 
in global markets, by 95% and 67% respectively. The ability to meet the demand of 
immunisation programs in procuring countries and having vaccine prequalification 
status were positively associated with a greater percent market share in the global 
vaccine market (2% and 126%). Having a larger proportion of domestic sales 
compared to export sales was also associated with a higher percent market share in 
the global vaccines market (2%). The producing country’s national income level was 
not associated with changes in percent market share in global markets. 
Determinants of viability in export markets: Percent market share (Model 5) 
Percent market share in export markets were influenced by a one percent increase in 
the producing countries’ national income (2.37%). Having consistent production and 
the ability to meet the demand of immunisation programs in procuring countries 
increased a DCVM’s export market shares by 200% and 2%. A vaccine’s 
prequalification status, private ownership and changes in ministry of health were 
positively associated with changes in percent market share for exports (139%, 661% 
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and 49%). The producing country’s birth cohorts as well as later stage GAVI vaccines 
were not determining factors for percent export market shares. These multivariate 
regression results are shown in Table 4.9.  
Post-estimation tests on the residuals were performed for each model and presented 
in Figures 4.7 – 4.11. The residuals show a normal distribution and does not suggest 
violations to the normality assumption. 
Results from the first sensitivity analysis that excluded reported multiple producers from 
the vaccine procurement data showed that there were not any significant difference in 
the percent market share for domestic markets or the global and export markets. The 
two other sensitivity analysis also did not show that there were any significant 
differences in the results.
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Table 4.9. Multivariate hierarchical linear regression of factors associated with revenue sizes and percent market share of vaccines produced by 
developing country vaccine manufacturers 
 MODEL 1 
(N=318) 
MODEL 2 
(N=192) 
MODEL 3 
(N=73) 
MODEL 4 
(N=318) 
MODEL 5 
(N=73) 
Explanatory Variable β (95% CI) P β (95% CI) P β (95% CI) P β (95% CI) P Β (95% CI) P 
Constant -1.21   -6.69   -24.39   -7.98   -24.39   
Surviving Infants (log) 0.40 0.14–0.65 0.002** 0.92 0.63 – 1.21 0.000*** -0.19 -0.64-0.27 0.427 0.24 0.03 - 0.48 0.047* -0.19 -0.64-0.27 0.427 
GNI per capita (log) 0.83 0.28–1.38 0.003** 0.66 1.72–1.15 0.008** 2.37 0.72 – 4.02 0.005** 0.35 -0.17 – 0.87 0.192 2.37 0.72–4.02 0.005** 
Number of vaccines 
products 
0.72 -0.02–0.17 0.131 0.06 -0.03-0.16 0.182    0.14 0.03 - 0.20 0.011*    
Consistent production 
supply 
1.222 0.48–1.97 0.001*** 0.80 0.06-1.55 0.035* 2.01 0.82-3.19 0.001*** 0.95 0.24 - 1.67 0.009** 2.00 0.82 – 3.19 0.001*** 
Vaccine technology 0.44 -0.20–1.07 0.178 0.64 0.05–1.23 0.035* 0.24 -0.57 – 1.04 0.563 0.67 0.24 – 1.10 0.002** 0.24 -0.57-1.04 0.563 
Sufficient supply 
against demand 
0.02 0.01–0.03 0.000*** 0.01 0.01–0.02 0.000*** 0.02 0.01 – 0.04 0.002** 0.02 0.01 - 0.03 0.000*** 0.02 0.01 -0.04 0.002** 
NRA                
Vaccine PQ status 1.59 0.83 – 2.26 0.000*** 0.30 -0.05 – 1.05 0.431 1.39 0.66 – 2.12 0.000*** 1.26 0.54 - 1.98 0.001*** 1.39 0.66- 2.11 0.000*** 
Manufacture status       6.61 3.93 – 9.28 0.000***    6.61 3.93 – 9.28 0.000*** 
Number of MOH, last 5 
years 
0.10 -0.05–0.25 0.181    0.49 0.14 – 0.84 0.006**    0.49 0.14 - 0.84 0.006** 
Proportion of export 
sales 
-0.02 -0.03 – -0.017 0.000***       -0.02 -0.03 - 0.02 0.000**    
                
Random effects Variance (95% CI) Variance (95% CI) Variance (95% CI) Variance (95% CI) Variance (95% CI) 
Vaccine 
(Level 1) 
1.74 1.18 – 2.55 1.47 0.92 – 2.34 0.15 0.0 – 4.12 0.85 0.43 – 1.70 0.22 0.03–2.08 
Manufacturer 
(Level 2) 
1.26 0.00–1459387 0.91 0.00–2.16e13 0.75 0.00–1.8e34 1.26 0.00–4.6e8 0.75 0.00–1.8e34 
Producing country 
(Level 3) 
1.26 0.00–1459766 0.91 0.00–2.16e13 0.75 0.00–1.8e34 1.26 0.00–4.6e8 0.75 0.00–1.8e34 
Residual 0.82 0.74–0.91 0.41 0.36–0.47 1.14 0.94–1.37 0.84 0.76–0.94 1.14 0.94–1.37 
Log-likelihood -582.79  -252.89  -123.24  -574.47  -123.24  
 
* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; bold number: significant. Note: Model 1: Revenue size for global market; Model 2: Revenue size for domestic market; Model 3: Revenue size 
for export market; Model 4: Percent market share for global market; Model 5: Percent market share for export market.
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   (a)      (b)  
  
Figure 4.7 Post-estimation tests on residuals of regression of factors influencing 
developing country vaccine manufacturers’ revenue size in global markets (Model 1). 
Note: (a) distribution of residual values; (b) residuals plotted against corresponding predicted 
values. 
 
  
   (a)      (b) 
Figure 4.8 Post-estimation tests on residuals of regression of factors influencing 
developing country vaccine manufacturers’ revenue size in domestic markets (Model 
2). Note: (a) distribution of residual values; (b) residuals plotted against corresponding 
predicted values. 
 
  
   (a)      (b) 
Figure 4.9 Post-estimation tests on residuals of regression of factors influencing 
developing country vaccine manufacturers’ revenue size in export markets (Model 3). 
Note: (a) distribution of residual values; (b) residuals plotted against corresponding predicted 
values. 
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   (a)      (b) 
Figure 4.10 Post-estimation tests on residuals of regression of factors influencing 
developing country vaccine manufacturers’ percent market share in global markets 
(Model 4). Note: (a) distribution of residual values; (b) residuals plotted against corresponding 
predicted values. 
 
  
   (a)      (b) 
Figure 4.11 Post-estimation tests on residuals of regression of factors influencing 
developing country vaccine manufacturers’ percent market share in export markets 
(Model 5). Note: (a) frequency distribution of residual values; (b) residuals plotted against 
corresponding predicted values 
 
4.4. Discussion  
During the study period, global market shares for vaccines produced by DCVMs were 
steady at 15 to 21% and within market types (domestic and export), the data showed 
a stable market share across the three years observed. The data also showed a 
contrast between domestic and export markets shares of DCVMs (95% compared to 
10%). The very high domestic market share suggests that there is nearly no 
competition for product sales within domestic vaccine markets.  
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The multivariate regression identified that all seven characteristics proposed by 
Milstien et al. (1997) were associated with market share of local vaccine production 
across markets: economies of scale and scope (surviving infants and number of 
vaccines), consistency of production, vaccine technology, supply sufficiency, credibility 
of vaccine quality (vaccine prequalification status), management structure of the 
company, and changes in health ministries. Additional factors that were included in this 
Chapter such as national income per capita and proportion of export sales were also 
found to be associated with vaccine production viability.  
Indicators used as proxies for economies of scale and scope were determinant factors 
for global markets, yet only economies of scale (number of surviving infants) were 
associated with domestic revenue. In export markets, neither of these factors were 
influential in increasing revenue. Given that the indicators for economies of scale and 
economies of scope were that of the producing country and not the procuring country, 
we cannot establish whether these factors from the procuring countries’ perspective 
were not influential in export markets. In fact, sufficient supply (observed for the 
procuring country) was shown to be significantly associated with export market share 
as well as other markets, indicating that economies of scale and scope may in fact be 
a determining factor in all three market types. 
Consistency of production was significant in all three market types that were 
investigated in the five models. This is an interesting finding given that various supply 
disruptions occur often in vaccine markets (Gurnani, Mehrotra, & Ray, 2012), (Batson 
et al., 2003). The impact of this factor in export markets seemed to be greater than in 
domestic markets, indicating that consistency of production may provide a competitive 
advantage for manufacturers supplying to export markets. 
Production of higher vaccine technology types was found to be a determining factor in 
global market shares and domestic revenue sizes. Vaccine technology levels not being 
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a determinant factor in export markets may be due to more advanced technology 
vaccine types being produced by ICVMs, as shown in Figure 4.3. As for vaccine 
technology levels being a determinant factor in domestic markets, this may be due to 
the changing landscape in vaccines, where WHO recommendations are issued for 
countries to shift from certain older vaccine types such as oral polio vaccine (OPV) to 
newer types, such as inactivated polio vaccines (IPV) in single-antigen and 
combination vaccines such as the hexavalent vaccine (DTP-HepB-Hib-IPV). 
Supply sufficiency was a significant factor in all five models. Given the high market 
concentrations in individual vaccine markets (i.e.: Hepatitis B vaccine market, 
hexavalent vaccine market, etc.) it is important for existing suppliers to meet the 
demand of the immunisation program and avoid the need for multiple vaccine sources, 
hence avoiding higher transaction costs (Milstien et al., 1997). 
Credibility of vaccine quality, identified using the indicator of vaccine prequalification 
status, was a determining factor in export market revenue and percent market share 
for global and export markets. A fully functional NRA however was not included in the 
five models due to being eliminated at the univariable analysis stage. This might be 
because the prequalification of a vaccine requires that the NRAs in the respective 
countries be fully functional (Dellepiane & Wood, 2015). Further, the variable for NRA 
used in the analysis was for NRAs that fulfil all 6 functions. However, procurement may 
still occur from manufacturing countries with NRAs having less than the six functions 
(though this is not ideal nor recommended). Detailed information in regards to the 
number of functions fulfilled by each WHO member-country’s NRA however was not 
publicly available; this research only had access to information identifying fully 
functional NRAs.  
The ownership type, as a proxy for management structure, was a determining factor 
for export markets, both in terms of revenue size (Model 3) and percent market share 
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(Model 5). In particular, the results suggested that manufacturers with private status or 
have private sector involvement such as public-private partnerships have a greater 
chance of increasing their revenue and percent market share when competing in export 
markets. This is likely because of the stronger domestic interest and captive market 
that state-owned manufacturers would have over their private sector competitors, 
therefore private sector manufacturers may find export markets more attractive.  
Health policy leadership in producing countries showed a high tendency for change 
(with an average of more than three health ministers across a five-year span). The 
number of Ministers of Health over the last five years as per Milstien et al. (1997) was 
found to be positively associated with revenue sizes in export markets (Models 3 and 
5) but not global or domestic markets. Immunisation programs are normally run with a 
long-term perspective, where demand is driven by the size of birth cohorts, which do 
not change over short periods of times. Furthermore, the indicator used for stability of 
health policy (the number of ministers of health) may not be an accurate proxy. In many 
countries, the body that regulates and licenses vaccines, the NRA, is often independent 
from the Ministry of Health structure. Changes in NRA leadership might be a better 
proxy for vaccine policy stability that should be investigated in future studies. 
Proportion of export sales, a proxy for market expansion strategy, was a significant 
factor in global revenue sizes and percent market share (Models 1 and 4), but not 
specifically in domestic or export markets. The effect of predominantly selling to export 
markets was negative, which suggests that having a strong domestic market presence 
is important in influencing viability.  
4.4.1. Limitations 
The study by Milstien et al. (1997) used primary data based on 13 country 
assessments, which provided more detail than the current study. However, the analysis 
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in this chapter was at the vaccine product level, a more disaggregated level than the 
Milstien study.  
In their study, Milstien et al. (1997) used the indicator ‘annual capital expenditure’ to 
represent production consistency. An attempt was made to include this in the current 
analysis by assessing capital productivity or capital intensity, which measures the 
capital intensity of a given industry. Capital productivity is a ratio obtained by dividing 
capital expenditure by total revenue for a given period (Sinclair et al., 2015), using 
gross fixed capital formation (GFCF) as a proxy for capital expenditure and 
manufacturing value added (MVA) for total revenue of the industry in question. These 
data were provided by the statistics team at UNIDO. However, there was insufficient 
data encompassing all vaccine producing countries observed. For this reason, capital 
productivity levels were not included as a representation of production consistency.  
Though the data on vaccine doses sold were derived from WHO member states, the 
corresponding vaccine price data were used based on assumptions derived from the 
V3P database, and were not identifiable by procuring country. As the vaccine prices in 
the V3P database varied by transaction, weighted average prices were determined by 
vaccine product, income level of procuring country and vaccine procurement method, 
whether directly procured or through a UN procurement agency.  
4.4.2. Conclusions 
This study was designed to identify and assess the critical factors that influence 
vaccine production viability among DCVMs. Changes within the vaccine industry, 
stemming from advances in technological breakthrough and regulatory standards, 
pose challenges for manufacturers globally. These challenges are even greater for 
DCVMs, for which markets in developing countries are large in size yet low in fiscal 
space.  
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This study adopted a systematic method to evaluate viability of local vaccine producers 
that was first established by Milstien et al. (1997), and used an updated framework to 
investigate viability for specific vaccine market types. This was done by identifying 
revenue sizes and percent market share as proxies for viability at the vaccine product 
level. To my knowledge this is the first reported study that has used multivariable 
regression analyses to investigate the determinants of viability of local vaccine 
production in developing countries.  
In general, the findings of this Chapter identified that vaccine viability factors influence 
a vaccine product’s revenue size and market share. The analysis also found that 
vaccine viability are influenced by economies of scale and scope (surviving infants and 
number of vaccines), consistency of production, vaccine technology, supply 
sufficiency, credibility of vaccine quality (vaccine prequalification status), management 
structure of the company, and changes in health ministries. National income per capita 
and proportion of export to total sales were also found to be associated with vaccine 
production viability. 
Revenue sizes were found to be influenced by national income levels, consistent 
production supplies and the ability to meet the needs of immunisation programs in 
procuring countries, whereas factors identified as influencing percentage of market 
share were: having consistent production, the ability to meet the needs of immunisation 
programs in procuring countries and having vaccines with prequalification status.   
The data suggest a sharp contrast between DCVMs’ market share domestic and export 
markets, and that production viability in domestic vaccine markets differ from its export 
markets. Though proxies for economies of scale and scope were determinant factors 
for global markets, only economies of scale (number of surviving infants) were 
confirmed to be associated with domestic revenue. In export markets, neither of these 
factors were influential in increasing revenue. However, we cannot establish whether 
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these factors, because they were observed from the producing countries’ perspective, 
were not influential in export markets. In fact, sufficient supply (observed for the 
procuring country) was shown to be significantly associated with export market share 
as well as other markets, indicating that economies of scale and scope may in fact be 
a determining factor in all three market types. 
The findings also suggest that consistency in production is important in maintaining 
viability in domestic markets, and is even more important for DCVMs interested in 
venturing into export markets. This may be quite challenging given that various supply 
disruptions occur often in vaccine markets (Gurnani, Mehrotra, & Ray, 2012), (Batson 
et al., 2003). Further, the analysis suggests that establishing a strong domestic market 
prior to expanding globally.   
The study indicates that DCVMs’ viability in export markets may not be dependent on 
its technological capacity, however with the changing landscape of vaccine technology 
due to recent WHO recommendation in switching from more traditional types to safer 
and more advanced options, DCVMs need to enhance their ability in to produce higher 
technology type vaccines to maintain its domestic viability  
The study also suggest that manufacturers with private status or have private sector 
involvement such as public-private partnerships have a greater chance of increasing 
their revenue and percent market share when competing in export markets. This is 
likely because of the stronger domestic interest and captive market that state-owned 
manufacturers would have over their private sector competitors, therefore private 
sector manufacturers may find export markets more attractive.
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 A mixed-effects model of the association 
between procurement factors and prices of vaccines 
produced by developing countries  
5.1. Introduction 
Vaccines prices affect a country’s decision on adopting a new vaccine into their 
immunisation program because of the cost implications for the procuring country. 
Evidence suggests that vaccine price is among the most important factors in 
determining access of countries to new vaccines (Kaiser, 2008; Munira & Fritzen, 2007; 
Shearer et al., 2010), however vaccine price transparency remains an issue that WHO 
argues is key in implementing the Global Vaccine Action Plan (GVAP). 
Countries procuring vaccines directly from the manufacturer, as opposed to bulk 
procurement through an international agency, often do not have a way to know the 
current market price paid by other countries. Evidence has shown that the prices that 
countries have paid were not necessarily driven by their income status (Milstien et al., 
2003). Milstien et al. (2003) measured the prices that different income level countries 
were paying for their Hepatitis B vaccine, which at the time was a NUV. They reported 
that prices middle income countries were paying were often above $1 per dose (which 
is around the UNICEF price level), and that many of these countries were paying prices 
at large range (US$0.4 to US$7.8555). 
This situation of asymmetric information, which often exists in regards to vaccine 
prices, is defined as a situation where the different parties involved in a transaction do 
not have the same level of information, therefore making it difficult to achieve an optimal 
level of pricing that fulfils Pareto Optimum (Pindyck & Rubinfeld, 1989). Pareto 
                                               
55 Data based on member-country reporting to WHO in 2002. 
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optimum is an economic concept that defines an allocation to be optimal if no other 
allocation exists that can make one individual better-off without causing the other 
parties involved to be worse-off. By providing information to both procuring and 
producing countries, issues with asymmetric information can be overcome. In effort to 
increase transparency in prices and reduce the problem of asymmetric information, 
WHO has established the Vaccine Product, Price and Procurement (V3P) project. 
Information is known to be an important economic factor, particularly when economic 
resources are scarce and in the presence of uncertainty (Stapleton & Nicholson, 1998). 
Having pricing information may determine the actions of the procurer in their decision 
to purchase vaccines given the resources/budgets that are available to them, and for 
manufacturers, their pricing behaviours will also determine how well they can recoup 
their investment and achieve viability in the vaccines market.  
Vaccine pricing policies are often shaped by a complex set of factors. These can range 
from maximising profits right thought to signalling quality (especially if producer is new 
to market) or simply recovering costs. Some goals are set for the short-term and some 
for the long-term. An understanding of the factors that influence the setting of vaccine 
prices is also important. Knowledge of these factors will help explain how well DCVMs 
set prices given knowledge of costs, which is important in establishing how effective 
they are in recouping costs and ensuring profitability and viability. This is important in 
determining a manufacturer’s ability to remain viable in the vaccine market.  
This chapter aims to identify and quantify the effect of procurement factors on vaccine 
prices sold by developing country manufacturers. Though procurement factors is not a 
theoretical concept, it is defined as the terms and agreements made during a vaccine 
procurement between a vaccine manufacturer and its clientele. These factors are 
assumed to influence the pricing decision of vaccine manufacturers, and include but 
not limited to: size of procured volumes, presentation sizes and formulation types, 
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income level of the consumer, procurement mechanisms used, product type and 
technology level, contract terms, and competition level. By gaining an understanding 
of how procurement factors influence vaccine pricing behaviour, this may allow 
manufacturers to organize themselves to ensure viability.  Three outcome variables 
were investigated that includes all vaccine types as a well as by technology level, 
defined as traditional and modern vaccines. The findings will allow developing country 
vaccine producers to align their production plans according to the factors influencing 
their vaccine sales.  
This chapter is organised as follows: a description of the variables used in the analysis 
along with the econometric methods are presented in section 5.2. Section 5.3 presents 
the results of the regression model of the association between procurement factors 
and vaccine prices sold by developing countries, followed by a discussion, summary, 
study limitations and conclusions in section 5.4. 
5.2. Methods 
5.2.1. DCVM vaccine prices 
Price-per-dose data, self-reported by procuring countries, were obtained from the V3P 
project. This is the most complete dataset on vaccines prices to date. A subset of the 
dataset, including prices of vaccines produced by DCVMs for all vaccines sold to 
immunisation programmes globally as reported to WHO, from 2005 to 2015, was used 
in the analyses.  
5.2.2. Explanatory variables 
The following explanatory variables were used in the analysis: 
 Volume: number of vaccine doses procured in each transaction; 
 UN Procurement: whether vaccine procurement was facilitated by a UN 
procuring agency such as UNICEF and PAHO; 
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 Contract: the different contract lengths that may have been arranged, if any, 
between the vaccine manufacturer and procurer. It was hypothesised that the 
longer the contract length, the more secure was the demand for the vaccines, 
resulting in a decreased price;  
 Formulation: formulation presentation of the vaccine. This included categories 
such as multi-dose vials, single-dose vials, prefilled syringes and lyophilised 
vaccines; 
 Formulation size: the number of doses in the formulation presentation, mostly 
applicable to vial formulations; 
 Vaccine category: the different technology categories of the vaccine (i.e.: 
bacterial, viral, combination, conjugate and recombinant vaccines); 
 Vaccine technology: the level of new technology accessed by the manufacturer 
for the vaccine. Vaccines were categorised by traditional and modern vaccines 
based on WHO and GAVI’s classification of vaccine priorities and market-
shaping strategies for developing countries56. The first category, traditional 
vaccines, included those introduced through the initial EPI program, prior to 
GAVI’s establishment. All other vaccines were categorised as modern 
vaccines; 
 Income group (procurer): national income level of the purchasing country, 
based on the World Bank country classification and income thresholds (see 
Appendix 1 in Chapter 2); 
 Income group (producer): national income level of the producing country, based 
on the World Bank country classification and income thresholds (see Appendix 
1 in Chapter 2); 
 Number of prequalified substitutes: number of competing products. This was 
the sum of similar vaccine products produced by different manufacturers, plus 
                                               
 56 Phase I (2000-06), Phase II (2007-10), Phase III (2011-15) and Phase IV (2016-20), please 
refer to: http://www.gavi.org/about/strategy/  
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vaccine products by the same manufacturer that were prequalified and had 
different formulation presentation. Vaccine products that may have the same 
antigens, for instance Hepatitis B and DTP-HepB, were not considered 
substitutes because different countries have different preferences in regards to 
specific antigens that suit their population and epidemiological conditions 
(Jarrett, 2008; Pauly & Cleff, 1996). 
More detail on the variables assessed as procurement factors in influencing vaccine 
prices of developing countries are provided in Tables 5.4 and 5.5. 
5.2.3. Statistical analysis 
The outcome data were grouped at multiple levels (unit, vaccine, manufacturer, country 
and year) but not nested (i.e. groups at different levels sat across groups at other levels, 
for example manufacturer A sold vaccine X to a number of different countries in year 
Y; these transactions are treated as different data points). Three outcome variables 
were modelled: 
 Price per dose for all vaccines (Model 1) 
 Price per dose for traditional vaccines (Model 2) 
 Price per dose for modern vaccines (Model 3) 
Linear regression models were applied given that the outcome variables were 
continuous variables. These outcome variables were log transformed to ensure a near-
normal distribution, due to the skewness of the data. Volume (i.e. number of doses 
produced), one of the explanatory variables, was also log transformed. The normal and 
logarithmic transformation for price and volume data can be seen in Figure 5.1. Graph 
(1b) in Figure 5.1 shows that the log transformed data for vaccine prices has a bimodal 
distribution57. The subsequent graphs (2b) and (3b) in Figure 5.1 show the log 
                                               
57  A bimodal distribution is a continuous probability distribution with two different modes, usually 
appears as distinct peaks. 
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transformed vaccine prices for the different technology types (traditional and modern 
vaccine) which account for the bimodality distribution in the overall vaccine data. 
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Figure 5.1. Logarithmic transformations of outcome and explanatory variables for 
vaccines produced by developing country manufacturers. Note: (1a) price of all vaccines; 
(1b) price of all vaccines – log transformed; (2a) price of traditional vaccines; (2b) price of 
traditional vaccines – log transformed; (3a) price of modern vaccines; (3b) price of modern 
vaccines – log transformed; (4a) volume of all vaccine transactions; (4b) volume of all vaccine 
transactions – log transformed. 
 
Data were imported to STATA 14.0 (Stata Corporation, College Station, Texas) where 
each observation was linked to its corresponding vaccine type-, manufacturer- and 
country level explanatory variable. In building the model, a univariate analysis was 
conducted, where a high significance threshold of P>0.2 was used for selecting 
variables for subsequent multivariate analysis, to avoid potential exclusions of false 
positives (Table 5.1). Multicollinearity was investigated using Pearson’s pairwise 
correlation coefficients (Table 5.2). No pairs of explanatory variables had a correlation 
coefficient of >|0.6| and thus no variables were excluded due to multicollinearity. 
Heteroscedasticity was also tested using Breusch-Pagan / Cook-Weisberg (Table 5.3).  
Multivariable mixed-effect linear regression models were developed using a backward 
stepwise variable selection method, with transaction, vaccine type, manufacturer and 
country level random effects to account for clustering. Variables were excluded from 
the model if they exceeded the threshold of P≤0.2.
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Table 5.1. Univariate regression of factors associated with price per dose of vaccines produced by developing country manufacturers 
Explanatory variable 
Model 1 
(n=284) 
Model 2 
(n=177) 
Model 3 
(n=107) 
β (95% CI) P β (95% CI) P β (95% CI) P 
Constant -0.77   -1.13   0.45   
Volume (log) -0.14 -0.20 - -0.08 0.000* -1.65 -1.89 - -1.42 0.000* -0.36 -0.66 - -0.06 0.019* 
UN Procurement -1.32 -1.57 - -1.07 0.000* -1.57 -1.81 -1.34 0.000* -0.32 -0.61 -0.04 0.027* 
Contract -0.06 -0.15 – 0.02 0.138* -0.09 -0.18 – 0.01 0.055* -0.05 -0.14 - 0.03 0.237* 
Formulation type 0.45 0.30 – 0.59 0.000* 0.19 0.01 - 0.36 0.037* 0.33 0.19 - 0.47 0.000* 
Formulation size -0.16 -0.17 - -0.14 0.000* -0.12 -0.14  -0.09 0.000* -0.11 -0.14 - -0.08 0.000* 
Vaccine technology          
Bacterial -1.57 -1.82 - -1.33 0.000* -0.73 -1.16 - -0.30 0.001* -0.02 -0.75 -  0.70 0.949 
Viral 1.54 1.24 - 1.84 0.000* 0.73 0.30 - 1.16 0.001* 0.40 -0.28 - 1.07 0.245 
Combination 1.83 1.48 - 2.18 0.000* – – – 0.01 -0.66 – 0.68 0.970 
Conjugate 1.15 -1.18 – 3.48 0.333 – – – -0.67 -2.35 – 1.01 0.433 
Recombinant 0.98 0.43 – 1.54 0.001* – – – -0.83 -1.56 - -0.11 0.025* 
Income level 
(Producing country) 
0.14 -0.14 – 0.43 0.334 0.54 0.27 - 0.81 0.000* 0.75 0.29 - 1.21 0.002* 
Income level 
(Procuring country) 
0.73 0.54 - 0.94 0.000* 0.88 0.67 - 1.09 0.000* 0.56 0.36 - 0.75 0.000* 
Number of PQ 
substitutes 
0.04 0.01 – 0.71 0.009* -0.03 -0.09 - 0.02 0.193* 0.05 0.03 - 0.071 0.000* 
*: p-value ≤ 0.2. Note: Model 1: Price per dose for all vaccines; Model 2: Price per dose for all traditional vaccines; Model 3: Price per dose for modern vaccines.
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Table 5.2. Correlation matrix of explanatory variables associated with price per dose of vaccines produced by developing country manufacturers 
 Volume 
(log) 
UN 
Procurement 
Contract 
Formulation 
type 
Formulation 
size 
Vaccine 
technology 
Income level 
(Producing 
country) 
Income level 
(Procuring 
country) 
Number of PQ 
substitutes 
Volume 
(log) 
1.000         
UN Procurement 0.260 1.000        
Contract 0.158 0.225 1.000       
Formulation type - 0.030 -  0.082 - 0.051 1.000      
Formulation size 0.207 0.199 - 0.049 - 0.347 1.000     
Vaccine 
technology 
0.083 - 0.043 0.084 0.184 - 0.508 1.000    
Income level 
(Producing 
country) 
- 0.267 - 0.270 - 0.104 0.215 - 0.032 - 0.246 1.000   
Income level 
(Procuring 
country) 
- 0.578 - 0.424 - 0.278 0.155 - 0.253 - 0.061 0.320 1.000  
Number of PQ 
substitutes 
0.005 0.141 0.111 0.046 - 0.184 - 0.052 - 0.033 - 0.037 1.000 
Note: None of the correlation estimations exceeded the correlation coefficient threshold of |0.6|, therefore there are no observed multicollinearity in the model  
 
Table 5.3. Breusch-Pagan / Cook-Weisberg test for heteroskedasticity  
Ho   Constant variance 
Variables  fitted values of logprice 
chi2(1)  0.04 
Prob > chi2   0.8373 
Note: the test statistic has a p-value above 0.05, therefore the null hypothesis of homoscedasticity cannot be rejected.
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The form of the mixed-effects multivariate regression models were: 
Model 1 (Price per dose for all vaccines): 
𝑳𝒐𝒈(𝑽𝑷𝒊𝒋𝒌𝒕) = 𝜷𝟎𝒊𝒋𝒌𝒍𝒕 + 𝜷𝟏𝒋𝒌𝒍𝑽𝒐𝒍𝒖𝒎𝒆𝒊𝒋𝒌𝒍𝒕 + 𝜷𝟐𝑼𝑵𝑷𝒓𝒐𝒄𝒊𝒋𝒌𝒍𝒕 + 𝜷𝟑𝑭𝒐𝒓𝒎𝒖𝒍𝒂𝒆𝒋𝒌𝒍 +
𝜷𝟒𝑭𝒐𝒓𝒎𝒖𝒍𝒂𝒕𝒊𝒐𝒏 𝒔𝒊𝒛𝒆𝒋𝒌𝒍 + 𝜷𝟓𝑽𝒙𝑪𝒂𝒕𝒋𝒌𝒍 + 𝜷𝟔𝑽𝒙𝑻𝒆𝒄𝒉𝒊𝒋𝒌 + 𝜷𝟖𝑾𝑩𝒄𝒂𝒕𝒊𝒋𝒌𝒍 +
𝜷𝟗𝑴𝒂𝒏𝒖𝒇𝑾𝑩𝒄𝒂𝒕𝒌𝒍𝒕 + 𝜷𝟏𝟎𝑺𝒖𝒃𝒔𝒕𝒋𝒌𝒕 + Ɛ𝒊𝒋𝒌𝒍𝒕    Equation 5.1 
 
Model 2 (Price per dose for traditional vaccines): 
𝑳𝒐𝒈(𝑽𝑷𝒊𝒋𝒌𝒕) = 𝜷𝟎𝒊𝒋𝒌𝒍𝒕 + 𝜷𝟏𝒋𝒌𝒍𝑽𝒐𝒍𝒖𝒎𝒆𝒊𝒋𝒌𝒍𝒕 + 𝜷𝟐𝑼𝑵𝑷𝒓𝒐𝒄𝒊𝒋𝒌𝒍𝒕 +
𝜷𝟒𝑭𝒐𝒓𝒎𝒖𝒍𝒂𝒕𝒊𝒐𝒏 𝒔𝒊𝒛𝒆𝒋𝒌𝒍 + 𝜷𝟓𝑽𝒙𝑪𝒂𝒕𝒋𝒌𝒍 + 𝜷𝟖𝑾𝑩𝒄𝒂𝒕𝒊𝒋𝒌𝒍 + 𝜷𝟗𝑴𝒂𝒏𝒖𝒇𝑾𝑩𝒄𝒂𝒕𝒌𝒍𝒕 +
𝜷𝟏𝟎𝑺𝒖𝒃𝒔𝒕𝒋𝒌𝒕 + Ɛ𝒊𝒋𝒌𝒍𝒕                 Equation 5.2 
 
Model 3 Price per dose for modern vaccines: 
𝑳𝒐𝒈(𝑽𝑷𝒊𝒋𝒌𝒕) = 𝜷𝟎𝒊𝒋𝒌𝒍𝒕 + 𝜷𝟏𝒋𝒌𝒍𝑽𝒐𝒍𝒖𝒎𝒆𝒊𝒋𝒌𝒍𝒕 + 𝜷𝟐𝑼𝑵𝑷𝒓𝒐𝒄𝒊𝒋𝒌𝒍𝒕 +
𝜷𝟒𝑭𝒐𝒓𝒎𝒖𝒍𝒂𝒕𝒊𝒐𝒏 𝒔𝒊𝒛𝒆𝒋𝒌𝒍 + 𝜷𝟓𝑽𝒙𝑪𝒂𝒕𝒋𝒌𝒍 + 𝜷𝟗𝑴𝒂𝒏𝒖𝒇𝑾𝑩𝒄𝒂𝒕𝒌𝒍𝒕 + 𝜷𝟏𝟎𝑺𝒖𝒃𝒔𝒕𝒋𝒌𝒕 + Ɛ𝒊𝒋𝒌𝒍𝒕
               Equation 5.3 
 
Where:  
 𝑉𝑃𝑖𝑗𝑘𝑡, the outcome variable, is vaccine price per dose in unit i, vaccine j, 
manufacturer k, country l and year t;  
 𝑉𝑜𝑙𝑢𝑚𝑒𝑖𝑗𝑘𝑙𝑡, is volume level (in number of doses), in log form; 
 𝑈𝑁𝑃𝑟𝑜𝑐𝑖𝑗𝑘𝑙𝑡, is the mechanism in which the vaccine is procured (direct or bulk 
procurement); 
 𝐶𝑜𝑛𝑡𝑟𝑎𝑐𝑡𝑖𝑗𝑘𝑙𝑡, is the number of years of the contract between the procuring entity 
and manufacturer; 
 𝐹𝑜𝑟𝑚𝑢𝑙𝑎𝑒𝑗𝑘𝑙, is the category of the vaccine presentation, with 6 categories 
(1=capsule/tube; 2=multi-dose vial; 3=single-dose vial; 4=prefilled syringe; 5= 
lyophilised; 6=prefilled syringe and lyophilised); 
 𝐹𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑠𝑖𝑧𝑒𝑗𝑘𝑙, is the size of the vaccine presentation; 
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 𝑉𝑥𝐶𝑎𝑡𝑖𝑗𝑘 , is vaccine technology category, with four categories (1=bacterial; 2=viral; 
3=combination; 4=conjugate; 5=recombinant) 
 𝑉𝑥𝑇𝑒𝑐ℎ𝑖𝑗𝑘, is vaccine technology level from a developing country perspective
58, 
with two categories (0=Traditional EPI vaccines; 1=Modern NUV vaccines);  
 𝑊𝐵𝑐𝑎𝑡𝑖𝑗𝑘𝑙, is the vaccine procurer’s income level, with four categories as defined 
by the World Bank (1=low income, 2=lower middle income, 3=upper middle income, 
4=high income) 
 𝑀𝑎𝑛𝑢𝑓𝑊𝐵𝑐𝑎𝑡𝑘𝑙𝑡, is the manufacturer country’s income level, with four categories 
as defined by the World Bank (1=low income, 2=lower middle income, 3=upper 
middle income, 4=high income) 
 𝑆𝑢𝑏𝑠𝑡𝑗𝑘𝑡, is the number of manufacturers of the same vaccine that have 
prequalification.  
The level of significance for this mixed-effect linear regression was set at 𝑝 ≤ 0.05. 
5.3. Results 
5.3.1. Descriptive analysis 
Tables 5.4 and 5.5 show the summary statistics for the dataset used in this chapter. 
The dataset used in the analysis contained 392 observations, including vaccine price 
information from 43 procuring countries in all 5 WHO regions. Among countries that 
reported their procurement prices, one country was a low income country, 18 were 
lower-middle income countries, 17 were upper-middle income countries and seven 
were high income countries. These procurements were for 25 different vaccine types 
produced by 20 different manufacturers, from 8 different producing countries.
                                               
58 See section 4.2.2. in chapter 4, under ‘3.New technology’. 
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Table 5.4 Summary and definition of outcome and explanatory variables of factors associated with price per dose of vaccines produced by developing 
country manufacturers. 
Variable Definition Mean 
(Standard Deviation) 
Data source Last 
accessed 
2005 - 2015 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Price-per-
dose (US$) 
Price of 
vaccine 
procured, 
presented in 
dose scale 
1.17 
(1.75) 
N=392 
0.09 
(0.05) 
N=3 
0.11 
(0.06) 
N=8 
0.14 
(0.07) 
N=6 
0.08 
(0.04) 
N=3 
0.04 
(0.08) 
N=4 
0.90 
(1.33) 
N=5 
1.49 
(1.97) 
N=5 
0.77 
(1.03) 
N=4 
0.77 
(1.05) 
N=46 
1.51 
(2.31) 
N=119 
1.20 
(1.54) 
N=189 
V3P database 
(WHO) 
20/11/2016 
Volume 
(million 
doses) 
Number of 
doses 
procured in 
each 
transaction 
511.76 
(75.91) 
N=392 
16.9 
(8.66) 
N=3 
1.90 
(0.43) 
N=8 
35.98 
(11.62) 
N=6 
14.60 
(12.02) 
N=3 
4.72 
(2.26) 
N=4 
1.76 
(0.32) 
N=5 
1.50 
(0.27) 
N=5 
2.50 
(0.53) 
N=4 
37.18 
(16.47) 
N=46 
105.23 
(25.12) 
N=119 
289.49 
(65.78) 
N=189 
V3P database 
(WHO) 
20/11/2016 
Revenue  
($ million) 
Number of 
procured 
vaccine doses 
multiplied by 
price per dose 
389.88 
(105.61) 
N=392 
1.53 
(0.83) 
N=3 
0.23 
(0.07) 
N=8 
5.18 
(2.12) 
N=6 
1.82 
(1.67) 
N=3 
0.35 
(0.14) 
N=4 
1.95 
(1.52) 
N=5 
1.80 
(0.96) 
N=5 
1.81 
(1.01) 
N=4 
28.61 
(15.09) 
N=46 
86.81 
(21.91) 
N=119 
259.78 
(102.05) 
N=189 
V3P database 
(WHO) 
20/11/2016 
No. of PQ 
substitutes 
Number of 
competing 
products. 
Vaccine 
substitutes are 
the number of 
similar vaccine 
products 
produced by 
different 
manufacturers, 
with 
prequalification 
status. 
8.50 
(4.83) 
N=357 
6.67 
(1.15) 
N=3 
6.13 
(2.30) 
N=8 
6.13 
(3.27) 
N=6 
5.33 
(0.58) 
N=3 
7.25 
(3.86) 
N=4 
7.80 
(3.11) 
N=5 
8.60 
(2.70) 
N=5 
10.75 
(3.50) 
N=4 
7.14 
(3.25) 
N=37 
8.86 
(5.33) 
N=105 
8.84 
(5.05) 
N=117 
List of 
prequalified 
vaccines 
(WHO) 
20/11/2016 
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Table 5.5 Summary and definition of categorical explanatory variables of factors associated with price per dose of vaccines produced by developing 
country manufacturers. 
Variable Definition Indicator 
2005 - 2015 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
N % N % N % N % N % N % N % N % N % N % N % N % 
Procurement  
mechanism 
Whether vaccine 
was procured 
directly from 
manufacturer or 
through 
procurement 
agency, such as 
UNICEF, PAHO 
and GAVI. 
UN 
Procurement 
220/392 56.12 3/3 100 8/8 100 6/6 100 3/3 100 4/4 100 5/5 100 5/5 100 4/4 100 26/46 56.52 57/119 47.90 99/189 52.38 
Self-
Procurement 
169/392 43.11 0/3 0 0/8 0 0/6 0 0/3 0 0/4 0 0/5 0 0/5 0 0/4 0 20/46 43.48 61/119 51.26 88/189 46.56 
Other 3/392 0.77 0/3 0 0/8 0 0/6 0 0/3 0 0/4 0 0/5 0 0/5 0 0/4 0 0/246 0 1/119 0.84 2/189 1.06 
Contract 
Identifies the 
different contract 
lengths that may 
have been 
arranged, if any, 
between the 
vaccine 
manufacturer 
and procurer. 
Single delivery 47/323 14.55 0/3 0 0/8 0 0/6 0 0/3 0 0/4 0 0/5 0 0/5 0 0/4 0 0/3 0 15/105 14.29 32/177 18.08 
Contractual 276/323 85.45 3/3 100 8/8 100 6/6 100 3/3 100 4/4 100 5/5 100 5/5 100 4/4 100 3/3 100 90/105 85.71 145/177 81.92 
Formulation 
Formulation 
presentation of 
vaccine 
Multi-dose vial 290/392 73.98 3/3 100 7/8 87.50 6/6 100 2/3 66.67 3/4 75.00 3/5 60.00 5/5 100 4/4 100 34/46 73.91 80/119 67.23 143/189 75.66 
Single-dose vial 59/392 15.05 0/3 0 0/8 0 0/6 0 0/3 0 0/4 0 1/5 20.00 0/5 0 0/4 0 6/46 13.04 23/119 19.33 29/189 15.34 
Prefilled syringe 4/392 1.02 0/3 0 0/8 0 0/6 0 0/3 0 0/4 0 0/5 0 0/5 0 0/4 0 0/46 0 3/119 2.52 1/189 0.53 
Lyophilised 39/392 9.95 0/3 0 1/8 12.50 0/6 0 1/3 33.33 1/4 25.00 1 20.00 /5 0 0/4 0 6/46 13.04 13/119 10.92 16/189 8.47 
Vaccine 
Category 
Identifies the 
different 
technology 
categories of the 
vaccine (i.e.: 
bacterial, viral, 
combination, 
conjugate and 
recombinant) 
Bacterial 
vaccines 
220/392 56.12 2/3 66.67 4/8 50.00 3/6 50.00 3/3 100 4/4 100 2/5 40.00 2/5 40.00 1/4 25.00 34/46 73.91 68/119 57.14 97/189 51.32 
Viral vaccines 97/392 24.74 1/3 33.33 3/8 37.50 2/6 33.33 0/3 0 0/4 0 2/5 40.00 2/5 40.00 2/4 50.00 8/46 17.39 25/119 21.01 52/189 27.51 
Combination 
vaccines 
55/392 14.03 0/3 0 0/8 0 0/6 0 0/3 0 0/4 0 1/5 20.00 1/5 20.00 1/4 25.00 3/46 6.52 19/119 15.97 30/189 15.87 
Conjugate 
vaccines 
1/392 0.26 0/3 0 0/8 0 0/6 0 0/3 0 0/4 0 0/5 0 0/5 0 0/4 0 0/46 0 0/119 0 1/189 0.53 
Recombinant 
vaccines 
19/392 4.85 0/3 0 1/8 12.50 1/6 16.67 0/3 0 0/4 0 0/5 0 0/5 0 0/4 0 1/46 2.17 7/119 5.88 9/189 4.76 
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Vaccine 
technology 
type 
Identifies level of 
new technology 
accessed by the 
manufacturer for 
the vaccine. 
Traditional 
vaccine 
264/392 67.35 3/3 100 7/8 87.50 5/6 83.33 3/3 100 4/4 100 3/5 60.00 3/5 60.00 2/4 50.00 36/46 76.09 79/119 66.39 120/189 63.49 
NUVs 128/392 32.65 0/3 0 1/8 12.50 1/6 16.67 0/3 0 0/4 0 2/5 40.00 2/5 40.00 2/4 50.00 11/46 23.91 40/119 33.61 69/189 36.51 
Income 
group – 
Procuring 
country 
National income 
per capita of the 
procuring and 
the purchasing 
country, based 
on the World 
Bank country 
classification 
and income 
thresholds 
LIC 8/392 2.04 0/3 0 0/8 0 0/6 0 0/3 0 0/4 0 0/5 0 0/5 0 0/4 0 0/46 0 0/119 0 8/189 4.23 
LMIC 204/392 52.04 3/3 100 8/8 100 6/6 100 3/3 100 4/4 100 5/5 100 5/5 100 4/4 100 25/46 54.35 52/119 43.70 89/189 47.09 
UMIC 153/392 39.03 0/3 0 0/8 0 0/6 0 0/3 0 0/4 0 0/5 0 0/5 0 0/4 0 21/46 45.65 56/119 47.06 76/189 40.21 
HIC 27/392 6.89 0/3 0 0/8 0 0/6 0 0/3 0 0/4 0 0/5 0 0/5 0 0/4 0 0/46 0 11/119 9.24 16/189 8.47 
Income 
group – 
Producing 
Countries 
National income 
per capita of the 
procuring and 
the purchasing 
country, based 
on the World 
Bank country 
classification 
and income 
thresholds 
LIC 10/392 2.55 3/3 100 7/8 87.50 0/6 0 0/3 0 0/4 0 0/5 0 0/5 0 0/4 0 0/46 0 0/119 0 0/189 0 
LMIC 270/392 68.88 0/3 0 1/8 12.50 6/6 100 2/3 66.67 3/4 75.00 5/5 100 5/5 100 4/4 100 27/46 58.70 85/119 71.43 133/189 70.37 
UMIC 112/392 28.57 0/3 0 0/8 0 0/6 0 1/3 33.33 1/4 25.00 0/5 0 0/5 0 0/4 0 19/46 41.30 34/119 28.57 56/189 29.63 
Note: Data as reported by V3P participating country members to WHO (2005 – 2015); Last accessed: 20/11/2016.
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The data accounted for 512 million doses of vaccines and total revenue of 
approximately US$390 million. The weighted average price of vaccines procured from 
DCVMs was less than $1 per dose59, ranging from US$0.01 to US$15.80 (Table 5.6). 
By contrast, the weighted average price of vaccines for all manufacturers as reported 
to WHO was $ 3.6760. Whilst the data were reported from 2005 to 2015, 92.5% of the 
responses were from 2013 to 2015 (Table 5.7). 
In regards to the income levels of the producing countries, 68.9% of producers in the 
dataset were lower-middle income countries, while 28.6% were upper-middle income 
countries and less than 3% were low-income countries. The details of data description 
are presented in Tables 5.4 and 5.5. Results of the univariate analyses are shown in 
Table 5.8. 
Table 5.6. Summary of vaccine prices-per-dose sold by developing country vaccine 
manufacturers to V3P participating countries. 
                                               
59 Weighted average price for all observations is approximately $ 0.76 
60 Based on observation of full V3P dataset, which includes vaccine producers from both 
developing countries and industrialised countries, as presented in Chapter 2, sub-section 2.8.1 
and Table 2.3 
Vaccine Weighted average 
price per dose 
(US$) 
Minimum 
price per dose 
(US$) 
Maximum 
price per dose 
(US$) 
Number of 
observations 
BCG 0.50 0.03 3.55 67 
DT-IPV 0.92 8.09 8.09 1 
DTwP 0.26 0.09 3.14 43 
DTwP-HepB 0.36 3.20 3.20 1 
DTwP-Hib 1.24 1.24 2.80 2 
DTwP-Hib-HepB 0.37 1.19 5.10 34 
Cholera 0.51 0.47 0.47 1 
HepB Adult 1.21 0.21 3.80 7 
HepB Pediatric 2.68 0.22 1.96 12 
Hib 6.02 0.78 0.78 1 
Influenza Adult 2.23 1.97 10.40 5 
IPV 0.12 1.89 3.36 7 
JE Inactd 0.88 0.50 1.50 2 
JE LiveAtd 4.45 0.42 10.50 5 
DT 1.80 0.11 7.58 32 
Measles 3.06 0.14 4.46 29 
MMR 0.53 0.50 4.50 27 
MR 0.48 0.52 1.73 19 
Rabies 8.49 2.86 15.80 4 
Rubella 8.29 8.29 8.29 1 
Td 0.29 0.01 2.07 34 
TT 0.52 0.03 2.55 38 
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Source: 
Data 
based 
on 
vaccine 
prices reported to V3P, WHO (2005 – 2015)  
 
Table 5.7. Average vaccine revenue based on sales of vaccines produced by developing 
country vaccine that were reported by V3P participating countries to WHO during 2005 – 
2015 (US$ million) 
YEAR MEAN STD.DEV 
NO. OF 
OBSERVATIONS 
2005 - 2015 389.88 105.61 392 
2005 1.53 0.83 3 
2006 0.23 0.07 8 
2007 5.18 2.12 6 
2008 1.82 1.67 3 
2009 0.35 0.14 4 
2010 1.95 1.52 5 
2011 1.8 0.96 5 
2012 1.81 1.01 4 
2013 28.61 15.09 46 
2014 86.81 21.91 119 
2015 259.78 102.05 189 
Typhoid 10.66 0.49 4.22 3 
bOPV1,3 0.02 0.13 0.26 4 
tOPV 0.37 0.09 2.79 13 
Total Average 0.76 0.01 15.80 392 
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Table 5.8. Univariate regression of factors associated with price per dose of vaccines produced by developing country manufacturers 
Explanatory variable 
Model 1 
(n=284) 
Model 2 
(n=177) 
Model 3 
(n=107) 
 β (95% CI) P β (95% CI) P β (95% CI) P 
Constant -0.77   -1.13   0.45   
Volume (log) -0.14 -0.20 - -0.08 0.000* -1.65 -1.89 - -1.42 0.000* -0.36 -0.66 - -0.06 0.019* 
UN Procurement -1.32 -1.57 - -1.07 0.000* -1.57 -1.81 -1.34 0.000* -0.32 -0.61 -0.04 0.027* 
Contract -0.06 -0.15 – 0.02 0.138* -0.09 -0.18 – 0.01 0.055* -0.05 -0.14 - 0.03 0.237* 
Formulation type 0.45 0.30 – 0.59 0.000* 0.19 0.01 - 0.36 0.037* 0.33 0.19 - 0.47 0.000* 
Formulation size -0.16 -0.17 - -0.14 0.000* -0.12 -0.14  -0.09 0.000* -0.11 -0.14 - -0.08 0.000* 
Vaccine technology          
Bacterial -1.57 -1.82 - -1.33 0.000* -0.73 -1.16 - -0.30 0.001* -0.02 -0.75 -  0.70 0.949 
Viral 1.54 1.24 - 1.84 0.000* 0.73 0.30 - 1.16 0.001* 0.40 -0.28 - 1.07 0.245 
Combination 1.83 1.48 - 2.18 0.000* – – – 0.01 -0.66 – 0.68 0.970 
Conjugate 1.15 -1.18 – 3.48 0.333 – – – -0.67 -2.35 – 1.01 0.433 
Recombinant 0.98 0.43 – 1.54 0.001* – – – -0.83 -1.56 - -0.11 0.025* 
Income level 
(Producing country) 
0.14 -0.14 – 0.43 0.334 0.54 0.27 - 0.81 0.000* 0.75 0.29 - 1.21 0.002* 
Income level (Procuring 
country) 
0.73 0.54 - 0.94 0.000* 0.88 0.67 - 1.09 0.000* 0.56 0.36 - 0.75 0.000* 
Number of PQ 
substitutes 
0.04 0.01 – 0.71 0.009* -0.03 -0.09 - 0.02 0.193* 0.05 0.03 - 0.071 0.000* 
*: p-value ≤ 0.2. Note: Model 1: Price per dose for all vaccines; Model 2: Price per dose for all traditional vaccines; Model 3: Price per dose for modern vaccines.
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5.3.2. Mixed-effects regression model 
Determinants of DCVM vaccine prices: overall 
Model 1 identified that a one percent increase in volumes of vaccines procured was 
associated with a 0.06% decrease in overall DCVM vaccine prices. Lower vaccine 
prices were also associated with a one-unit increase in the following factors: UN 
procurement method (44%61), vaccine formulation sizes (6%), bacterial vaccines (80%) 
and prequalified vaccine substitute (1%). By contrast, the following factors were 
associated with higher vaccine prices: NUVs (24%), viral vaccines (93%), combination 
vaccines (131%) and higher income level procuring countries (49%). Formulation 
presentation types, conjugate and recombinant vaccines and the income level of the 
producing country were not associated with DCVM vaccine prices. 
Determinants of vaccine prices: traditional vaccines 
For traditional vaccine types, Model 2 found that lower prices were associated with the 
following factors: UN procurement method (71%), larger formulation sizes (6%), 
bacterial vaccine types (75%), and number of prequalified vaccine substitutes (4%). By 
contrast, the following factors were associated with increase in modern DCVM vaccine 
prices: viral vaccines (75%), higher income level of producing country (20%) and higher 
income level of procuring country (51%).   
Determinants of vaccine prices: new and underused vaccines.  
For modern vaccines, Model 3 found that a one-percent increase in the log of volume 
of vaccines procured was associated with a 0.1% decrease in DCVM vaccine prices. 
Lower vaccine prices were also associated with larger formulation size (5%) and the 
recombinant vaccine category (106%). By contrast, vaccine prices increased in 
                                               
61 Values in parentheses indicate the percentage change in the outcome variable –log(price per 
dose) for a one unit change in the explanatory variable 
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association with a producing country’s income level (51%) and prequalified vaccine 
substitutes (4%).   
The mixed-effects regression models are presented in Table 5.9, while post-estimation 
tests on the residuals were performed for each model and presented in Figures 5.2 – 
5.4. The residuals show a normal distribution and there is little to suggest violation of 
the normality assumption.
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Table 5.9. Multivariate mixed-effect linear regression of factors associated with price-per-dose of vaccines produced by developing country vaccine 
manufacturers 
EXPLANATORY VARIABLE 
MODEL 1 
(N=338) 
MODEL 2 
(N=213) 
MODEL 3 
(N=125) 
 β (95% CI) P β (95% CI) P β (95% CI) P 
Constant -1.17   -1.14   0.57   
Volume (log) -0.06 -0.10 - -0.02 0.007** -0.04 -0.09 – 0.02 0.187 -0.10 -0.16 - -0.05 0.000*** 
UN Procurement -0.44 -0.67 - -0.21 0.000** -0.71 -1.03 - -0.38 0.000*** -0.19 -0.41 – 0.03 0.089 
Contract – – – – – – – – – 
Formulation type -0.01 -0.08 - 0.06 0.782 – – – – – – 
Formulation size -0.06 -.074 - -0.04 0.000*** -0.06 -0.08 - -0.042 0.000*** -0.05 -0.08 - -0.03 0.000*** 
Vaccine category          
Bacterial -0.80 -1.10 – -0.49 0.000*** -0.75 -1.10 - -0.41 0.000*** 0.48 -0.07 – 1.3 0.087 
Viral 0.93 0.39 - 0.97 0.000*** 0.75 0.41 - 1.10 0.000*** 0.02 -0.45 – 0.50 0.942 
Combination 1.31 0.25 - 1.11 0.000*** – – – -0.15 -0.64 – 0.34 0.533 
Conjugate -0.04 -2.07 - 0.59 0.960 – – – -0.98 -1.98 – 0.03 0.056 
Recombinant -0.09 -1.52 - -0.50 0.719 – – – -1.06 -1.54 - -0.59 0.000*** 
Vaccine technology 0.24 0.83 - 1.51 0.001*** – – – – – – 
Income level (Producing country) 0.12 -0.04 - 0.30 0.184 0.20 0.00 – 0.41 0.034* 0.51 0.13 – 0.90 0.009** 
Income level (Procuring country) 0.49 0.19 - 0.76 0.001*** 0.51 0.15 - 0.87 0.005** 0.15 -0.05 – 0.36 0.130 
Number of PQ substitutes -0.01 -0.025 - 0.02 0.556 -0.04 -0.08 – 0.01 0.014* 0.04 0.02 – 0.06 0.000*** 
          
Random effects Variance (95% CI) Variance (95% CI) Variance (95% CI) 
Procuring country (Level 1) 0.45 0.31 – 0.67 0.59 0.42 – 0.84 0.01 0.00 – 1.13 
Vaccine (Level 2) 0.56 0.47 – 0.67 0.46 0.35 – 0.61 0.09 0.03 – 0.24 
Manufacturer (Level 3) 0.00 0.00 – 0.00 0.00 0.00 – 0.00 0.00 0.00 – 0.00 
Residual 0.38 0.34 – 0.43 0.39 0.34 – 0.45 0.12 0.08 – 0.18 
Log-likelihood -319.00  -191.29    
* p≤0.05; ** p≤0.01; *** p≤0.001; bold number: significant. Note: Model 1: Price per dose for all vaccines; Model 2: Price per dose for all traditional vaccines; 
Model 3: Price per dose for modern vaccines.
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   (a)      (b) 
Figure 5.2 Post-estimation tests on residuals of regression of factors associated with 
price per dose of overall vaccine types produced by developing country manufacturers 
(Model 1). Note: (a) frequency distribution of residual values; (b) residuals plotted against 
corresponding predicted values. 
 
  
   (a)      (b) 
Figure 5.3 Post-estimation tests on residuals of regression of factors associated with 
price per dose of traditional vaccines produced by developing country manufacturers 
(Model 2). Note: (a) frequency distribution of residual values; (b) residuals plotted against 
corresponding predicted values. 
 
  
   (a)      (b) 
Figure 5.4 Post-estimation tests on residuals of regression of factors associated with 
price per dose of modern vaccines produced by developing country manufacturers 
(Model 3). Note: (a) frequency distribution of residual values; (b) residuals plotted against 
corresponding predicted values. 
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5.4. Discussion 
Prices of vaccines produced by DCVMs were found to be associated with the following 
procurement factors for all three vaccine markets observed (overall vaccines, 
traditional vaccines and modern vaccines): formulation sizes and number of 
prequalified vaccine substitutes. Formulation type, which was found to be a critical 
factor in vaccine production costs (Chapter 3 and 4), was not found to influence vaccine 
prices in this analysis.  
Data for overall vaccines however, showed that the log transformed price per dose has 
a bimodal distribution. The different vaccine technology types seem to be accountable 
for this bimodality, suggesting that separating the observation by traditional and 
modern vaccines was correct. Though vaccines can be grouped into three different 
categories based on their market structure and characteristics (Table 2.1)62, DCVMs 
mainly produce traditional vaccines and are expanding into NUVs (Jadhav et al., 2008). 
NUVs are often much more expensive than traditional vaccines and provide a higher 
incentive for manufacturers to invest given the increasing number of countries adopting 
new vaccines and the relatively low number of producers currently in the market 
(Burchett et al., 2012; Galambos, 2008). 
Larger formulation sizes such as multi-dose vial vaccines, relative to single dose 
vaccines, can result in lower production costs and lower storage space, thereby 
allowing manufacturers to offer lower prices. The effect of presentation size was also 
found to be a factor in vaccine prices for manufacturers globally (including ICVMs) in 
the V3P report of the WHO (WHO, 2016c). 
Competing vaccine products with prequalified status impose two issues for a vaccine 
manufacturer. One is that prequalified vaccines have access to larger vaccine markets 
                                               
62 As shown in Table 2.1 of Chapter 2, these categories are: traditional vaccines, NUVs and 
vaccines in development or also known as pipeline vaccines.  
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such as those represented by UNICEF, GAVI and PAHO. Second is that prequalified 
vaccines are usually the recommended and preferred choice for national immunisation 
programs (Dellepiane & Wood, 2015), particularly due to the assured quality and due 
diligence placed in the prequalification system. Competition in general, especially in 
imperfectly competitive markets such that of vaccines, tends to lower prices (Bulow, 
Geanakoplos, & Klemperer, 1985; Corts, 1998). A large part of the success gained by 
international health agencies such as GAVI has arisen due to the combined effects of 
competition and prequalified status in lowering vaccine prices and increasing access 
to NUVs for developing countries.  
Volume of vaccine procured was noted as a significant factor influencing lower vaccine 
prices globally in the V3P report of the WHO (WHO, 2016c). Though the findings of the 
current analysis found that a 1% increase in procurement volumes was associated with 
a 0.06% reduction in prices for overall vaccines and a 0.1% reduction for modern 
vaccines, the analysis found that, for traditional EPI vaccines in particular, larger 
volume transactions were not associated with changes in price. This may be due to the 
fact that traditional vaccines have saturated markets and those produced by DCVMs 
in general are priced near to their marginal costs.  
UN vaccine procurement implements a bulk purchase mechanism, thereby increasing 
leverage in negotiating prices with individual vaccine manufacturers and subsequently 
lowering vaccines prices (Berkley, 2014). UN vaccine procurement was found to be 
significantly associated with lower prices for overall and traditional DCVM vaccines, 
and was negatively but not significantly associated with prices of modern vaccines in 
the current analysis. The non-significant finding for modern vaccines could have arisen 
from DCVMs not yet securing prequalification status for modern vaccines, and thus not 
being affected by price-lowering effects of UN bulk procurement mechanisms.  
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Having longer-term contracts in place with procuring countries reduces uncertainty and 
transaction costs for DCVMs from having to conduct annual re-negotiations (WHO, 
2016c). However, this study did not find contracts to be a determining factor in any of 
the three models observed. Over 50% of the DCVM transactions in this study had a 
one-year contract, and only 30% were on longer-term contracts, with the remaining 
having single-delivery arrangements. The large proportion of annual contracts in the 
study may explain why longer-term contracts did not have a significant impact on 
vaccine prices.  
Another factor that was not found to be a determining factor for vaccine prices was the 
formulation presentation of a vaccine. Though formulation presentation was found to 
be a determining factor in production costs of vaccines (Chapter 3), the findings of the 
current analysis suggest that presentation is not considered by DCVMs as a factor in 
pricing their vaccines. This in part might stem from the fact that vaccine formulation 
presentations are often linked to particular requirements of immunisation programs in 
different countries, such a single-dose presentations being preferred by higher income 
countries (WHO, 2016c) and lyophilised formulations being preferred in high-
temperature countries and those with challenges in sustaining cold-chain systems. 
Therefore, despite the existence of lower priced vaccine presentations, the particular 
demands of a country’s immunisation programs may prevent different formulation 
presentations being substituted for each other. The data also showed that the majority 
(74%) of vaccine presentations in the dataset were multi-dose vial vaccines.   
The categories of vaccine technology (e.g. bacterial, viral) as well as having more 
advanced technology, were found to be associated with prices of vaccines produced 
by DCVMs. Bacterial and recombinant type vaccines were found to have a lower price, 
whilst viral vaccines and combination vaccines were found to have higher prices. 
Vaccine production processes and its cost implications are dependent on the category 
of vaccine being produced (Mercer Managment Consulting, 2002). However, the 
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dataset did not have enough variability between traditional and modern vaccines within 
the vaccine category types to generalise these findings. 
Finally, procuring countries with higher incomes were associated with higher vaccine 
prices, both in general as well as for traditional vaccine types; whereas producing 
countries with higher income levels were associated with higher vaccine prices for 
traditional and modern vaccines. This may be a result of two phenomenon where: one, 
given the paradigm of vaccine manufacturers having invested their R&D funding for 
vaccines catered to the developed world (Milstien et al., 2006; Wilson & Jones, 2010), 
and two, the tiered pricing mechanisms devised to increase uptake of NUVs by 
developing countries. Given that vaccine price information is generally asymmetric, 
vaccine manufacturers may be seeking opportunities to recoup their investments 
particularly when involving higher income countries (WHO, 2016c),  
The overall analysis on vaccine prices reflects a larger underlying question of how 
countries decide on their vaccine procurement. Factors contributing to a government’s 
decision to introduce and procure a product are known to be complex. In addition to 
necessary factors such as product availability, disease burden, affordability, 
programmatic feasibility, and cost-effective studies, a government’s decision is often 
also influenced by swing factors, such as WHO recommendations, regional policies, 
and the influence of public health champions, both locally and from the international 
community (Munira & Fritzen, 2007). Prices of vaccines produced by DCVMs differ 
from vaccines produced by other manufacturers given the different characteristics of 
the vaccines produced. DCVM vaccines are usually traditional vaccines with prices that 
are generally lower than those sold by multinational manufacturers. 
5.4.1. Limitations 
Through the V3P initiative, WHO is making an attempt to increase transparency in 
vaccine markets, particularly regarding vaccine prices paid by countries (WHO, 2016c). 
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The V3P dataset provides a subset of all vaccine transactions along with their prices 
and procurement terms and conditions, as provided by participating countries. In an 
attempt to confirm the data provided, WHO provides countries with a two-year period 
to report any necessary changes to the data they have provided. Because the data 
were a subset of all transactions, general assumptions regarding overall vaccine 
markets may be limited.  
Given that the data does not include the entire number of vaccine transactions, 
competition among different vaccine types used the number of prequalified status 
competitors as a proxy. This indicator is justified because these would be strong 
competitors for manufacturers in general. Ideally, the number of all substituting 
manufacturers that produce the same vaccines would have been the indicator used, 
however, this information was not available. 
A potential selection bias however may arise from the different types of vaccines being 
reported to the V3P. Most of the bacterial vaccines reported categories of vaccines  
data analysis presented this chapter are based on reported vaccine procurement by 
countries (both higher and lower income) procuring from DCVMs. The dataset used in 
this chapter indicates most of the bacterial vaccines were traditional vaccines, while 
most of the viral vaccines reported were NUVs, which the latter is usually more 
expensive than the traditional EPI vaccines. Given that the data uses a secondary 
source, it is not entirely clear how randomised was the data collection process. 
However, the proportion of the data categorised as bacterial and viral as well as 
traditional and NUVs categories are quite large. It is likely that there is a tendency of 
DCVMs to produce bacterial vaccines that are traditional and viral vaccines that are 
NUVs.  
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5.4.2. Conclusions 
The procurement factors that were found to influence lower prices of DCVM vaccines 
were competing products with prequalification status and formulation sizes. For 
traditional vaccines in particular, UN procurement transactions were found to have 
lower prices while transactions involving higher income levels countries, either as a 
producer or procurer, were associated with higher vaccine prices. Bacterial vaccines 
were associated with lower prices while viral vaccines were associated with higher 
prices. For modern vaccines, transactions involving larger volumes as well as 
recombinant vaccine types were found to be associated with lower prices. 
A better understanding of what factors contribute to the pricing of vaccines by 
developing country manufacturers will help DCVMs assess how that can be translated 
to the critical factors influencing production costs. This understanding will allow 
developing country manufacturers to better assess their pricing decisions and be more 
attuned to the critical factors influencing their costs, which in turn will assist producers 
to gain and sustain viability and by extension, to support the global supply of vaccines. 
This may also help navigate dialogue with each manufacturer’s local government and 
other key stakeholder in identifying the support needed to maintain and boost viability 
of local vaccine production in developing countries.  
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 Discussion 
Developing country producers supply over half of the vaccines used in developing in 
country immunisation programs. DCVMs vary by size, capacity and quality (CVI & 
WHO, 1999; Milstien et al., 1997). As the dynamics of the vaccine market have 
changed over time and will likely continue to change, it is important to identify the critical 
factors influencing viability of vaccine production in developing countries.  
The aim of this thesis was to analyse, from an economics perspective, the viability of 
local vaccine production, specifically in developing countries. This was achieved 
through the following assessments: 
1. An analysis of the cost structures in establishing vaccine manufacturing 
facilities in developing countries; 
2. An assessment of vaccine viability factors’ influence on revenue sizes and 
percent market shares of developing country production; and 
3. An assessment of procurement factors’ influence on prices of vaccines 
produced by DCVMs. 
6.1. Overall summary 
A review of the existing literature (Chapter 2) found that economic evaluations of 
vaccine production in developing countries have been limited. Constant changes have 
been reported to take place in the vaccine market. These changes, which stem from 
advances in biotechnology and tighter regulatory requirements, pose challenges for 
vaccine manufacturers to remain economically viable whilst at the same time producing 
vaccines that are efficacious and of high quality. Maintaining the global supply of 
vaccines has, therefore, been challenging, particularly to maintain the supply of 
vaccines to non-premium markets such as those in developing countries.   
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The cost-per-dose of vaccines produced by DCVMs, over three specified production 
scale and scope settings63, was found to be an average of $2.05. The average and 
range of costs-per-dose ($0.92 - $4.40) were in line with reported costs of vaccines 
produced by multinationals64. The vaccine markets faced by DCVMs however are 
mostly non-premium markets65, yet this may be compensated by other features found 
in developing country vaccine markets, such as the large size of the population and 
the high need for vaccines due to disease burden profiles66 and low domestic 
competition67. DCVMs may find particular challenges to sustain their viability when they 
produce vaccines for the export market, or when they produce new technology 
vaccines. 
From the three analyses conducted in this thesis, the following critical factors were 
found to influence viability of vaccine production in developing countries. 
 In establishing vaccine manufacturing facilities.  
a. To offset high fixed costs associated with vaccine production, two specific 
characteristics are important: large production scales (ideally over 20 million 
annual doses) and a multi-vaccine facility. 
b. Given the step-fixed-cost characteristics of fixed costs, manufacturers should 
have a high level of certainty over the production scale and scope.   
c. An estimated 10% of cost savings through economies of scale and scope can 
potentially be achieved by increasing the scale and scope of production 
                                               
63 The three settings observed were 1) Scenario A with 20 million annual doses of 1 vaccine 
product (average cost-per-dose: $2.30); 2) Scenario B with 20 million annual doses of 5 vaccine 
products (average cost-per-dose: $2.02); and 3) Scenario C with 100 million annual doses of 5 
vaccine products (average cost-per-dose: $1.82). 
64 No studies have presented the industry-wide cost of producing vaccines in developing 
countries. One report based its costing on vaccine production by multinational manufacturers, 
with costs ranging between $0.05 to $3-$4 per dose (Mercer Management Consulting, 2002). 
It is not clear however whether those costs included attrition rates, which were included in the 
calculations in this thesis.  
65 WHO report that vaccine markets in low and middle income countries contribute to only 18% 
of the total market value of vaccines. 
66 WHO report that 85% of the world’s population live in low and middle income countries, while 
93% of the burden of disease is found in these countries.  
67 Refer to market shares of DCVMs in their domestic markets (Table 4.5 in Chapter 4)  
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facilities, regardless of whether they are viral or bacterial vaccines. 
Recombinant vaccines can achieve higher cost savings (31%) while conjugate 
vaccines can achieve lower cost savings (15%). If the vaccine is recombinant, 
economies of scale can be twice as high, whereas if conjugate, only one-third 
as high. With regards to formulation presentation, economies of scale are 
achieved in order (from highest to lowest) by: prefilled syringe vaccines, and 
lyophilised, multi-dose and single-dose vaccines.  
d. Almost 20% of cost savings can be achieved if more vaccine products are 
produced in a facility, regardless of whether they are viral or bacterial vaccines. 
Recombinant vaccines can achieve higher cost savings (31%) while conjugate 
vaccines can achieve lower cost savings (15%). Little variation in cost savings 
was found based on formulation presentations, except for multi-dose types 
(26%).  
 Once production is up and running, the following aspects were found to be 
significant in ensuring a DCVM’s viability: 
a. In the domestic market: viability is enhanced by: larger scale of vaccines 
production, production supplies that are sustainable and reliable, producing 
vaccines with higher technology levels, manufacturers having autonomous 
management structures, and countries having higher income levels. 
b. In export markets, viability is enhanced by: larger numbers of vaccine types 
being produced, production supplies that are sustainable and reliable, sizes of 
production and supply that can sufficiently meet demand, prequalified vaccines, 
and manufacturers with autonomous management structures.   
 In selling its vaccines, the following procurement factors influence a DCVM’s pricing 
downwards: volume size of procurement, bulk-procurement method, larger 
formulation sizes, and higher vaccine technology, as well as lower income levels of 
procuring and producing countries. Also influential towards a DCVM’s pricing is the 
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category of vaccine technology (bacterial, viral and combination vaccine types in 
particular). The importance of all these factors varied by vaccine technology levels: 
a. Traditional EPI vaccines: the downward factors were UN procurement 
transactions, bacterial vaccine categories and number of competing vaccines. 
While the upward factors were producing and procuring countries with higher 
income levels (upwards), and viral vaccine categories. 
b. New and underused vaccines: downward factors were volume size of 
procurement, formulation sizes required and recombinant vaccine types. While 
upward factors were transactions involving producers with higher income 
levels68 and the number of competing vaccines. 
6.2. Discussion of critical factors 
Joint display (Table 6.1) and the convergent design method proposed by Creswell and 
Clark (2011), adopted here, can be used to identify the congruence of the findings from 
the three analyses. This approach is applicable because the analyses explored multiple 
related themes.  
Table 6.1. Congruence design based on the findings of the three viability analyses on 
cost structures, revenue size and percent market shares; and vaccine prices  
Results Cost 
Revenue size and Percent 
market share 
Vaccine Prices 
Overall Domestic Export Overall Traditional Modern 
Production Scale and 
scope 
X X X  X  X 
Vaccine category X    X X  
Technology level X    X   
Procurement method     X X  
Formulation 
presentation 
X       
Formulation sizes X    X X X 
Income level – 
Producing country 
 X X X  X X 
Prequalification status  X  X    
                                               
68 This refers to higher income countries within the developing country context 
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The objective of a convergent design method is to obtain an overall interpretation from 
triangulated results from different analyses conducted on a single topic (Creswell & 
Clark, 2011). Applying this method on the results in Chapters 3, 4 and 5, two particular 
factors were consistently found to be significant for viability across the three aspects 
assessed. These were: production scale and production scope. 
6.2.1. Production scale and production scope 
A number of studies in the literature report the significance of the scale and scope of 
production in maintaining the viability of local vaccine production (Mahoney, 1990; 
Mahoney et al., 2012; Mercer Management Consulting, 2002; Milstien et al., 1997). 
Across the three analyses conducted in this thesis, both production scope and 
production scale were found to be influential in minimizing production costs-per-dose, 
having a positive impact on revenue sizes and percent market shares and allowing 
manufacturers to offer lower prices to their consumers.  
In regards to production costs, economies of scope were estimated to save costs up 
to an average of 18.7%, and had a larger effect on cost savings than the economies of 
scale (10.1%). These findings suggest that despite the high fixed cost requirements in 
establishing new vaccine manufacturing facilities (Sloan, 2012), setting a production 
scale at 20 million annual doses and above, as well as establishing a multiproduct 
facility can offset the high fixed costs.  
Production scale and scope also affected market shares in overall markets, and 
specifically in domestic but not export markets. However, given the economies of scale 
indicator that was used in the regression was based on the producing country, we 
cannot conclude that economies of scale are not a determining factor in export 
markets. In fact, ‘sufficient supply’, which is another observed variable derived from the 
covariate of targeted population in procuring country, was shown to be significant in 
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export markets, implying that economies of scale may in fact be a determining factor 
in both domestic and export markets. 
For the analysis of vaccine prices, the volume of vaccines procured was found to be a 
significant factor. This can be linked to the size of production of the vaccine, in that 
large-volume procurements allow manufacturers to offer lower prices to consumers 
because the manufacturers view this factor as significant in reducing their production 
costs.  
6.2.2. Other driving factors 
A number of other factors were also prominent in the research findings, being identified 
by more than one analysis. These include vaccine categories, national income and 
formulation presentation. 
Vaccine categories 
Different vaccine technology categories (i.e.: bacterial, viral, combination, etc.) require 
different production processes that influence costs (Batson et al., 2003; Sinclair et al., 
2015). This has also been found to be the case for medicines in general (Mestre-
Ferrandiz et al., 2012). The findings in this thesis were in support of vaccine technology 
categories having an effect on the production costs and prices of vaccines produced 
by DCVMs.  
Some evidence was found that particular vaccine categories such as viral vaccines 
required relatively higher fixed costs, yet can have a large cost savings from higher 
production scales and scope; the effect of this vaccine category appeared to be higher 
relative to bacterial vaccines. However, to have greater certainty, a direct comparison 
between a vaccine category’s cost and price levels needs to be undertaken. This was 
not possible in the current research given the anonimity required for production cost 
data. 
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Formulation sizes 
Formulation sizes were found to be significant in driving production costs as well as 
lowering vaccine prices. The largest effects were found for higher-dose vial vaccines, 
for which transaction costs were lowest, and which require less storage space. 
However, this vaccine presentation type has also been associated with higher wastage 
rates, whereby health workers use the multi-dose vials yet cannot use the remaining 
doses when there are not enough patients for the vaccine to be administered (Drain, 
Nelson, & Lloyd, 2003; Lee et al., 2010).  
Interestingly, formulation presentations were found to be a driving factor for production 
costs but not vaccine prices. Formulary presentations are often pre-determined by the 
needs and preferences of the procuring country (Jarrett, 2008; Kristensen, Lorenson, 
Bartholomew, & Villadiego, 2016). Preferences over certain vaccine formulations are 
often based on perceptions or risks that a country has, and that the manufacturer takes 
as a given, and thus are price inelastic. For example, in countries where high 
temperatures are a major concern for vaccine stability, formulations are required to be 
heat-stable (e.g.: freeze-dried or lyophilised vaccines). Another example relates to 
countries where there may be concern over vaccine safety, leading to a requirement 
for manufacturers to use certain vaccine presentations such prefilled syringes over 
multi-dose vials, even if these may result in higher priced products (André, 2003; M. M. 
Levine & Sztein, 2004).  
National income levels 
An analysis of the effect of national income levels could not be undertaken in the 
analysis of cost structures (Chapter 3) because of the anonymity required for the 
respondents. With regards to the effect on market shares, national income levels were 
found to be a contributing factor for sales in domestic markets. However, the producing 
country’s income level was not found to be significantly associated with export market 
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share. The effect of national income was in line with findings from CVI & WHO (1999), 
however their study also suggested that what is most important is the commitment to 
invest in local vaccine production on the part of the government. 
With regards to vaccine prices, multiple aspects should be considered. The income 
level of the producing country was a determining factor for vaccine prices in overall 
markets as well as for traditional vaccine type markets. Traditional vaccine markets are 
saturated markets, with supplies dominated by DCVMs. Though DCVMs are keen to 
expand their production into NUVs (Jadhav et al., 2008; Milstien, Gaule, & Kaddar, 
2007; Wilson & Jones, 2010), the results suggested that DCVMs have market power 
over traditional vaccine types. This needs to be maintained until a strong supply of 
NUVs can be established.  
6.3. Limitations and prospects for future studies  
There were several limitations that need to be considered when interpreting the 
findings of this thesis. Analyses of the three different aspects of viability were based on 
different datasets, making it difficult to draw direct comparisons across the different 
aspects observed (cost, revenue sizes and market shares and vaccine prices). For 
instance, information regarding production costs was not available in the datasets for 
vaccine sales and vaccine prices. However, to date there are no single data sources 
that would cover all aspects of production costs, revenue and prices. This is the first 
study to assess all three aspects, industry-wide, from an economic perspective. 
Data collection for vaccine supply is known to be a relatively challenging task. Though 
much information has been collected on vaccine sales, this may not cover all vaccines 
sold in the market. This research limited its scope to where most data are available: 
the public vaccine market. Though the data covered may not have exhausted the full 
range of information on vaccine production, the thesis attempted to access and analyse 
data that were as complete as possible, given the resources available to the study.  
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A manufacturer’s viability is often quite specific to the context of the vaccines being 
produced or the market that the manufacturer faces. Ideally, a case study on a 
particular vaccine manufacturer would help confirm the industry-wide findings made in 
this thesis. Several attempts to engage a vaccine manufacturer for a detailed case 
study were made, however given the timeframe and other technical constraints, this 
was not possible for the thesis. The range of different viability aspects covered in this 
thesis however provides an overall assessment that is needed to answer the research 
questions. Whilst an in-depth case study did not materialise through the undertaking of 
this thesis, there would be value in engaging individual vaccine manufacturers for 
future research.  
Many vaccine manufacturers in developing countries are either public or private sector 
entities. Whilst this was not explored in detail in the thesis, there is scope for future 
research to explore and distinguish further the effects of a vaccine manufacturer’s 
status on their viability. Further, analysis on trends across regions or country types may 
also be explored in future research. 
Though the scope of this thesis was limited to the industrial perspective of vaccine 
production, it is acknowledged that efforts to address other determinants of vaccine 
demand, such as the extent and trajectory of disease epidemics, funding from national 
health care system, capacity and effectiveness to reach and vaccinate target 
population, regulatory, infrastructural, financial and political constraints could vastly 
increase the uptake of new vaccines and influence the global supply of vaccines. 
Future research of vaccine viability would benefit from exploring and incorporating the 
impact of these issues. 
6.4. Conclusions 
The interest in vaccine production viability in developing countries stems from the need 
to secure global supply of vaccines. Vaccine manufacturers in developing countries 
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vary by capacity, quality and structure. These manufacturers however must all face 
stringent international GMP standards and local regulatory requirements in producing 
vaccines for public health programs. Domestically, there is not much competition in 
producing vaccines. However, as DCVMs expand their production to export markets, 
they are in direct competition with multinational vaccine manufacturers, which often 
have larger R&D and production capacities.  
In the past, it has been assumed that vaccines can be produced at a much lower cost 
in developing countries than in high-income countries (CVI & WHO, 1999). The cost 
analysis in this thesis however, suggest that the overall cost per dose of vaccines 
produced in developing countries are only slightly lower than what is found in 
developed countries. The findings also suggest that higher production scale and scope 
contribute to cost savings. Countries with large population sizes and high burden of 
infectious diseases would therefore have a competitive advantage in lowering vaccine 
production costs compared to smaller countries. This has also been suggested by 
previous studies (Batson et al., 1994; van Noort, 1992).  
However, even when a vaccine is produced at an economical cost, the producer’s 
viability will also depend on how well it can compete with other manufacturers in the 
market. The viability factors found in the thesis as the most influential factors were (in 
descending order): having autonomy in the manufactures’ management structure, 
higher national income levels, having consistent and reliable supply of production and 
prequalified vaccine status.  
Finally, viability is also dependent on how manufacturers price their vaccines, and 
whether these are in line with the factors influencing their production costs. The findings 
in this thesis suggest that the volumes of vaccines procured are not a large contributing 
factor in DCVM pricing behaviour, though UN procurement methods have a larger 
effect on how DCVMs price their vaccines. More advanced vaccines are set at a higher 
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price, however the descriptive analysis in Chapter 4 shows that half of the vaccines 
produced by DCVMs are EPI traditional vaccines, and a large proportion of their 
vaccine production (63%) is not prequalified.  
Based on these findings and a review of the literature, this thesis recommends that to 
achieve and sustain viability in producing vaccines, developing country manufacturers 
need to secure sufficient production scales and identify multiple vaccine products that 
can be produced within their facilities. Manufacturers need to establish strong domestic 
sales and consistent supply before expanding into export markets. The ability to fulfil 
the global demand for a given vaccine does not contribute as much in increasing 
revenue sizes or market shares. In order to establish competitiveness in export 
markets, developing country manufacturers should consider investing in the 
prequalification processes, especially when considering supplying UN vaccine 
markets.  
In addition to these, developing country manufacturers must also explore potential 
support from key stakeholders and health advocates such as the WHO, World Bank, 
BMGF among others, especially given the role of DCVMs in sustaining the global 
supply of vaccines. Governments in developing countries must enable policies that 
support viable vaccine production in developing countries. Though the thesis findings 
suggests that viability in domestic markets are currently established, strong national 
regulatory authorities (NRAs) need to be maintained. This is especially important given 
the changing landscape of vaccine technology and in regards to DCVM efforts in 
expanding production to export markets once strong domestic presence is established. 
Equally important are industrial policies that support manufacturers in obtaining higher 
technology capacity. Information provision regarding vaccine market prices needs to 
continue, such as those collected and disseminated through the V3P project.  
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Further, given the importance of production scale and scope on the viability vaccine 
production, proposals for regional vaccine manufacturing, in cases where a single 
country production may not be viable, should be considered as an option and explored 
further for its feasibility. Dialogue and exploratory research among existing networks 
such as the Developing Country Vaccine Regulator’s Network, Health Impact Fund and 
other initiatives need to continue with the goal of strengthening vaccine production 
capacity and may explore potential funding solutions to increase the incentives and 
reduce the risks of investing in vaccines for developing countries.
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